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A b s t r a c t
IV
Schizophrenia is a severe psychiatiic disorder associated with hallucinations, 
delusions, affective flattening, lack of motivation, social isolation and cognitive 
impairments. Features of the cognitive deficits observed in schizophrenic patients 
and in animal models of schizophrenia, such as attentional processes, cognition, 
working memory and behavioural flexibility, require the activation of the 
prelimbic cortex (PrL) and the ventral orbital cortex (VO), which are subregions 
of the prefrontal cortex. The thalamic reticular nucleus (Rt) also plays a key role 
in the regulation of these cortical functions by exerting an inhibitory control over 
the thalamo-cortical projections. The physiological role of a specific brain region 
could be associated with its gene expression profile. Moreover, the genes 
specifically expressed or enriched in one region could play a key role in the 
neuropathology of neuropsychiatrie disorders.
The aim of the project was two-fold: to identify genes enriched in thiee brain 
regions implicated in some aspects of cognition and neurobiological alteration 
observed in schizophrenia models (PrL, VO and Rt) compared to one control 
region (primary motor cortex, Ml); and to analyse the expression of selected 
enriched genes in a chronic PCP animal model of schizophrenia (Coclnan et al 
2003).
The expression profiling of the PrL, VO and Rt was performed using a 
combination of laser-assisted microdissection, linear amplification and GeneChip 
microarray analysis. The microdissections were performed on coronal sections 
dissected from 6 naïve rat brains using the Leica AS LMD system. After 
extraction, the total RNA was linearly amplified, labelled and hybridised onto 
Affymetrix Rat Genome 230 2.0 arrays. The data were analysed according to the 
Rank Product method (Breitling et a l, 2004). The regional overexpression of 
some selected genes was validated by in situ hybridisation (ISH) on six naïve 
brains. The expression of these genes was then analysed by ISH after a clironic 
intermittent PCP treatment (2.58mg/kg) in six treated and six control rat brains.
This study shows that the expression of many genes is differentially regulated in 
the selected areas. In the Rt, 429 transcripts were overexpressed compared to the 
cortical areas. Intra-cortical variations were also observed: 233 transcripts were 
overexpressed in the Pii compared to the other cortical areas, whereas 83 
transcripts were enriched in the VO. The selectively expressed genes were 
involved in several biological mechanisms, such as neurotransmission, ion 
transport, neuronal development and synaptic plasticity. Ten genes were selected 
according to their levels of expression for the validation of both small and large 
differential expression by ISH. Expression analysis by ISH confirmed the 
overexpression in the PrL, VO and Rt predicted by the LMD-microan'ay for all 
genes tested. Wolframin, a gene which is likely to be involved in intracellular 
calcium trafficking that is the causative factor of Wolfram syndrome, showed 
significant decreased expression in the PrL in the PCP model of schizophrenia 
(p<0.05). Wolfi'amin could be directly involved in the psychiatric conditions 
obseiwed in the majority of Wolfram syndrome patients.
Genome-wide expression analysis combined with laser-assisted microdissection 
showed that anatomical and functional differences between brain regions are 
associated with differential gene expression. Alterations of the region-specific 
expression could be crucial for psychiatric diseases; therefore this approach is 
exceptionally useful for the selection of candidate genes to study in models of 
psychiatric disorders such as schizoplrrenia. Using the LMD-microarray approach 
followed by ISH validation, this project defined the gene expression profiles of 
the Prl, VO and Rt in the rat brain and identified a novel gene with decreased 
expression in a clironic PGP model of schizophrenia.
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1. In t r o d u c t io n
1.1 Schizophrenia
Schizophrenia is a psychiatric disorder that affects the most complex and 
developed functions of the human brain. Thought, language, communication, 
social interaction, motivation and cognitive functions are dramatically 
compromised in schizophrenic patients. This condition is differentiated from other 
diseases with a psychotic component, such as delusional disorder and schizo­
affective disorder, on the basis of the combination of symptoms displayed by the 
patients and their duration. The American Psychiatric Association’s fourth edition 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) defines 
schizophi'enia as “a disturbance that lasts for at least 6 months and includes at 
least 1 month of active phase symptoms” including positive and negative 
symptoms (refer to sections 1.1.2 and 1.1.3). Also, subtypes of schizoplirenia are 
classified according to the prevalence of some symptoms over others (refer to 
section 1.1.5).
The German physicist Emile Kraeplin first described the disorder currently 
known as schizophrenia according to modem scientific diagnostic criteria in 1887. 
Kraeplin named this condition "'dementia praecox’" (early dementia), to 
distinguish it from other forms of dementia that commonly occur in senescence, 
such as Alzheimer’s disease. The temi “schizoplirenia” was applied to the mental 
disorder described by Kraeplin by the Swiss psychiatrist Eugen Bleuler in 1911, 
who considered the definition "dementia praecox''’ misleading, as this condition is 
not always associated with mental deterioration. The word schizophrenia, which 
originates from the Greek words for “split” (a%t^m) and “mind” (cpppv), was 
coined to describe the fragmented thinking of patients. This definition should 
not be referred to multiple or split personality, which is not a feature of 
schizophi'enia.
Schizophi'enia has a characteristic time course. The onset is typically in late 
adolescence-early adulthood. Clinical signs are not frequently detectable before 
puberty, though in some cases a prodromal phase of the illness might be observed. 
Prodromal features include cognitive and mood symptoms, social withdrawal and 
obsessive behaviours (McGlashan, 1996); however, they are not fully specific and 
lack diagnostic validity. Schizoplnenia is a clironic disease, with untreated 
patients usually undergoing a gradual exacerbation of the illness, characterised by 
persistent and severe negative symptomatology and cognitive impairment (see 
sections 1.1.3 and 1.1.4) with typically frequent manifestation of positive 
symptoms (see section 1.1.2). Usually, the severity of the symptoms becomes 
stable ill the senescence (Lewis et al., 2000).
1.1.1 Diagnostic criteria for schizophrenia
Schizoplirenia is diagnosed according to the guidelines outlined in the DMS- 
IV and in the tenth revision of the hitemational Classification of Diseases (ICD- 
10), which is the official diagnostic manual of the World Health Organisation 
(WHO). The DMS-IV is commonly used in the United States, whereas the ICD- 
10 is the prevalent manual employed by psychiatrists in Europe. Both publications 
describe the same characteristic symptoms outlining unifonn diagnostic criteria; 
in fact scientific publications can refer to either manuals. Moreover, the diagnostic 
criteria outline exclusion cases to facilitate the differentiation between 
schizoplirenia and other conditions with a psychotic component.
The core symptoms of schizophi'enia can be divided into three main 
categories: positive symptoms, negative symptoms and cognitive impairment. The 
positive symptoms, which include delusions, hallucinations, thought disorder, 
disorganised behaviour and catatonic motor behaviour (see section 1.1.2 for 
detailed description) are an excess or distortion of a normal function, whereas the
negative symptoms, such as affective flattening and avolition (see section 1.1.3), 
consist of a diminution or loss of normal functions. When diagnosing 
schizophrenia it is essential that a number of core symptoms are shown for a 
significant portion of time during a 1-month period, and that signs of the disorder 
persist for at least 6 months (DMS-IV). The importance of this time scale is due to 
the presence of psychotic symptoms for a limited time in other disorders such as 
schizoplirenifonn disorder, schizoaffective disorder, delusional disorder, brief 
psychotic disorder and drug-induced psychosis. The diagnosis is complicated by 
the heterogeneity of schizophrenia; in fact different types of symptoms can be 
predominant in specific subsets of patients (see section 1.1.5). Also, although both 
the ICD-10 and the DMS-IV outline the diagnostic criteria in detail, the 
identification of the symptomatology relies on the patient’s verbal descriptions.
1.1.2 Positive symptomatology of schizophrenia
1.1.2.1 Delusions
Delusions are defined by the DMS-IV as “erroneous beliefs that usually 
involve a misinterpretation of perceptions or experiences”. Delusions may have 
many themes, sometimes depending on the cultural background of the patient. 
Persecutory delusions, including the belief of being tonnented, followed, spied on 
or subjected to ridicule can be frequent, as well as referential delusions, such as 
the belief that gestures, passages from books or newspaper are specifically 
directed to oneself.
Interestingly, the presence of bizarre delusions is a relatively specific feature 
of schizophrenia, although it may be difficult to judge the bizarreness of false 
beliefs (DMS-IV). However, there are some examples of bizarre delusion that are 
common in the disease; these include the patient’s belief that his or her thoughts
have been taken away by an external force (“thought withdrawal”), that external 
thoughts are being inserted in his or her mind (“thought insertion”) or that his or 
her actions are being directed by an outside force (delusions of control).
1.1.2,2 Hallucinations
Schizophrenic patients can experience hallucinations involving any sensory 
modality, although auditory hallucinations are by far the most common. Distorted 
perceptions are considered a symptom of schizophrenia only if they occur in a 
normal sensorial context, as opposed to hallucinations perceived while falling 
asleep (hypnagogic) or while waking up (hypnopompic). On the other hand, some 
specific types of auditory hallucination are considered specific to schizophrenia 
symptomatology. These include two or more external voices conversing with each 
other and an external voice keeping a running commentary on the patient’s actions 
(DMS-IV).
1.1.2.3 Thought disorder
Disorganised thinking is considered one of the core symptoms of 
schizoplirenia. This characteristic is reflected by disorganised speech, and can be 
difficult to define, as a mild form of this symptom can be common and non­
specific to schizophrenia. Thought disorder in schizophrenic patients can be very 
severe, impairing the patients’ communication skills and consequently their 
ability to interact in social environments. In some cases disorganised thinking can 
lead to incoherent and incomprehensible speech.
1.1.2.4 Disorganised behaviour
Disorganised behaviour usually manifests itself in schizoplirenic patients as 
the inability to perform goal directed actions. Frequently patients are unable to 
organise activities that are necessary for everyday life, such as arranging meals or 
keeping personal hygiene; occasionally inappropriate sexual behaviour and 
unmotivated and unpredictable agitation can occur. It is worth noting that these 
symptoms are separate from behaviour emanating from delusional beliefs.
1.1.2.5 Catatonic motor behaviour
Catatonic motor behaviour is defined as a marked decrease in reactivity to the 
external environment (DMS-IV). In some cases this symptom can be very severe, 
resulting in a complete unawareness of the suiTounding environment (catatonic 
stupor) that can be associated with rigid posture and resistance to attempts to be 
moved (catatonic rigidity). The assumption of unusual postures (catatonic 
posturing) and puiposeless unstimulated excessive motor activity (catatonic 
excitement) can also be observed, especially in a subtype of schizoplirenia (refer 
to section 1.1.5).
1.1,3 Negative symptomatology of schizophrenia
As mentioned previously, negative symptoms reflect a deficit in normal 
functions and are an important feature of schizophrenia that contribute 
substantially to the morbidity of this disease. The evaluation of negative 
symptoms can be difficult due to a number of confounding factors. For example
mood disorders and also side effect of antipsychotic medication can mimic 
affective flattening or avolition (see below).
1.1.3.1 Affective flattening
Affective flattening is a common symptom in schizoplirenic patients. It is 
usually manifested as a distinctly reduced range of emotional expressiveness; for 
example the patients may show poor eye and body language when interacting 
with peers, coupled with inexpressive and uinesponsive facial expression.
1.1.3.2 Alogia
Alogia is defined as a “decreased fluency and productivity of speech” (DMS- 
IV) that reflects impoverished thought. It is cmcial to differentiate this symptom 
from the unwillingness to speak, which is not related to impaired thinking.
1.1.3.3 Avolition
Avolition is the “inability to initiate and persevere in goal-directed activities” 
(DMS-IV). The patients showing this symptom usually show very little interest in 
participating in social activities and work. It is important to differentiate this 
symptom fiom side effects of antipsychotic drugs or behaviour that is dependent 
on delusions.
1.1.4 Cognitive dysfunction in schizophrenia
Cognitive impairments are disturbances in basic cognitive function such as 
attention, executive functions and specific forms of memory, particularly working 
memory (Lewis et a l, 2000). These impairments are considered a core feature of 
schizoplirenia (Park et al, 1992) and play a pivotal role in a patient’s behavioural 
disturbances and functional disability; for example, social interaction is 
compromised by the difficulty in correctly perceiving and processing the 
emotions displayed by others both in facial expression and vocal communication 
(Edwards et al, 2002).
Impairments in working memory and attentional processes, which are linked 
to disturbances of the prefrontal cortex (Park et al, 1992; Goldman-Rakic, 1994) 
are particularly evident. Schizophrenic patients perform poorly in tests 
specifically designed to assess executive function, such as the Wisconsin Card 
Sort Test (WCST) (Park, 1997) and spatial working memory, such as the 
oculomotor delayed response tasks (Park et a l, 1992). Briefly, in the WCST the 
subject is required to flexibly decipher and apply rules concerning the 
arrangements of cards. The test involves sorting the cards according to a specific 
rule, such as shape or colour; once a pattern is established, the subject is asked to 
arrange the cards applying a different rule. The capability to maintain and shift 
attention and to formulate abstract concepts (behavioural flexibility) is crucial for 
performance in the WCST. Schizophrenics also perfomi poorly in the classic 
Tower of Hanoi test (Goldberg et a l, 1990). This is anoter task used to assess 
executive function, and requires the subject to rearrange a tower of discs of 
decreasing sizes with the fewest moves.
It has been shown that cognitive impairments are present even in first-episode 
previously untreated patients, suggesting that these symptoms are an intrinsic 
characteristic of schizophrenia, rather than the consequence of prolonged 
neuroleptic treatment (Bilder et a l, 2000). Moreover, an attenuated form of the 
cognitive impairments can be detected in the prodromal phase of the illness.
before the onset of other symptoms (Jones et al, 1994), as well as in non­
schizophrenic relatives of patients (Camion et a l, 1994),
Cognitive impainnents have gi'eat importance in the complex psychopathology 
of schizoplirenia, and, similar to negative symptoms, are insufficiently 
ameliorated by drug therapy. The persistence of severe cognitive impairment is a 
determinant factor for progression of the disease and complicates the re­
integration of patients in social activities and work environment.
1.1.5 Subtypes of schizophrenia
Subtypes of schizophrenia are differentiated according to the predominant 
symptomatology at the time of diagnosis. Importantly, the clinical characteristics 
of the disorder may change over time and in some cases patients may show 
symptoms that are representative of different subtypes of schizoplirenia.
L I .5.1 Paranoid schizophrenia
Paranoid schizophrenia is characterised by the prevalence of positive 
symptoms such as delusions and hallucinations. Delusions may be multiple and 
bizarre, but they are usually organised coherently. Hallucinations can also be 
related to the context of delusions. Frequently, patients suffering from paranoid 
schizophi'enia can be anxious, aloof or irritable due to typical persecutory theme 
of their delusions. Disorganised speech, avolition and affective flattening are not 
predominant in this subtype of schizoplnenia; moreover, cognitive impairments 
are not severe. Usually paranoid schizoplnenia has a considerably better prognosis 
than other subtypes, possibly due to the relatively intact cognitive function of this
subclass of patients. Also, positive symptoms can be controlled by treatment with 
antipsychotics.
1.1.5.2 Disorganised/hebephrenic schizophrenia
Disorganised schizophi'enia, historically known as hebeplirenic, is 
characterised by the prevalence of thought disorder, disorganised behaviour and 
affective flattening. In hebephrenic patients, the capacity of performing goal- 
directed actions is severely impaired. This clinical profile frequently causes 
serious disruption of activities necessary for everyday and working life such as, 
organising meals, keeping personal hygiene, perfomiing in a work environment. 
Cognitive impairment is also a core feature of this subtype of schizophrenia, 
which is usually associated with poor prognosis and early onset.
1.1.5.3 Catatonic schizophrenia
When catatonic motor behaviour is marked, schizopln*enia is classified as 
catatonic even if other symptoms are present. The psychomotor disturbances 
(refer to section 1.1.2.5) can represent a risk factor for malnutrition, exhaustion 
and self-harming; therefore catatonic patients usually require adequate supervision 
and are usually hospitalised.
1.1.5.4 Undifferentiated schizophrenia
Schizophrenia is classified as undifferentiated when the symptoms shown by 
the patients correspond to the core features of the disease, but do not meet the 
criteria to be diagnosed as paranoid, disorganised or catatonic schizophrenia. This
10
situation may occur when there is no clear prevalence of one type of 
symptomatology.
1.1.5.5 Residual schizophrenia
Residual schizoplirenia is usually a transition period between the acute phase 
of the disease and a complete remission, although it could be persistent for several 
years with or without relapses. It is characterised by negative symptoms such as 
affect flattening and avolition. Positive symptoms are absent or very attenuated.
1.1.6 Pharmacotherapy of schizophrenia
Early pharmacological treatments of schizophrenia were based on sedation of 
agitated patients and included administration of drugs such as morphine, 
potassium bromide, chloralium hydrate and hyoseine (Shorter, 1997). Sleep 
therapy induced by a combination of barbiturates and insulin coma were also 
common treatments until the mid-1950s (Ban, 2004). While these approaches 
were undoubtedly effective to control agitation and aggressive behaviour of some 
patients, they had very marginal, if any, benefit for the remission of the symptoms 
of schizopluenia.
Chlorpromazine was the first drug with relatively specific antipsychotic 
properties that allowed the treatment of schizophrenia whilst avoiding generalised 
non-specific sedation. This compound was synthesized and introduced for clinical 
use in the early 1950s (Charpentier et al, 1952; Delay et al, 1952). A few years 
later, haloperidol, which is still commonly used, was introduced (Divry et al, 
1959). The introduction of these drugs in the therapy of psychosis not only
11
improved the conditions of patients, but also prompted the development of 
modem neuropsychopharmacology, hnportantiy, the finding that these 
antipsychotics are antagonists of the dopamine D2 receptor (Creese et al, 1975) 
led to the development of the dopamine hypothesis of schizoplirenia (Snyder, 
1976) (see section 1.3.1). Unfortunately, the blockade of dopamine receptors also 
induces severe extrapyramidal manifestations, such as bradykinesia and tardive 
dyskinesia, which are the most prominent side effects of this class of drugs (Farde 
et al, 1992). Other limitations of chlorpromazine, haloperidol and other dmgs 
with similar pharmacological profile include limited beneficial effect for the 
negative symptoms and cognitive impairments of schizophrenia and the fact that a 
relatively high proportion of patients do not respond to the treatment (Kane, 
1987).
The introduction of a second generation of antipsychotics including clozapine, 
olanzapine, quetiapine and risperidone provided the psychiatrists with a wider 
range of drugs to treat the symptoms of schizophrenia, and contributed to the 
revision of the postulate that the effectiveness of this class of drugs is dependent 
on their dopamine D2 receptor antagonism. The pharmacology of these 
compounds is complex, as they interact with several receptors in the central 
nervous system, including serotonin 5-HT2A; however they usually lack 
prominent anti-D2 activity, opposed to the first generation of antipsychotics. 
These drugs, also classified as atypical antipsychotics, do not induce prominent 
extrapyramidal side effects. Despite this advantage, these drugs represent only a 
limited improvement in the treatment of schizophrenia compared to the typical, 
first-generation antipsychotics, as many key symptoms such as the cognitive 
disturbances (see section 1.1.4) remain untreatable (Davis et al, 1980). Moreover, 
reh'actory patients do not respond or respond only partially to pharmacological 
treatment regardless of which class of antipsycho tics is used (Kane, 1987; 1996).
Although substantial advances since the early phannacotherapeutic approaches 
have significantly improved the conditions of schizoplurenic patients, the drugs 
currently available are certainly not sufficient to effectively resolve the 
symptomatology of this disease. Wliile some subtypes of the disease, such as
12
paranoid schizophrenia, respond relatively well to antipsychotics, treatment of 
patients with prevalent cognitive impaiiments is less likely to be successful. 
Improvement of the understanding of the neurobiological basis of cognitive 
deficits could contribute to the development of novel phamiacological treatments 
to ameliorate this core symptom of schizoplirenia.
The heterogeneity of schizophrenia is another important factor that needs to be 
considered for the development of imiovative pharmacotherapeutical approaches. 
Subpopulations of patients are likely to respond differently to different 
combinations of drugs; therefore improved diagnosis coupled with specific 
therapeutic approach could be one of the goals for the future generation of 
treatments (Ban, 2004).
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1.2 The neuropathology of schizophrenia
The attempt to identify schizoplirenia-linked neuropathological alterations that 
can be reliably measured has been a major challenge for the neuroscience 
coimnunity since this disease was first described. In fact, Kaeplin was convinced 
that the syndrome he identified as dementia praecox one century ago was an 
organic brain disease, although the diagnostic criteria were, and still are based on 
the assessment of the psychopathological profile. For a long time the efforts to 
categorize measurable pathological changes in the schizophrenic brain have been 
fmstrated by a number of factors, including inadequate techniques. The 
inconsistency of the data collected before the development of CT (computed 
tomography) and MRI (magnetic resonance imaging) are reflected by the 
infamous statement that schizophrenia is the “graveyard of neuropathologists” 
(Plum, 1972). The new imaging tecluiiques, coupled with improved 
methodologies for post-mortem studies have allowed some of the difficulties that 
affected the earlier studies to be partially overcome. Recent consistent findings 
have prompted a new enthusiasm for the investigation of the neuropathological 
changes in the schizoplrrenic brain and appear to support that schizophrenia is an 
organic brain disease (Ron et al, 1990; Weinberger, 1995), as initially postulated 
by Kraeplin. Nevertheless, some data are still contradictory (see below) and 
further studies are needed to clarify whether some neuropathological alterations 
are shown in specific subsets of patients only. The clinical differences between 
various schizoplirenia subtypes can be an obstacle to the identification of a 
general neuropathological profile; therefore the diagnostic criteria must still rely 
on the psychopathology, taking little advantage of the limited consistent evidence 
available about the organic alterations of the schizophrenic brain.
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1.2.1 Macroscopic alterations in the schizophrenic brain
1.2.1.1 Whole brain volume
A number of studies report a statistically significant decrease in whole brain 
volume of schizophrenic patients compared to control subjects; however these 
data have been contradicted by several reports of negative findings (reviewed by 
Shenton et al, 2001). Despite the inconsistency of data regarding decreased whole 
brain volume in schizoplirenia, it is possible that small changes are associated at 
least to some subsets of cases. Statistically significant reduced brain volume has 
been demonstrated in patients with childhood schizophi*enia (Jacobsen et al, 
1996), suggesting that this neuropathological abnormality could be specifically 
associated with early-onset forms of the disease, as concluded by Shenton et al, 
2001 .
It is also important to consider that the size of head and brain is very variable 
in the general population, and can be influenced by factors such as age, gender 
and nutritional deficits. This variability can be a confounding factor when 
studying small but important changes.
1.2.1.2 Size o f ventricles
Enlargement of the lateral ventricles is one of the most consistent macroscopic 
alterations measured in the schizophrenic brain (Daniel et al, 1991; van Horn et 
al, 1992). The development of imaging techniques such as CT and MRI has been 
cmcial to measure the ventricular size in a reliable and non-invasive way, leading 
to interesting findings. Yotsutsuji et al. (2003) showed that the ventricular 
enlargemnt is particularly evident in the temporal horn portion of the lateral 
ventricles using high-resolution three-dimensional MRI. Interestingly, these 
findings are concordant with data from post mortem analyses (Roy et al, 1998;
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Nieman et al, 2000), confirming the consistency of this neuropathological 
change.
The ventricular enlargement is associated with a loss of brain tissue, 
suggesting that the reduction of grey matter volume in the region surrounding the 
temporal horn of the lateral ventricles is a feature of schizophrenia (Lawrie et al,
1996).
Unfortunately the enlargement of the lateral ventricles cannot be considered as 
a specific feature of schizophrenia, as this abnormality can also be observed in 
other conditions, such as Alzheimer’s disease and Huntington’s chorea (Brown et 
al, 1986; Wang et al, 2002).
L2.L2 Temporal lobe
The temporal lobe is another brain region that shows robust changes in the 
schizophrenic brain. Interestingly, Kraepelin (1919) believed that some symptoms 
such as delusions and hallucinations could be related to neuropathological 
alterations of the temporal lobe. Almost a century later, teclmological advances in 
neuroimaging allowed demonstration of this intuition. Barta et a l, (1990) and 
Shenton et al (1992) reported that the severity of auditoiy hallucinations and 
thought disorder could be correlated with a decrease in size of the superior 
temporal gyrus. Other studies, however, show no significant ventricular or cortical 
size change (Dwork, 1997; Heckers et a l, 1990). It is worth considering that in 
many cases contradictory results can be due to methodological differences 
between studies. Crucial factors that can influence measurements are the thickness 
of slices, the landmarks used to define boundaries between lobes, and the choice 
of measuring grey matter or grey matter and white matter combined (reviewed by 
Shenton et al, 2001).
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1.2.1.3 Frontal lobe and limbic system structures
The frontal lobe includes structures that are crucial for the neuropathology of 
schizopluenia, such as the prefrontal cortex (PFC). Neuroimaging studies in 
human brain and lesion studies in non-human primates have demonstrated the 
correlation between PFC activation and working memory, (reviewed by Honey et 
al, 2006), which enables the short-temi retrieval of information for goal-directed 
action. Working memory is central to everyday functioning and plaiming, which 
are severely disrupted in schizophrenia, and also contributes to other cognitive 
processes. Consistent data show that many aspects of the cognitive deficits 
observed in schizopluenia (see section 1.1.4) are due to working memory 
impairment and are associated with dysfunctional PFC (Goldman-Rakic, 1994; 
Honey et al, 2006).
Despite the well-documented functional abnonnalities in the schizopluenic 
prefrontal cortex, the available data about structural changes in the frontal lobe are 
contradictory (DeLisi et al, 1991; Lawrie et al, 1999; Sanfilipo et al, 2000). 
Interestingly, studies that did not find significant frontal lobe volume changes in 
the schizophrenic brain, reported a correlation between the volume of this area 
and structures of the limbic system in the schizophrenic brains only (Wible et al, 
1995). The same study also reported a coirelation between the severity of negative 
symptoms and frontal lobe volume reduction. Breier et a l (1992) also found a 
correlation between frontal lobe and temporal lobe volume in schizophrenia. 
Although these findings do not prove that the prefrontal dysfunction in 
schizopluenia is correlated to structural changes, they suggest that some 
macroscopical neuropathological alterations may exist but are difficult to detect. It 
is worth considering that the majority of studies on fi'ontal lobe neuropathology 
have been conducted measuring the volume of the whole lobe (Shenton et al,
2 0 0 1 ), although this brain area is not functionally and anatomically uniform. 
Perhaps alternative approaches coupling liigh anatomical specificity with 
improved teclmology could reveal evidence of prefrontal neuropathological 
alterations in the near future.
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1.2.1.4 Other brain regions
MRI and CT studies have been performed in a number of non-cortical brain 
structures. The thalamus has been the focus of many investigations for its 
importance in the modulation of cortical activity. In fact, the ventral anterior and 
dorsomedial thalamic nuclei are crucial relay stations that establish reciprocal 
connections with the prefrontal cortex, suggesting that these brain subregions may 
play a role in schizoplirenia (Andreasen et al, 1994). hi fact, it is known that 
thalamic activity is important for filtering the sensorial input and controlling 
attentional processes (Jones, 1985; Fuster, 1989). Interestingly, there is evidence 
of neuropathological alteration in the thalamus from post mortem studies 
(Pakkenberg, 1987; Pakkenberg, 1990). Reports from imaging studies are more 
contradictory, partially due to the teclmical difficulties encountered when 
applying this technique to measure thalamic nuclei (Andreasen et al, 1990). 
Nevertheless, significant reduction of signal intensity in the thalamus of 
schizophrenic brains was reported by Andreasen et al (1994). Moreover, a study 
reporting no significant difference between schizophrenic thalamus and control, 
noted a correlation between early onset of the disease and decreased thalamic 
volume (Corey-Bloom et al, 1995).
Neuropathological abnormalities were also reported in other brain structures 
such as the basal ganglia, the corpus callosum, the olfactory bulbs and the 
cerebellum (Turetski et al, 2003; Mamah et al, 2006; Brambilla et al, 2005). 
Interestingly, the cerebellum establishes connections with the cortical association 
areas and limbic structures such as hippocampus and amygdala, suggesting that 
this area contributes to cognitive processing (Schmahmami, 1996); hence the 
cerebellum may be an interesting candidate for investigating schizophrenia-related 
neuropathological abnormalities. Significant increase in white matter volume of 
the cerebellar vermis was reported by Levitt et al (1999); the same study also 
noted a correlation between this change and the severity of positive symptoms, 
thought disorder and impaired verbal memory. Increased white matter volume in
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the cerebellum can be interpreted as a sign of abnonnal neurodevelopment (Levitt 
eta l, 1999).
Evidence of macroscopic abnormalities in the schizophrenic brain is 
progressively more convincing thanks to the development of non-invasive 
imaging thechniques such as MRI. The most substantial data show significant 
neuropathological changes in the lateral ventricles, temporal lobe, frontal lobe and 
sub cortical regions such as thalamus, cerebellum, basal ganglia and corpus 
callosum (see above). The large number of regions involved in the 
neuropathological changes associated with schizophrenia suggests that this 
disease affects the connectivity of multiple areas which are likely to be 
functionally related. This scenario is compatible with the hypothesis that the 
abnormalities observed in the schizoplu'enic brain have a neurodevelopmental 
origin (for review see Weinberger, 1995). However, it is worth mentioning that 
the maeroscopic alterations alone are not likely to explain the complex 
dysfunctions shown by schizoplu'enic patients; thus this type of information needs 
to be supported by data showing cellular and molecular alterations (for review see 
Harrison, 1999).
1.2.2. Cytoarchitectural abnormalities in schizophrenia.
Many studies are aimed at investigating the microscopic neuropathology of 
schizopluenia. Understanding the possible pathological changes at the neuronal 
level may be very relevant to the aetiology of this disease, as neurodegeneration is 
not commonly associated with schizopluenia (Hanison et al, 1999). The 
eytoarchitecture studies usually analyse the brain at the cellular and subcellular 
level, taking into account a number of neuronal characteristics that could change
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in pathological conditions, such as number, density, size and morphology of 
neurons.
The focus has been mainly on the extended limbic system, whose activity is 
essential for higher cognitive and affective functions. Abnormalities in the 
eytoarchitecture and lamination of the enthorinal cortex (anterior 
parahippocampal gyrus) (Jakob et a l, 1986), disarray of hippocampal pyramidal 
neurons (Kovelman et a l, 1984) and abnormal location of cortical subplate 
neurons (Akbarian et a l, 1993) have been reported; however other groups failed 
to replicate these findings (Akil et a l, 1997; Altshuler et a l, 1987; Anderson et 
al, 1996).
Decreased cellular size affecting neurons in the hippocampus and the 
dorsolateral prefrontal cortex (DLPFC) has been shown fairly convincingly 
(Harrison 1999). Image analysis techniques were employed to measure the size of 
the cell bodies, demonstrating that hippocampal pyramidal neurons have a smaller 
mean size in schizophrenia (Zaidel et a l, 1997), as well as lamina IIIc neurons in 
DLPFC (Rajkowska et a l, 1998). Some studies suggest that size reduction is 
accompanied by increased neuron density (Harrison 1999).
The other relatively robust cytoarchitectural abnormality found in 
schizophrenia is in the dorsal thalamus, which is smaller and contains fewer 
neurons (Danos et a l, 1998; Pakkenberg, 1990; Pakkenberg, 1992). Interestingly, 
the neurons in mediodorsal nucleus of thalamus are reciprocally connected with 
prefrontal cortex neurons, consistent with the hypothesis that schizophrenia is 
caused by pathological changes of neuronal circuitry.
It has also been demonstrated that pathological abnormalities affect specific 
sub-cellular structures such as axons, dendrites and synaptic terminals. Synaptic 
protein levels are lower in the hippocampus and parahippocampal gyrus 
(Eastwood et a l, 1995); these changes particularly affect the excitatory pathways 
of this region, supporting the involvement of the glutamatergic system in the 
neuro chemistry of schizoplirenia (see below). Studies performed on the DLPFC 
have found lower density of dendritic spines on layer III pyramidal neurons 
(Garey et a l, 1998) as well as lower expression of synaptophysin (Glantz et al.
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1997), a marker of synaptic density. Evidences of synaptic abnormalities have 
also been shown in the thalamus, where the synaptic protein rabSa is significantly 
reduced (Blennow et al., 1996), and in the striatum, where altered sizes of caudate 
nucleus synapses were obseiwed with electron microscopy (Harrison, 1999).
Synaptic studies highlight the impaired comiectivity affecting the 
schizophrenic brain. The regions involved are pivotal to most of the complex 
functions disrupted in schizophrenia; the changes found in the hippocampal 
formation confiim the involvement of the limbic system together with other 
regions anatomically and functionally interconnected such as the thalamus and the 
neocortex. The pathological changes primarily affect glutamatergic excitatory 
pathways in the hippocampus and the DLPFC, although the GABAergic system is 
also clearly involved and its role is important for the modulation of synaptic 
connectivity between the affected regions (see below).
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1.3 Neurochemical abnormalities in schizophrenia
Schizophrenia is also characterized by specific changes in neurotransmission 
systems. Most of the research about schizophrenia neurochemistry has been 
inspired by phannacology: the mechanisms of action of both antipsychotic and 
psychotomimetic compounds form the basis of the neurotransmitter hypothesis of 
schizophrenia.
1.3.1. Dopamine hypothesis.
Many studies focus on a possible alteration of dopaminergic transmission in 
schizophrenia. The dopamine hypothesis is supported by the fact that antagonists 
of dopamine receptors such as haloperidol and chlorpromazine are effective for 
the treatment of the positive symptoms of schizophrenia. Also, it is well known 
that amphetamine, which stimulates the release of catecholamines from synaptic 
tenninals, can mimic the positive symptoms of schizophrenia in healthy 
individuals and exacerbates pre-existing psychosis in schizoplirenic patients 
(Connell, 1958; Angrist et a l, 1974). The psychotomimetic effect of 
amphetamine is consistent with the hypothesis that schizoplu-enia could be 
associated with hyperactivity of the dopaminergic system.
Analysis of dopamine receptor distribution and expression within the affected 
regions of the brain attempts to confirm the dopamine hypothesis. Dopamine 
receptors are classified into two classes: Di-like receptors, namely Di and D5 , 
which activate adenylyl cyclase via Gg coupling; and D2-like receptors, including 
D2 , D3 and D4 , which couple via Gi/o to inhibit adenylyl cyclase. The latter are 
particularly important in schizophrenia, since typical antipsychotics are 
antagonists of the D2 receptor. It has been shown that D2 receptor subset densities
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are increased in the schizophrenic brain, but it is not clear whether this change is 
due to pharmacological treatment or to the illness itself (Nordstrom et a l, 1995; 
Zakzanis et a l, 1998). Data on Di and D3 receptors alterations are controversial 
(reviewed by Harrison 1999), as are those about the D4  receptor, which is 
particularly interesting being one of the sites of action of clozapine, an effective 
atypical antipsychotic. Abnomial dopamine metabolism has also been 
demonstrated (Elkashef et a l, 2000), but pharmacological treatment cannot be 
excluded as a cause of this change (reviewed by Wong et a l, 2003). Interestingly 
positron emission tomography (PET) and single photon emission tomography 
studies show an increased release of dopamine from synaptic terminals in 
response to amphetamine in schizophrenia, suggesting a hyperresponsiveness of 
dopaminergic neurons (reviewed by Harrison 1999).
Dopaminergic hyperactivity has been considered for a long time as the main 
cause of schizophrenia; indeed there is a correlation between dopamine D% 
receptor binding and clinical efficacy of typical antipsychotic drugs (Creese et al, 
1976). However, the attempts to demonstrate a specific molecular alteration in the 
dopaminergic system have not yielded definitive results as yet. Furthermore the 
dopamine hypothesis is not sufficient to explain all the complex features of 
schizophi'enia: amphetamine does not mimic the negative symptoms and cognitive 
impairment, and effective atypical antipsychotic such as clozapine and risperidone 
are not solely antagonists of the D2 receptor. Nevertheless, dopamine is likely to 
play an important role in schizophrenia pathology and should be considered as 
one of the components of a complex scenario involving other neurotransmission 
systems and neuropathological alterations.
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1.3.2. Serotoninergic system involvement.
Lysergic acid diethylamide (LSD)-induced hallucinations and behaviour 
resemble some symptoms of schizoplirenia (Breier, 1995). As this drug is a 5-HT 
agonist, it has been hypothesised that the serotoninergic system may play a role in 
the pathology of schizophrenia. Overexpression of the 5-HTia receptor has been 
demonstrated in the frontal cortex of schizophrenic patients, while the expression 
of 5-HTzA receptors in the same region of the affected brain is decreased (Burnet 
et a l, 1996). Interest centres on a possible role of 5 -HT2a receptors because it is 
one of the sites of action of several atypical antipsychotics, such as clozapine, 
risperidone, olanzapine and quetiapine. These drugs have a complex 
pharmacological profile and interact with many different classes of receptor, 
including serotoninergic, dopaminergic, histaminergic, adrenergic and muscarinic 
receptors. Their affinity for the D2 receptor is usually lower than typical 
antipsychotics, so they cause less side effects connected with dopaminergic 
system inliibition, such as extrapyramidal effects (Seeman et a l, 1997). At the 
same time, they are slightly more effective in ameliorating negative symptoms 
and cognitive impairment (MoHer, 2003). For these reasons, a clarification of the 
role of the serotoninergic system in schizophrenia and its interaction with 
dopaminergic and glutamatergic pathways would be an important achievement.
1.3.3. Glutamate hypothesis.
Glutamate is the main excitatory neurotransmitter in the brain, and it binds 
both to metabotropic and ionotropic receptors. The excitatory signalling is 
principally mediated by ionotropic receptors, which are classified into tlmee 
classes named after their specific ligands: AMP A (amino-hydroxy- 5 -methyl-4- 
isoxazole propionic acid), kainate (kainic acid) and NMD A (N-methyl-D-aspartic 
acid). Phencyclidine (PCP), mainly a NMD A non-competitive antagonist, induces
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a psychotic response that closely resembles the symptoms of schizophrenia (see 
chapter 5) (Lnby et a l, 1959). In contrast to amphetamine and LSD, PCP can 
mimic not only positive symptoms, but it can also cause negative symptoms and 
cognitive impairment, producing a psychosis so close to schizophrenia that is 
diagnostically difficult to differentiate (Olney et a l, 1999). Ketamine, another 
NMDA antagonist, induces an array of symptoms resembling schizophrenia more 
h'equently in adults than in children; this compound interestingly mimics the age- 
dependent vulnerability to the illness (Farber et al, 1995). Consequently, a 
hypofunction of NMDA receptors has been proposed as an interesting model of 
the disease.
Some changes of the glutamatergic system have been reported in 
schizoplirenia: a decreased concentration of glutamate in the cerebro-spinal fluid 
(Kim et a l, 1980) and altered expression of AMP A and KA receptors in the 
prefrontal cortex and hippocampus (Deakin et a l, 1989; Kerwin et a l, 1990). No 
consistent abnormalities in NMDA receptor density have been shown, but the 
subunit composition has been shown to be altered in the hippocampus, where a 
relative decrease of the NRi subunit has been reported (Gao et a l, 2000). NMDA 
receptors lacking the NRi subunit are non-functional, so this finding suggests a 
hypofunction of glutamatergic system in the hippocampus (Goff et a l, 2001).
Although NMDA receptors are not the main site of action for antipsychotics, 
recent research reports that some drugs affect glutamatergic neurotransmission. 
Clozapine, but not haloperidol, indirectly enliances NMDA-receptor-mediated 
neuro transmission in rat prefrontal cortical neurons in vitro (Arvanov et al, 
1997). Indeed both clozapine and the selective 5 -HT2a antagonist M l00907 
interfere with the PCP-induced blockade of NMDA receptors in rat prefrontal 
cortex (Wang et a l, 1998), suggesting a role for serotoninergic system in the 
NMDA hypofunction model. Furthermore, it has been shown that clozapine may 
entrance the glycine modulatory site occupancy on NMDA receptors; the 
occupation of this site is necessary for the glutamate-mediated activation of the 
ionotropic receptor (Coyle et a l, 2002). These findings suggest that the ability of 
atypical antipsychotics to ameliorate negative symptoms and cognitive behaviour
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could be related to their interaction with the glutamatergic system (Goff et al,
2001). Dopaminergic neurotransmission also seems to be involved in the 
modulation of NMDA receptors: the Dz receptor blockade by antipsychotic drugs 
promotes the expression of the NRi subunit of NMDA receptor in rats (Leveque 
et al, 2 0 0 0 ).
For many years the focus of schizophrenia research has been on dopaminergic 
hyperfunction and anti-Da activity of antipsycho tics. However the dopamine 
hypothesis does not explain important features of the disease such as the negative 
symptoms and cognitive impairments; in fact amphetamine only induces positive 
psychotic symptoms, and typical D2 antagonist are not effective in ameliorating 
negative symptoms or cognitive deficits. The glutamate hypothesis is considered 
more useful than the dopamine hypothesis for several reasons: the PCP-induced 
psychosis closely resembles schizophrenia; and the administration of this drug to 
animals produces a robust model of the disease (see section 5.2). In particular the 
glutamate theory and PCP models are very useful to study negative symptoms and 
cognitive impairment, and they might help to identify new pharmacological 
targets for improved therapy. Nevertheless, it is unlikely that changes in 
glutamatergic neurotransmission alone are the cause of such complex symptoms 
and macroscopic alterations: D2 antagonism is still important for the effectiveness 
against positive symptoms, and atypical drugs such as clozapine have a multi­
receptor pharmacological profile. Many experimental evidences support the 
hypothesis of a complex neuropathological scenario, where the glutamatergic 
system is central, but structural changes and interactions with other 
neurotransmission systems must also be considered.
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1,3.4. GABAergic neurons: their interaction with dopaminergic and 
glutamatergic systems and role in schizophrenia.
The excitatory function of glutamatergic neurons can regulate inhibitory 
pathways by synapsing on serotoninergic, noradrenergic and GABAergic neurons, 
which express NMDA receptors. Furthennore, some GABAergic neurons have an 
inhibitory feedback function, so the glutamatergic primary neurons can regulate 
their own firing through the activation of NMDA receptors on the GABAergic 
interneurons (Olney et a l, 1999). In such a model, an impairment of NMDA- 
receptor-mediated neurotransmission simultaneously affects inhibitory control 
over multiple excitatory pathways in relevant regions of brain (Olney et al,
1999).
GABAergic neurons also express dopamine receptors and could be indirectly 
involved in the action of antipsychotics. Specifically D4 receptors, one of the 
pharmacological targets of clozapine, are principally located on GABAergic 
neurons including the chandelier cell subset (see below) (Mrzljak et a l, 1996).
Reduced activity and expression of glutamic acid decarboxylase (GAD67), the 
synthetic enzyme for G ABA, have been demonstrated in the PFC of 
schizoplrrenic brains (Akbarian et a l, 1995). GAD65, another isoform of the 
glutamic acid decarboxylase, also shows reduced expression in the cerebellum of 
schizophrenic patients; however this alteration is also present in bipolar dosorder 
and depression (Fatemi et al, 2005). Impaired re-uptake and release of GAB A in 
schizoplirenia (Reynolds et a l, 1990) confirm the importance of the GABAergic 
system. Interesting changes have been found in a particular subset of GABAergic 
neurons named chandelier cells. These neurons regulate the excitatory output of 
pyramidal glutamatergic neurons in schizophrenia-related regions of the brain 
such as the PFC. Their modulatory action is particularly effective as they synapse 
only on the axon initial segment of pyramidal neurons, close to the generation site 
of the action potential (DeFelipe et a l, 1985). A decrease in the density of 
chandelier cell axons in the PFC has been shown in schizophrenia (Lewis, 2000),
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suggesting that impaired inliibitory control by specific GABAergic neurons could 
be pivotal in schizoplmenia neurochemistry. Moreover it has been shown that 
expression of parvalbumin, a calcium-binding protein localized in the chandelier 
cells, is is lower in the PFC of schizophrenics (Beasley et al, 2002; Hashimoto et 
al, 2003).
Recent findings on GABAergic system involvement in schizophrenia enlarge 
the outlook on the complex neurochemistry of this disease. It is becoming more 
and more clear that the glutamatergic hypothesis has to be integrated with 
information about other neurotransmission pathways that could influence the 
neural circuitry affected by schizoplirenia. In this scenario GABAergic neurons, 
particularly the chandelier subset, play a key role in the modulation of excitatory 
transmission both within and between brain regions affected by neuropathological 
abnormalities, such as prefrontal cortex and thalamic nuclei (Lewis, 2000). The 
studies performed by Lewis and co-workers suggest that schizophrenia is 
associated with a specific dysfunction of the connectivity between inhibitory 
chandelier cells and excitatory pyramidal neurons in the PFC (reviewed by Lewis 
et al, 2005). The evidence supporting this hypothesis include reduced expression 
of GAD67, G ABA transporter 1 (GATl) and parvalbumin in the chandelier cells 
of schizoplirenic PFC, while the expression of these genes remain uchanged in 
other subtypes of inliibitory interneurons (Hashimoto et al, 2003). Moreover, 
Pierri et al (2003) showed that the expression of the a 2  subunit of the GABAa 
receptor is increased in the axon initial segment of pyramidal neurons in 
schizophrenic PFC, where chandelier cells establish synaptic comiections. The 
upregulation of GABAA(% 2 could be an adaptative response to compensate the 
deficient release of G ABA from the chandelier cells synaptic terminals (Lewis et 
al, 2005),
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1.4 Animal models of schizophrenia
1.4.1 Modelling prefrontal cortex dysfunction in rats: limitations and 
advantages
One of the difficulties that schizophrenia research has to face is the limited 
availability of post mortem human tissue. Moreover even when the samples size is 
large enough, questions usually arise about the possibility that the results are 
influenced by the long pharmacological treatment that patients usually undergo. 
Indeed long years of therapy and superimposed pathologies or ageing can make 
the interpretation of data very complex. For these reasons, animal models of 
schizoplirenia are very useful to provide the right amount of tissue for the studies 
under rigorously controlled conditions.
On the other hand, animal models of schizophrenia, and, more generally, of 
psychiatric diseases, are very difficult to assess. The first obvious reason is that 
schizophrenia pathology involves the most developed functions of human brain, 
such as complex social interactions, perceiving and expressing emotion, thought 
and language. These functions are less developed or completely absent in other 
mammals, included the commonly used experimental animals, such as rodents. 
Another reason is the lack of knowledge about the aetiology of schizoplurenia. In 
fact it is very difficult to provoke in healthy animals a syndrome of which we do 
not know the pathological basis.
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1.4.1.1 The prefrontal cortex in humans and rodents: anatomical heterogeneity 
and functional homologies
The complexity of schizophrenia is reflected by the number of brain regions 
that have been associated with this disease in studies investigating 
neuropathological, neurochemical and functional alterations (see sections 1.3 and
1.4). These findings suggest that the symptomatolgy of schizophrenia is 
dependent on multiple alterations in different brain regions. Nevertheless, it is 
clear that the dorsolateral prefrontal cortex play a key role in this disease (see 
sections 1.3 and 1.4), therefore it is necessary to consider whether it is realistic to 
model human prefrontal cortical function in animals.
The anatomical and functional correspondence between human and rodent 
brain stmctures has often generated controversies in the scientific community, 
especially when concerning regions responsible for the higher primate-specific 
functions (Brown et al, 2002). hi fact, the prefrontal cortex is arguably the most 
unique region to the human brain, as it underlies the most evolved functions such 
as attentional control, decision-making, and temporal organisation of behaviour 
(Shallice et al, 1998; Damasio, 1998; Fuster, 2000).
Anatomically, it is evident that there are important differences between the 
primate brain and the rodent brain at the level of the dorsolateral prefrontal cortex. 
In primates, this region is defined by the incoming projections from the 
mediodorsal thalamic nucleus (Rose et al, 1948). In rats, the mediodorsal nucleus 
projects to the medial and orbital prefrontal cortex, but not to the dorsolateral 
regions; therefore rats do not have a brain region that matches the human 
dorsolateral prefrontal cortex by neuro anatomical criteria only (Brown et al,
2002). On the basis of this observation, one could disregard any research 
attempting to use rodents as a model of higher cognitive functions or psychiatric 
conditions that involve the dorsolateral prefrontal cortex, such as schizophrenia. 
Nevertheless, comparative neuroscience between primates and rodents cannot be 
limited to the mere neuroanatomy, but must also take into account functional
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analogies and homologies. In this specific case, it is necessary to question whether 
the rat medial and orbital prefrontal cortex may underlie functions that are 
equivalent to those localised in the human dorsolateral prefrontal cortex. If the rat 
shows complex behaviour that would require the activation of the dorsolateral 
prefr ontal cortex in primates, then such a functionally homologous region should 
exist in the rodent brain (Brown et al, 2002).
Modelling prefrontal cortical functions in rat is very difficult for a number of 
reasons, including obvious species-specific features such as language and verbal 
reasoning. Also, it is important to specifically adapt the tests to the species in 
order to analyse the cognitive substrate of behaviour. Many studies in the 
literature are designed to analyse how the prefrontal cortex affects processes 
dependent on working memory. Interestingly, it has been demonstrated that 
specific damage to the rat medial prefrontal cortex causes behavioural deficits in 
working memory-dependent tasks that are similar to those observed in primates 
with lesioned dorsolateral prefrontal cortex (de Bruin et al, 1994; Joel et al, 
1997; Kesner, 2000). These findings suggest that, similarly to primates, 
behavioural flexibility is severely affected in rats with lesions at the level of the 
prefrontal cortex.
Impaired behavioural flexibility is also thought to have a role in the attentional 
deficits shown by prefrontal cortex lesioned rats (Brown et al, 2002). The five- 
choice serial reaction time task is a popular test to measure selective attention in 
which the rat is presented a visual cue in one of five possible locations; a number 
of parameters such as the duration of the stimulus can be varied to modulate the 
attention load required for the task (Carli et al, 1983). This important 
experimental approach has been used to show the attentional deficits of rats with 
lesioned prefrontal cortex (Muir et al, 1996; Granon et al, 1998). Importantly, 
the impairments observed were not compatible with perceptual attention 
difficulties, but they suggested a deficit in behavioural flexibility (Miner et al,
1997).
Behavioural flexibility is a key function of the human dorsolateral prefr ontal 
cortex that is relevant to the symptomatology of schizopluenia (refer to section
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1.1.4). Deficits of this important function have been shown to underlie the 
impaimients in reversal learning observed in rats with lesioned prefrontal cortex 
perfonning visual discrimination tasks (Bussey et al, 1997). In particular, these 
deficits seem to affect the behaviour based on “higher order rules”, which 
involves the abstraction of associations to formulate rules necessary for strategic 
goal-directed behaviour (Kesner, 2000). The Wisconsin Card Sort Test is one of 
the most important tasks employed to study the abstraction of higher order rules in 
humans; interestingly, schizophrenic patients show performance impairments in 
this test (Park, 1997). It is possible to use a formally equivalent attentional set- 
shifting task to analyse this type of behaviour in rats (Bin'ell et al, 2000). hi this 
test rats are trained to search for a food reward that is hidden in a bowl under a 
digging medium. The animals are presented with two bowls, only one of which 
contains the reward. The animals are faced with a choice that has to be made on 
the basis of multiple parameters, such as odour, type of digging medium and 
texture. The test involves a series of sessions that allow analysis of reversal 
learning, intra-dimensional and extra-dimensional shift. This experimental 
approach led to the demonstration that rats, in a similar manner to monkey and 
humans, are able to process the stimuli in order to foixn higher order rules 
necessary for complex strategic behaviour (Birrell et al, 2000). It has been shown 
that specific lesions of the medial and orbital prefrontal cortex in the rat brain 
cause impairments of the attentional set shifting; in particular, the medial 
prefrontal cortex is directly linked to the extradimensional shift of the attentional 
set (attentional flexibility), whereas the orbital part is associated with reversal 
learning (Binell et al, 2000) (see also section 3.1.1).
The observations discussed above suggest that although the rat brain does not 
have a region that is anatomically analogous to the human dorsolateral prefrontal 
cortex (Preuss, 1995), these animals show some aspects of the complex behaviour 
that requires the activation of this region in primates. Lesion studies clearly show 
that the medial and orbital subregions of the rat prefr ontal cortex are necessary for 
these functions; therefore they may be considered at least partially equivalent to 
the primate dorsolateral prefrontal cortex from a functional standpoint (Brown et
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al, 2002). This information supports the study of rat prefrontal cortex as useful 
model of cognition, especially to complement research on schizophrenia, as the 
studies performed using human tissue can be affected by limited availability of 
material and several confounding factors (see above). Still, it is important to 
acknowledge that studies on the rat prefrontal cortex cannot aim to model the 
functions of the primate dorsolateral prefrontal cortex in a comprehensive way, 
but they rather constitute a simplified model of cognition with common key 
features that allow the extrapolation of useful information about human 
behaviour, cognition and pathological alterations (Brown et al, 2002).
Taking in consideration the issues discussed above, a number of different 
animal models of schizophrenia have been developed. None of them is able to 
mimic comprehensively the complex aixay of schizoplmenia features, but animal 
models are undoubtedly successful in reproducing some important biological and 
behavioural characteristics of this illness. The schizophrenic-like alterations in 
animals are usually ameliorated by antipsychotic treatment; therefore animal 
models are particularly useful to study drug action and to predict new possible 
pharmacological targets.
Three criteria are usually considered to evaluate the suitability of an animal 
model: construct validity, face validity and predictive validity. Construct validity 
is the ability to emulate the aetiological basis of the disease; face validity criterion 
is defined as the capability to mimic the symptoms of human disease; predictive 
validity criterion is met when drugs that have established effectiveness against the 
human disease, are able to restore the physiological parameters in the animal 
model, whereas other classes of drugs should be inactive.
1.4.2. Environmental animal models of schizophrenia.
Some features of schizophrenia are reproduced in animals by specific 
enviromnental manipulation. The types of enviromnental stress used to model 
schizophrenia are usually designed to mimick some proposed aetiological factors 
for the disease; examples include isolation-rearing (Valzelli et al, 1977), pre­
weaning non-handling (Shalev et al, 1998), hypoxia (Schwarzkopf et al, 1992) 
and prenatal maternal malnutrition (Morgane et al, 1993). Isolation-rearing 
produces a number of relevant changes such as enhanced DA-agonist induced 
stereotypic movement and spontaneous hyperactivity (Lillrank et a l, 1995). 
Moreover, similarly to schizophrenic patients, isolated-reared animals show 
impaired pre-pulse inhibition (PPI) (Cilia et al, 2001). This test analyses deficits 
in sensorimotor gating, measuring the ability to modify a startle response to a loud 
tone. The startle response is normally attenuated by a low volume “warning 
sound”, the pre-pulse; this inliibition is clearly impaired in schizophrenic patients. 
Interestingly, the abnormalities caused by isolation-rearing are reversible by 
atypical antipsichotics (Bakshi et al, 1998).
Hypoxia and prenatal maternal malnutrition are also used to provoke 
schizophrenic-like behaviour. Consistent with the dopamine hypothesis these 
environmental models are associated with neurochemical changes in the 
dopaminergic system (Lillrank et a l, 1995).
Environmental models are useful to investigate the neurobiological and 
behavioural changes caused by environmental stressors that could be involved in 
the aetiology of schizophrenia. Also, these animal models might be useful to 
analyse the gene-environment interactions and how stressors influence gene 
expression. Nevertheless, the construct validity of these models remains limited, 
since no environmental stressor alone has been proved to cause schizophr enia.
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1.4.3 Lesion models of schizophrenia.
Lesion models are based on specific damage to brain regions that are crucial to 
the functions impaired in schizophrenia. Although this approach cannot reproduce 
the aetiology of the disease, lesion models can be useful to understand the 
importance of specific brain regions to cognition and behaviour. Also, models 
based on specific neuronal damage in the foetus and newborn animals are relevant 
to the neurodevelopmental aspect of schizophrenia.
An example of neuroselective induced toxicity relevant to schizophrenia is the 
foetal administration of methyl-azoxymethanol acetate (MAM) (Johnston et al, 
1988). This compound selectively destroys rapidly dividing neurons, causing a 
disruption of the eytoarchitecture of the prefrontal cortex and the hippocampus. 
The behavioural abnormalities observed in this model include hyperactivity and 
cognitive impairment (Johnston et al, 1988). Interestingly, a recent study reported 
that the hippocampal parvalbumin-containing intemeurons are decreased in the 
MAM model (Penschuck et al, 2006).
Another well-known lesion model with relevance to neiurodevelopment is 
based on neonatal ventral hippocampal insult. This model mirrors some 
neurochemical abnoraialities of schizophrenia. In fact, neonatal hippocampal 
lesions modify dopamine levels in key areas such as the prefrontal cortex and 
enhance dopamine-mediated behaviour (Lipska et al, 1992). This model is 
mainly relevant to the dopamine hypothesis of schizophrenia, and it can be used 
in combination with amphetamine exposure. The main behavioural alterations 
include hyperactivity, impaired pre-pulse inhibition and deficits in spatial learning 
and working memory (Lipska et al, 1995; Chambers et al 1996). It is interesting 
that the behavioural abnormalities observed in the hippocampal lesion model are 
strain dependent, suggesting a relevance to the contribution of genetic factors to 
the neuropathology of schizophr enia (reviewed by Wong et al, 2003).
The medial prefrontal cortex is another target area for lesion model of 
schizophrenia. Specific excitotoxic lesions are induced by intracranial injection of
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ibotenic acid in neonatal rats. Similarly to the ventral hippocampal lesion 
approach, this model reproduces alterations of the dopaminergic system (Flores et 
al, 1996). The medial prefrontal cortex and ventral hippocampal lesion models 
target two of the areas that are most affected in the schizoplirenic hrain (see 
section 1.3). It is important to note that these regions are reciprocally 
interconnected, therefore lesions in the hippocampus will influence prefrontal 
cortical function and vice versa (Carr et al, 1996).
1.4.4. Pharmacological models of schizophrenia.
The administration of psychotomimetics to animals induces biochemical and 
behavioural changes that can mimic those ohseiwed in the human psychiatric 
disease.
Phanuacological models of schizophrenia have extremely limited construct 
validity. Face validity is also limited, hut a number of tests confirm 
schizoplrrenic-like behaviour and biological changes in these models. The third 
criterion, predictive validity, is often met, therefore pharmacological studies 
largely benefit hom the analysis of these models.
1.4.4.1 Dopaminergic agents
Consistent with the dopamine hypothesis (see section 1.4.1), animal models 
based on the administration of direct or indirect dopamine agonists such as 
apomorphine and amphetamine are useful for predicting the activity of 
compounds against positive symptoms of schizophrenia. The face validity of 
dopaminergic models is supported by a number of behavioural tests. Dopamine 
agonists cause hyperlocomotion and stereotypy (Kokkinidis et a l, 1980).
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Although it could be argued that schizophrenic patients do not always show these 
behavioural disturbances, antipsychotics attenuate amphetamine-induced 
stereotypic behaviour. PPI is also disrupted in this model, as well as in 
schizoplirenics (Swerdlow et a l, 1998). The PPI deficit parameter is corrected by 
antipsychotics; furthermore this response is correlated both to antipsychotic 
potency and D2 receptor affinity (Marcotte et al, 2001),
Behavioural tests and antipsychotics action support the face validity and the 
predictive validity of this dopamine model. Nevertheless, the hyperdopaminergic 
state is not associated with negative symptoms in humans, therefore limiting the 
usefulness of this model to the study of positive symptoms.
1.4.4.2 Serotoninergic agents
The effects of the two major classes of hallucinogenic dmgs, indoleamines 
(LSD) and phenethylamines (mescaline) are mainly due to their interaction with 
5 -HT2A receptors. The psychotomimetic properties of these drugs in humans are 
well known; moreover, the affinity of atypical antipsychotics such as clozapine 
for the 5-HT2A receptors supports the role of the serotoninergic system in the 
neurochemistry of schizoplirenia (see section 1.4.2). Administration of LSD to 
rats is known to cause PPI deficits (Geyer et al, 1987); also, it has been 
demonstrated tbat both LSD and mescaline can alter glutamatergic 
neurotransmission in rats (Yamada et al, 1999). However, despite the 
acknowledged involvement of the serotoninergic system in schizophrenia, the 
usefulness of the administration of 5-HT2a agonists as a model of the disease is 
controversial. In fact, chronic administration of LSD induces behavioural 
habituation, which is not compatible with schizoplnenia (Marcotte et al, 2001) 
and other pharmacological models can induce a broader range of schizoplirenia- 
like neurochemical and behavioural alterations (5.1.3).
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1.4.4.3 Glutamatergic transmission inhibitors
The psychotomimetic effect of NMDA antagonists is perhaps closer to 
schizophrenia than any other psychoactive compound. Unlike amphetamine and 
LSD, phencyclidine-induced psychosis can mimic both the positive and negative 
symptoms and cognitive deficits in humans, therefore the glutamatergic model 
promises to be more comprehensive than the dopaminergic one (reviewed by 
Jentsch etal, 1999). Indeed, phencyclidine (PCP) models are widely used, and 
their face validity is demonstrated by several behavioural tests. For details on PCP 
pharmacology and PCP models of schizophrenia refer to section 5.1.
1.4.5. Genetic models of schizophrenia.
Another strategy to reproduce schizoplirenic symptoms in animals is genome 
manipulation. It is clear that genes play a key role in the aetiology of this disease 
(see section 1 .6 ), therefore genetic animal models promise new insights. 
Knockout mutants are the most common genetic models. As schizophrenia is a 
complex polygenic disease, it is unlikely that the deletion of a single gene can 
reproduce comprehensively the features of the human disease. Nevertheless, some 
genes are known to be very influential. It would be interesting to understand the 
behavioural and biological consequences of their deletion, and how they interact 
with other relevant genes.
Consistent with the dopamine hypothesis and the glutamate hypothesis, the 
disruption of key genes for neurotransmission such as the dopamine transporter 
and the NR-1 subunit, of the NMDA receptor, causes schizophi enia-like biological 
and behavioural changes (see below). The dopamine transporter knockout (DAT- 
KO) mutant mice show hyperlocomotion and increased stereotypic behaviours 
(Ralph et a l, 2001; Spielewoy et a l, 2000), as well as deficits in sensorimotor
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gating (Ralph et al, 2001). Neuroleptic treatment reverses the hyperlocomotion, 
showing that this model has a degree of predictive validity. The NR-1 knockdown 
(NRl-KD) mice also show increased locomotion and stereotypy; in addition 
social interaction is consistently impaired (Molm et a l, 1999). Typical 
antipsychotics reverse the hyperlocomotion, while clozapine ameliorates the 
impairments in social behaviour (Molm et a l, 1999).
The deletion of some genes abnormally expressed in schizophrenia can 
provoke histological and cytoarchitectural abnormalities similar to those observed 
in schizoplirenia. The reeler mouse, which has the Rein gene mutated, is affected 
by abnormal neuronal migration and growth during development (Curran et a l,
1998). Mutation of the Dabi gene causes similar cytoarchitectural abnormalities 
(Rice et a l, 1998), suggesting that these two genes are involved in 
neurodevelopmental processes possibly disrupted in schizoplirenia.
Although these genetic models are far from mimicking all the 
symptomatology of schizoplirenia, they can be useful to highlight the 
consequences of specific alterations in the neuro transmission pathways. The 
advances in linkage and gene expression studies could pave the way to the 
development of new, relevant genetic models. As many genes are involved in 
schizophrenia, it would be as useful, as well as challenging, to create animals with 
a complex genotype producing a schizophrenia-like phenotype. In this way a 
degree of constmct validity could be achieved.
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1.5 Schizophrenia and genes
If the neuropathology of schizoplirenia needs to be clarified, the aetiology of 
this disease is even more obscure. Although a definitive cause of schizoplirenia is 
far from being discovered, it is widely accepted that genetic factors play a very 
important role. The first evidence comes from the epidemiological studies 
performed during decades of research. An invaluable analysis of epidemiological 
studies from different countries, leading to interesting conclusions was perfonned 
by Gottesman (1991).
The average risk for developing schizophrenia is much higher in 
schizoplnenics’ close relatives than in the general population (Gottesman, 1991). 
Furthermore, the higher the genetic correlation with a patient, the higher the risk 
of developing the illness. For instance, monozygotic twins of schizophrenics, who 
share the same genome, have an average risk of 50%; first-degree relatives such 
as patients’ siblings (including fraternal twins) or children have an average risk of 
about 15%; while the risk associated to the general population is 1% (Gottesman, 
1991). hrterestingly, adoption studies show that the average risk does not change 
when children are brought up by healthy adoptive parents rather than by their 
natural, schizoplirenic parents, suggesting that genetic factors are more influential 
than sharing the same stressful enviromnent of a schizophrenic parent 
(Gottesman, 1991). This finding is confirmed by the fact that spouses of patients 
have the same average risk as the general population. Although epidemiological 
data seem to support a genetic model of the disease, the pattern of familial risk 
demonstrates that schizophrenia is not caused by a single gene mutation inherited 
according to the simple Mendelian model; but it is rather due to a multifactorial- 
polygenic condition probably combined with enviromnental factors.
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1.5.1. Is schizophrenia correlated with specific gene alterations?
Numerous attempts to identify schizophrenia-susceptibility genes by linkage 
and association studies have led to interesting but often contradictory results (see 
chapter 6 ). The complexity of the neuropathology of schizophrenia and the 
heterogeneity of the schizoplirenifoiin phenotypes contribute to the difficulties 
encountered by the researchers exploring the genetics of this disorder. However, 
the genetic approach may have the advantage of identifying genes that are 
necessarily involved in the aetiology of the disease, rather than being secondary 
alterations caused by pathological processes or phamiacological treatments (Ross 
et ah, 2006).
Although the results of studies based on a genetic approach remain difficult to 
inteipret due to the many inconsistencies, recent meta analysis have contributed to 
clarify the useful information reported in the single studies, (see chapter 6 ) 
(Badner et al, 2002; Lewis et al, 2003; Harrison et al, 2005). Interestingly, the 
data available from the literature convincingly shows that schizoplirenia is linked 
to some genes that are possibly involved in the neurochemical changes observed 
in this disease.
Straub et al (2002) first showed that the gene encoding for dysbindin is 
significantly linked to schizoplirenia. This finding has been replicated in 
subsequent studies (Ross et al, 2006) Dysbindin is localised in the presynaptic 
terminals and may have a role in signal transduction.
Neuregulin-1 is a strong candidate gene for schizophrenia (Harrison et al, 
2006; Stefansson et a l, 2003; Stefansson et a l, 2 0 0 2 ); neuregulin- 1  is present in 
glutamatergic synapses and has an important role in neuro develop ement as it is 
involved in neuron migration and cellular differentiation. The involvement of 
neuregulin- 1  in the neuropathology of schizophrenia is one of the most consistent 
findings from genetic studies and is supported by gene expression data (Law et 
al, 2006).
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The COMT (Catechol-O-methyltransferase) gene has also been shown to be 
associated to schizophrenia (Kunugi et a l, 1997; Li et a l, 2000; ShiJ&nan et al,
2002). This gene encodes for the enzyme responsible for the clearance of 
dopamine from the synaptic teiminal; therefore it could be directly involved in the 
neurochemical mechanisms underlying the neuropathology of schizophrenia 
(Craddock et al, 2006; Tunbridge et al, 2006).
Another interesting finding is the disruption of the gene DISCI (Disrupted in 
schizoplirenia) due to a chromosomal translocation identified in a Scottish 
population affected by schizoplu'enia, schizoaffective disorder and major 
depression (Blackwood et a l, 2001; Millar et a l, 2001). Although the exact 
function of DISCI is unclear, this gene could be involved in brain development, 
synaptic transmission and plasticity (Ross et al, 2006). hiterestingly, the study of 
the Scottish phenotype using imaging and neuropsychology techniques suggests 
that DISCI could be particularly relevant to cognitive endophenotypes, as it is 
associated with altered hippocampal function and altered working memory in this 
group of patients (Callicott et al, 2005; Cannon et al, 2005; Porteous et al, 
2006).
The findings briefly summarised above are among the most consistent data 
available to date from genetic studies on schizoplirenia (see also chapter 6). This 
type of approach has generated a vast amount of useful data whose discussion is 
beyond the scope of this thesis. Many of these results have often proved to be 
impossible to reproduce, even though the inconsistency of data from genetic 
studies should not induce excessive scepticism. In fact, variability may reflect the 
fact that schizophi'enia is a heterogeneous polygenic disorder. Nevertheless, in this 
scenario it is clear that the identification of susceptibility genes and, above all, 
their interaction with other genes and environmental factors cannot be found by 
genome-wide scans alone, but requires biological evidence from studies analysing 
their impact on the neuropathology of schizoplirenia at different levels (Hanison 
et al, 2005).
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1.5.2. Microarray analysis of gene expression in schizophrenia
Gene expression studies have given an important contribution to the 
understanding of molecular pathology in psychiatric disorders (reviewed by 
Iwamoto et al, 2006; Mimics et al, 2006). This approach is very useful to 
complement the information from genetic studies. In fact, expression changes in 
human post mortem brain tissue can be due not only to genetic abnormality, but 
also to environmental factors and secondary indirect causes. In a complex 
condition such as schizophrenia, the neuropathological phenotype results from a 
combination of primary abnoiTnalities and secondary changes (Mimics et al, 
2006). The primary alterations can be a direct consequence of genetic abnormality 
or can have environmental origin. These changes are likely to cause a number of 
secondary downstream alterations that can contribute cmcially to the pathological 
mechanisms (Mimics et al, 2006). As an example, adaptional changes can be 
considered as a subset of secondary alterations reflecting the attempt of the cells 
to re-establish physiological conditions in response to a primary lesion. CuiTent 
knowledge suggests that secondary gene expression changes in the schizoplirenic 
brain greatly outnumber those that are directly caused by polymorphisms in the 
encoding gene (Mimics et al, 2006). Importantly, secondary alterations can be 
very informative, as they can underlie similar pathological processes in patients 
that do not show the same genetic abnormalities.
One of the advantages of gene expression studies over genome-wide scans is 
that the former strategy also allows the analysis of pathological changes caused by 
environmental and secondary factors. However, traditional approaches that allow 
the expression analysis of one or few genes at a time can be severely limiting in 
schizoplirenia research for a number of reasons. Firstly, the neuropathology of this 
disease is likely to be due to small expression changes of multiple genes; 
secondly, the limited knowledge about the aetiology of schizophrenia complicates 
the formulation of hypotheses and the choice of specific candidate genes.
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In this context, the recently developed teclmologies for transcriptome analysis 
based on oligonucleotides microarray can be very helpful, as they allow genome- 
wide scans at the mRNA level in a comprehensive and hypothesis-free mamier 
(see also chapter 3). Micro array analysis has been recently employed for the 
transcriptome profiling of a nimiber of psychiatric conditions such as autism, 
anxiety, major depression, bipolar disorder and schizophrenia (reviewed by 
Mimics et al, 2006). Not surprisingly, some of the data on gene expression in 
schizoplirenic post mortem brain tissue are contradictory probably due to common 
issues such as variability of diagnostic criteria and comorbidity with other 
disorders. Nevertheless, this powerful teclmology has allowed the identification of 
some interesting expression changes of multiple genes belonging to functional 
classes controlling synaptic transmission, energy metabolism and functions of 
non-neuronal cell populations such as oligodendrocytes (Iwamoto et al, 2006). 
Moreover, a number of findings from microarray studies are concordant with 
previous data showing expression changes of genes controlling the GABAergic 
and glutamatergic neurotransmission systems in schizoprenia both at the mRNA 
and protein level (Mimics et al, 2006).
One of the most consistent finding from expression studies in schizoplxrenia is 
the decreased expression of synaptic markers. Interesting data from microarray 
studies demonstrate that the mRNAs encoding for proteins that participate in 
synaptic function, such as synaptophysin, synaptotagmin I, synaptotagmin IV and 
synaptic plasma membrane proteins (SNAP 23 and SNAP 25) are underexpressed 
in the schizophrenic prefrontal cortex (Mimics et al, 2000; Hemby et al, 2002). 
Mimics et al, (2000) also showed that the expression changes reported in their 
microarray study are not likely to be a consequence of pharmacological treatment 
with neuroleptics, as rhesus monkeys clrronically treated with haloperidol did not 
show those alterations.
Interestingly, the expression of genes controlling the mitochondrial energy 
metabolism also seems to be altered in schizoplirenia. Middelton et al (2002) 
showed that transcripts encoding for proteins involved in ornithine and polyamine 
metabolism, mitochondrial malate shuttle system, transcarboxylic acid cycle,
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aspartate and alanine metabolism, and ubiquitin metabolism are underexpressed in 
the schizophrenic prefrontal cortex. Iwamoto et al (2005) also reported 
downregulated expression of genes controlling the mitochondrial metabolism in 
schizophrenia, although this abnormality was not specific as it was also found in a 
group of bipolar disorder patients. Another study that combines data from 
transcriptomics and proteomics approaches conclude that altered expression of 
genes controlling mitochondrial metabolism and oxidative stress can be a 
landmark of the expression profile of schizophrenia (Prabakaran et al, 2004). 
Although the abnormalities summarised above may be present in other psychiatric 
conditions (Iwamoto et al, 2005) and are not likely to be primary deficits, these 
convincing findings show how microarray-based transcriptome analysis can 
contribute to the identification of important characteristics of schizophrenia that 
are not directly related to the neurochemical and neurotransmission alterations.
Recent microairay studies support previous evidence suggesting that white 
matter changes are a feature of schizophrenia (reviewed by Davis et al, 2003). 
Evidence of dowmegulation of oligodendrocyte transcripts in schizoplirenia first 
came from the microarray study performed by Hakak et a l (2001). This group 
reported that 35 genes controlling myelination and oligodendrocyte function are 
underexpressed in the prefrontal cortex of elderly, hospitalised patients. Another 
microarray study also reported underexpression of oligodendrocytic transcripts in 
a younger group of patients (Pongrac et al, 2002), suggesting that this type of 
molecular abnormality is not found in clnonic, elderly subjects only. Further 
evidence of gene expression abnormalities in the oligodendrocites of 
schizoplirenic brains was reported by Tkachev et al, (2003) and Sugai et al 
(2004), suggesting that dysregulation of white matter function and development 
could be a core feature of schizophrenia neuropathology.
Data from transcriptome profiling of schizophrenic post mortem brain tissue 
also contributed to confirm precedent evidence of altered glutamatergic and 
GABAergic neuro transmission systems (Mimics et al, 2006). One of the best- 
documented molecular abnomialities in the schizophrenic prefrontal cortex is the 
altered function of the chandelier subset of GABAergic intemeurons, which show
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specific changes including decreased density of parvalbumin-iminunoreactive 
axon cartridges (Lewis et al, 2000) and dowmegulation of genes controlling the 
biosynthesis of GAB A, such as GAD67 (Akbarian et al, 1995; Lewis et al,
2000) (see also section 1.4.4). Interestingly, the dowmegulation of GAD67 in the 
schizoplnenic prefrontal cortex was also foimd in the microarray study performed 
by Mimics et al (2000). The same study also reported expression changes of the 
glutamatergic system, which showed underexpression of the mRNA encoding for 
the AMPA2 receptor.
Although microarray technology has been applied to schizophrenia research 
only recently, it has already given a substantial contribution to the understanding 
of molecular alterations underlying this psychiatric disease. It is predictable that in 
the near future transriptome profiling will produce even more robust and reliable 
data, following teclniological improvements of the array chips. In fact, the current 
literature reports a mixture of consistent data, such as the findings surmnarised 
above, but also less reliable results that could not be reproduced independently 
(Mimics et al, 2006; Iwamoto et al, 2006). This inconsistency is partially due to 
the variability observed when different microarray platforms are employed for 
transcriptome profiling. However, the new generation of oligonucleotide chips is 
already setting higher standards of reliability (see also section 3.1.4).
On the other hand, it is important to emphasise that the challenge of 
understanding the molecular abnormalities that underlie schizoplirenia cannot be 
resolved by teclniological advances alone, as inconsistency of data from post 
mortem human tissue also depend on a number of other factors. Effect of clnonic 
pharmacological treatment, diagnostic inconsistency, comorbidity of other 
diseases especially in older patients, and diversity between subjects in crucial 
parameters such as age, dmg abuse and post mortem interval are all confounding 
factors that are very difficult, if not impossible to eliminate when analysing 
human brain tissue (Pongrac et al, 2002; Mimics et al, 2004). Obviously, despite 
these issues, transcriptomic profiling of human diseased tissue remains one of the 
strongest methodologies to elucidate the molecular basis of schizoplirenia, 
especially if the findings are supported by evidence from studies based on other
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approaches. In this context animal models can be an invaluable source of material 
to study the molecular basis of specific schizophrenia-like neurobiological and 
behavioural alterations under uniform and rigorously controlled conditions (refer 
to sections 1.4 and 5.1).
Another source of variability in gene expression studies of psychiatric 
disorders is the neuroanatomical and cellular diversity of the brain areas that are 
involved in the neuropathological processes. This issue is particularly relevant, 
because modest changes affecting specific subregions or even cell populations are 
likely to have a great impact on the neurobiological processes, but they are 
difficult to detect when the samples include material from non-relevant 
neighbouring regions. This complication can be potentially overcome using 
advanced methods of sample collection, such as laser-assisted microdissection, 
that allow to perform transcriptome profiling of specific brain subregions or even 
cell populations (refer to sections 3.1.4 and 3.1.5).
Despite the enormous efforts to clarify the aetiology and the neuropathological 
basis of schizoplirenia, many aspects of this disorder remain unclear. However, 
the growing evidence from studies based on different approaches is shedding light 
on important molecular abnoiinalities that lie at the basis of the complex 
symptomatology shown by the patients (Harrison et al, 2005; Ross et al, 2006). 
It cannot be overemphasised that progress in the understanding of schizoplirenia 
molecular pathology can only come from coordinated efforts and integration of 
data obtained using different strategies. While genetic studies and gene expression 
of post mortem brain tissue remain crucial to investigate the molecular alterations 
associated with the human disease, infomiation obtained from animal models is 
an essential integration and is invaluable for the analysis of specific 
neurobiological and behavioural abnormalities (see section 1.4). Identification of 
novel potential drug targets and drug development will also benefit from a better
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understanding of the schizophienia-like molecular abnormalities observed in 
animal models.
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2. M a t e r ia l s  a n d  M e t h o d s
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2.1 Materials
Phencyclidine hydrochloride (PCP) was obtained from Sigma-Aldrich, Poole, 
UK.
Diethyl pyrocarbonate (DEPC), dithiotlireitol (DTT), polyadenylic acid, 
isopentane and poly-L-lysine were all obtained from Sigma-Aldrich, Poole, UK. 
Acetic acid, Amberlite IRN-150L monobed mixed resin, sodium chloride (NaCl) 
and sodium pyrophosphate were all obtained from BDH, Poole, UK. 
Etliylendi aminetetr a- acetic acid (EDTA), methanol, sodium dihydrogen 
ortophosphate (NaH2P0 4 ), di-sodium hydrogen ortophosphate (Na2HP0 4 ) were 
all obtained from Fisher Chemicals, Loughborough, UK. Dextran sulphate was 
obtained from Amersham Biosciences, Chalfont St Giles, UK. 0.9% saline was 
obtained from Baxter Healthcare Ltd, Northampton, UK.
The source of other materials used for histology, immunohistochemistry, 
molecular biology and in situ hybridisation teclmiques is reported in brackets 
within the description of the relevant procedures below.
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2.2 Laser-assisted microdissection/mlcroarray study
2.2.1 Animals and tissue preparation
Male hooded Long Evans rats (Harlan, Oxon, UK) were housed under a 12h 
light/dark cycle, 55% humidity and received standard rat chow and water ad 
libitum. The animals, weighing 290-33Og, were killed by cervical dislocation, 
then decapitated, the brains removed and quickly frozen in isopentane at -42°C. 
The brains were stored at -80°C until further processing. Experimental procedures 
were carried out in accordance with the UK Animal (Scientific Procedures) Act, 
1986 and associated guidelines.
Six rat brains were used to cut 10pm coronal sections in a cryostat (CM1850, 
Leica Microsystems, Wetzlar, Germany) at ~20°C from the following Bregma 
levels according to Paxinos and Watson (1998): 3.7mm, prefrontal cortex and -  
1.4mm, anterior thalamus. The sections were mounted onto PET membrane slides 
(Leica Microsystems), previously treated with RnaseZap (Ambion, Austin, TX, 
USA) for nuclease inactivation. Briefly, the slides were incubated in undiluted 
RnaseZap solution for 5 minutes, and then rinsed with diethylpyrocarbonate 
(DEPC)-treated water.
The DEPC-treated water was prepared by adding 0.1% DEPC (Sigma) to 
deionised water followed by overnight incubation and autoclaving at 120°C. This 
treatment was used to ensure the deactivation of nucleases present in the deionised 
water.
After mounting the sections, the slides were immediately frozen on diy ice, 
avoiding air-drying to preserve morphological integrity. The slides were stored at 
-80°C in a box containing silica gel until further processing.
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Total RNA isolation (2.2.5)
RNA amplification (2.2.6)
Histological staining (2.2.2)
Data acquisition (2.2.10) 
and Analysis (2.2.11)
Labeling (2.2.7), fragmentation (2.2.8) and 
Microarray Hybridisation (2.2.9)
Identification of Prelimbic cortex (PrL), Ventral Orbital cortex (VO), 
Primary Motor cortex (M1) and Reticular Thalamic nucleus (Rt) followed by 
Laser-assisted m icrodissection (2.2.4)
F ig u r e  2 .1
Flow-chart summarisings the steps of the Laser-assisted Microdissection/Microarray 
experimental strategy for gene expression profiling of the rat Prelimbic cortex (PrL), 
Ventral Orbital cortex (VO) Primary Motor cortex (Ml) and Reticular Thalamic nucleus 
(Rt). Refer to sections indicated in brackets for detailed description of each method.
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2.2.2 H istological staining
All the steps of the histological staining procedure were performed under 
rigorous nuclease-free conditions. The Coplin jars used for the fixing and washing 
solutions were baked at 180°C for a minimum of 2 hours to ensure nuclease 
deactivation. The slides were taken from -80°C and immediately fixed in ice-cold 
acetone for 3 minutes. After fixation, the slides were placed horizontally on a 
rack; the staining solution was pipetted onto the sections and allowed to incubate 
for 3 minutes at room temperature. The staining solution consisted of 1% 
toluidine blue (Sigma) dissolved in DEPC-treated water. The solution was filtered 
using 0.2 pm pore size filters (Minisart, Sartorius, Epsom, UK) before use. After 
staining, the slides were washed twice in DEPC-treated water for 15 seconds and 
once in 75% ethanol for 1 minute at room temperature. The stained slides were 
air-dried for 3-5 minutes, stored in a box with silica gel and immediately used for 
the microdissection.
2.2.3 Immuiiohistoehemical staining
Sections adjacent to those used for LMD (10 pm, anterior thalamus level) 
were mounted on poly-L-lysine coated glass slides (previously baked at 180°C 
and coated in a 0.01% poly-L-lysine solution made up in DEPC-treated water). 
The slides were immediately frozen on dry ice until further processing.
Frozen sections were fixed in ice-cold acetone for 3 minutes, then rinsed in 
phosphate buffered saline (PBS: 1.3M NaCl, 70mM Na2HP0 4  and 30mM 
NAH2PO4  in DEPC-treated water). The slides were transfeiTed in a H2 O2 solution 
(0.3 % v/v H2 O2 in methanol) for 10 minutes for quenching of endogenous 
peroxidase. Sections were incubated with normal goat serum (5% diluted in PBS,
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Vector Laboratories, Peterborough, UK) for 5 minutes, followed by incubation 
with anti-GAD65/67 primary antibody (rabbit anti-glutamic acid decarboxylase 
65/67, IgG fraction, Sigma; 1:1000 dilution in PBS) for 10 minutes. Sections were 
washed with a stream of PBS, and then incubated with secondary antibody 
(biotinilated anti-rabbit IgG raised in goat. Vector Laboratories, 1:500 dilution in 
PBS with 3% nonnal goat serum) for 5 minutes. Sections were washed with a 
stream of PBS, then incubated with avidinDH-biotinilated horseradish peroxidase 
complex (ABC reagent, Vector Laboratories) for 3 minutes. Sections were washed 
with a stream of PBS, then incubated with nickel chloride-3,3’-diaminobenzidine 
(DAB substrate kit. Vector Laboratories) for 2 minutes followed by a wash in 
deionised water and air-drying. The dry, stained sections were coverslipped using 
Histomount™ histological mounting medium (National Diagnostics, UK).
2.2.4 Identification of regions and Laser Microdissection
The prelimbic cortex (PrL), the ventral orbital cortex (VO), and the primary 
motor cortex (Ml) were identified on the toluidine-blue stained sections referring 
to the anatomical landmarks reported by Paxinos and Watson (1998). The 
reticular thalamic nucleus (Rt) was also identified referring to Paxinos and 
Watson (1998). Additionally, the exact position of the Rt in the toluidine blue 
stained section was clarified by comparing it to the adjacent immuno-stained 
section (see above). As the Rt is very rich in GABAergic neurones, GAD65/67 
immunoreactivity can be considered a marker for this anatomical region.
Microdissections were perfonned using the Leica AS LMD system (Leica 
Microsystems, Wetzlar, Germany).
The microscope stage and the rack holding the tubes for collection of the 
microdissected samples were cleaned using tissue soaked in RNase Zap (Ambion, 
Austin, TX, USA) to prevent nuclease contamination of the sections.
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The dehydrated stained sections were placed on the microscope stage, and the 
UV laser was used to dissect the region of interest. The procedure was performed 
according to a conservative estimate of the anatomical boundaries to prevent 
contamination of the sample with material from neighbouring regions. All the 
microdissections were performed using the following laser parameters: aperture 
14; intensity 45; speed 2; offset 23 using 4X objective. The microdissected tissue 
was collected by gravity in a sterile tube cap placed underneath the slides 
containing 20 pi of RLT lysis buffer (RNeasy Micro kit, Qiagen, Valencia, CA, 
USA). This method ensured that the tissue would be dissolved in a nuclease- 
deactivating buffer immediately after dissection. After adjusting the volume to 75 
pi with RLT buffer and spimiing to collect the sample at the bottom of the tube, 
the crude lysates were frozen on dry ice. The time elapsed between the staining 
procedure and the collection of the microdissected sample in RLT buffer was kept 
to a minimum (30 minutes maximum) to prevent RNA degradation. For the same 
reason, each section was used for the microdissection of one sample only. Each of 
the 24 samples (four brain regions from six biological replicates) consisted of one 
specific region dissected bilaterally from one stained section. The crude lysates 
were stored at -80°C until RNA isolation.
2.2.5 Total RNA isolation
Total RNA was isolated using the RNeasy Micro kit (Qiagen, Valencia, CA, 
USA). The frozen samples were thawed at room temperature and vortexed for 30 
seconds. 75 pi of 70% ethanol were added to the homogenised lysates. After 
mixing by pipetting, the samples were loaded onto RNeasy MinElute Spin 
Columns (RNeasy Micro kit, Qiagen, Valencia, CA, USA) and centrifuged for 15 
seconds at 10,000 rpm. The flow-through was discarded and the columns were 
washed according to the following procedure: 700 pi buffer RWl (RNeasy Micro
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kit, Qiagen, Valencia, CA, USA) followed by 15 seconds centrifugation at 10,000 
rpm; 500 pi buffer RPE (RNeasy Micro kit, Qiagen, Valencia, CA, USA) 
followed by 15 seconds centrifugation at 10,000 rpm; 500 pi 80% ethanol 
followed by 2 minutes centrihigation at 10,000 rpm. The columns were 
transferred into a collection tube and eluted with 13 pi RNase-free water (Ambion 
Austin, TX, USA) by centrifuging for 1 minute at 13,000 rpm. The volume of 
eluate collected was approximately 11 pi. An aliquot of the total RNA solution 
(2.4 pi) was used for quality assessment performed on the Agilent 2100 
Bioanalyzer using the RNA 6000 Pico Lab Chip kit (Agilent Technologies, Palo 
Alto, CA, USA). The samples were stored at -80°C until further processing.
2.2.6 RNA amplification
In order to obtain enough material for the microarray hybridisation, two 
rounds of linear amplification were performed. The total RNA was linearly 
amplified using the ExpressAit mRNA Amplification kit. Nano Version (Ai'tus- 
Biotech, Hamburg, Germany). This kit employs a teclmology that is a variation of 
the classic linear isothermal amplification strategy based on in vitro transcription 
with T7 RNA-polymerase (Van Gelder et ah, 1990; Ebei*wine et al, 1992). 
Briefly, the original mRNA is reverse-transcribed to cDNA using oligo(dT)s as 
primers, without introducing the T7 promoter. In the following step, double 
stranded cDNA (dsDNA) is generated using a special “Trinucleotide Primer” 
(Box-random-trinucleotide primer), that allows preferential priming near the 3’- 
ends of nucleic acid molecules. At this stage the functional T7 promoter is 
inserted by denaturing the dsDNA, and priming the second strand in reverse 
orientation, using a T7-promoter/oligo(dT). The product of this reaction is a 
dsDNA with a functional T7-promoter at one end and the Box sequence tag at the 
other end. This product can be used as template for the in vitro transcription,
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Round I Round II
2nd strand cDNA synthesis (2.2.6.9) 
Followed by cDNA purification and 
concentration (2.2.6.10)
Array target preparation 
(labelling IVT) (2.2.7)
1st strand cDNA synthesis (2.2.6.7)
Followed by aRNA removal (2.2.6.8)
1st strand cDNA synthesis (2.2.6.1) 
Followed by RNA removal (2.2.6.2)
In vitro transcription (IVT) (2.2.6.5) 
Followed by aRNA purification and 
concentration (2.2.6.6)
2nd strand cDNA synthesis (2.2.6.3)
Followed by cDNA purification and 
concentration (2.2.6.4)
F ig u r e  2 .2
Flow-chart summarisings the steps of the two rounds of RNA linear amplification 
performed in order to obtain enough material for the microarray hybridisation from each 
individual microdissected sample. Refer to sections indicated in brackets for detailed 
description of each step.
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generating amplified antisense RNA (aRNA) with defined sequences at both ends. 
The aRNA can be re-amplified without further shortening of the fragments, as the 
reverse transcription is primed using the Box sequence tag instead of random 
primers. After the second strand synthesis using T7-promoter/oligo(dT) primers, 
the dsDNA can be used as template for the second round of in vitro transcription, 
incorporating biotin-labelled ribonucleotides.
The detailed procedure describing the two-rounds amplification of each 
sample is reported below (see figure 2.2). All reagents were provided with the 
ExpressArt mRNA Amplification kit, Nano Version (Artus-biotech, Hamburg, 
Germany), except for the materials used for the aRNA purification. This 
procedure was performed using the RNeasy Mini kit (Qiagen, Valencia, CA, 
USA). The manufacturers do not specify the concentrations of the compounds in 
the buffers and reagents solutions.
No-template negative control amplifications were carried out in parallel with 
samples. Positive control amplifications to check the performance of the kit were 
also performed using total RNA provided by the manufacturer.
2.2.6.1 First round - First strand cDNA synthesis
The total RNA eluates were thawed at room temperature. 1.0 pi dNTP-Mix 
and 1.5 pi oligo(dT) were added to 7.5 pi total RNA solution (7.5 pi RNase-ffee 
water for the no-template negative controls) and incubated for 4 minutes at 65 °C 
in a themiocycler with heated lid (PGR Sprint, ThermoHybaid, Waltham, MA, 
USA), followed by cooling at 37°C. A mix composed of DEPC-treated water (4 
pi), 5X reverse transcription buffer (4pl), RNase inliibitor (Ipl), and reverse 
transcriptase enzyme (Ipl) was added to the reaction tube. The reaction mix was 
incubated in a thermocycler using the following conditions: 37°C for 5 minutes, 
42°C for 50 minutes, 45°C for 10 minutes, 50°C for 10 minutes and 70°C for 15 
minutes. After incubation the samples were immediately cooled on ice.
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2.2.6.2 First round - RNA removal
The RNA was removed from the hybrid double stranded product by adding a 
mix composed of DEPC-treated water (3 pi), 5X extender buffer (Ipl) and RNase 
(Ipl). The reaction mix was incubated for 20 minutes at 37°C in a thermocycler.
2.2.6.3 First round-Second strand cDNA synthesis
The following mix was added to the reaction tube: DEPC-treated water (14 
pi), 5X extender buffer (4pl), “Trinucleotide Primer” (Ipl), and d-NTP-mix (Ipl). 
The reaction mix was incubated in a thermocycler at 96°C for 1 minute followed 
by cooling at 37°C for 1 minute to allow primers amiealing. A mix composed of 
DEPC-treated water (3 pi), 5X Extender Buffer (Ipl), and Extender Enzyme A 
(DNA polymerase, 1 pi) was added to the reaction tube, followed by incubation at 
37°C for 30 minutes in a thermocycler. At this stage the product consisted of 
dsDNA with the Box sequence tag incorporated in one end. The following steps 
are designed to incorporate the functional T7-promoter in the dsDNA. The 
following mix was added to the reaction tube: DEPC-treated water (3 pi), 5X 
Extender Buffer (Ipl), and Primer Erase enzyme (1 pi). The reaction mix was 
incubated at 37°C for 5 minutes and 96°C for 6 minutes in a thermocycler. The 
tube was immediately placed on ice. After spinning to collect the liquid, 5 pi of 
T7-promoter/oligo(dT) primer were added to the reaction mix, followed by 
incubation in a themiocycler at 96°C for 1 minute and 37°C for 1 minute to allow 
primers amiealing. A mix composed of DEPC-treated water (2 pi), 5X extender 
buffer (2pi), and extender enzyme B (DNA polymerase, 1 pi) was added to the 
reaction tube, followed by incubation at 37°C for 30 minutes and at 65°C for 15 
minutes in a themiocycler. The reaction mix was cooled on ice.
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2.2.6.4 First round -  cDNA purification and concentration
The dsDNA was purified using spin columns (supplied with the ExpressArt 
mRNA Amplification kit) and then concentrated by ethanol precipitation. After 
synthesis, the dsDNA reaction mix was diluted with 350 pi Binding Buffer, and 3 
pi Carrier DNA were added. The solution was loaded onto the spin column and 
centrifuged at 13,000 rpm for 1 minute. The flow-through was discarded and the 
column washed twice with 500 pi Washing Buffer, centrifuging at 13,000 rpm for 
1 minute. The dsDNA was eluted with 50 pi Elution Buffer, incubating for 1 
minute at room temperature and centrifuging at 13,000 rpm for 1 minute. The 
elution step was repeated to maximise the amount of dsDNA extracted from the 
coluimi. The total volume of eluate collected was 100 pi. The dsDNA was 
concentrated by ethanol precipitation. 10 pi Sodium Acetate (3M solution) and 2 
pi Precipitation Carrier (Pellet Paint Co-Precipitant, Merck Biosciences Ltd, UK. 
This reagent was supplied with the ExpressArt mRNA Amplification kit) was 
added to the eluate. After mixing, adding 220 pi absolute ethanol, and incubating 
for 2 minutes at room temperature, the mix was centrifuged at 13,000 rpm for 10 
minutes at room temperature. The supernatant was discarded, and the pellet 
washed with 200 pi 70% ethanol. The sample was centrifuged at 13,000 ipm for 5 
minutes at room temperature, and the supernatant completely removed. The pellet 
was air-dried leaving the reaction tube open for 5 minutes at room temperature in 
a sterile hood to prevent air-borne contamination. The dsDNA pellet was 
dissolved in 8 pi Solubilisation Buffer.
2.2.6.5 First round —In vitro transcription
The dsDNA incorporating a functional T7 promoter was used as template for 
the amplification via in vitro transcription (IVT). A mix composed of NTP mix (8
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1^1), lOX rVT Buffer (2|il), and T7 RNA polymerase (2p,l) was added to the 
dsDNA solution tiom the purifieation/concentration step. The IVT reaction mix 
was incubated overnight at 37°C in a hybridisation oven (Shake hr'Stack, 
ThermoHybaid, Waltham, MA, USA).
2.2.6.6 First round — aRNA purification and concentration
After overnight incubation, 1 pi DNase I was added to the IVT reaction mix, 
followed by incubation at 37°C in a thermocycler. Once the DNA template was 
degraded, the amplified aRNA was purified using the RNeasy Micro kit (Qiagen, 
Valencia, CA, USA). The aRNA solution was diluted with 80 pi RNase-free 
water, then 350 pi RLT Buffer were added. After mixing, 250 pi absolute ethanol 
was added to the solution, which was then loaded onto the spin column. The 
sample was centrifuged at 10,000 rpm for 15 seconds. The flow-thi’ough was 
discarded and the column washed with 500 pi RPE Buffer, centrifuging as for the 
previous step. The washing step was repeated with the same amount of buffer, 
centrifuging at 13,000 rpm for 2 minutes. The aRNA was eluted with 50 pi RNase 
free water, incubating for 1 minute at room temperature and centrifuging at
13,000 rpm for 1 minute. The elution step was repeated to maximise the amount 
of aRNA retrieved from the column. The final elution volume was 100 pi. The 
aRNA was then concentrated by ethanol precipitation. The procedure and the 
reagents are the same employed for the dsDNA concentration (see above). The 
aRNA pellet was dissolved in 5 pi RNase fi'ee water.
2.2.6.7 Second round — First strand cDNA synthesis
All the aRNA synthesised in the first round of amplification was used as 
template for the second round reverse transcription. A mix composed of dNTP-
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mix (1 pi), Box primer (2 pi) and Reaction Additive (2 pi) was added to the 5 pi 
of aRNA solution Rorn the concentration step. The reaction mix was incubated at 
65°C for 4 minutes in a thermocycler, then immediately cooled at 45°C. A mix 
composed of RNase free water (4 pi), 5X Reverse Transcription Buffer (4 pi), 
RNase inhibitor (1 pi) and Reverse Transcriptase enzyme (1 pi) was added to the 
reaction mix, followed by incubation at 45°C for 30 minutes and 70°C for 15 
minutes. After incubation, the sample was immediately cooled on ice.
2.2.6.8 Second round - RNA removal
This step was performed as described for the first round of amplification.
2.2.6.9 Second round — Second strand cDNA synthesis
A mix composed of RNase fr ee water (10 pi), 5X Extender Buffer (4 pi), T7- 
promoter/oligo(dT) primer (5 pi) and dNTP-mix (1 pi) was added to the reaction 
mix, followed by incubation at 96°C for 1 minute and 37°C for 1 minute to allow 
the primers to anneal. A mix composed of RNase free water (3 pi), 5X Extender 
Buffer (1 pi) and Extender Enzyme B (DNA polymerase, 1 pi) was added to the 
reaction mix and incubated at 37°C for 30 minutes and 65°C for 15 minutes in a 
thermocycler. After incubation, the sample was immediately cooled on ice.
2.2.6.10 Second round — cDNA purification and concentration
The reaction solution was diluted with 275 pi Binding Buffer and 3 pi Carrier 
DNA was added. This mixture was loaded onto a spin column. The rest of the 
procedures of purification and concentration were performed as described for the
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first round of amplification. The dsDNA pellet was dissolved in 8 pi 
Solubilisation Buffer and frozen at -80°C until further processing.
2.2.7 Array target preparation and purification
The dsDNA synthesized in the second round of linear amplification was used 
as template for the labelling via in vitro transcription. The labelling IVT is in fact 
the last step of the amplification procedure; at the same time the product of this 
reaction is the biotin-labelled aRNA needed for the microarray hybridisation. The 
labelling IVT is essentially an ordinary in vitro transcription reaction performed 
using biotin-labelled ribonucleotides. The labelling IVT was performed using the 
GeneChip IVT Labelling Kit (Affymetrix, Santa Clara, USA). All reagents were 
provided with the GeneChip IVT Labelling Kit. The purification of the labelled 
aRNA was performed using the RNeasy Mini kit (Qiagen, Valencia, CA, USA). 
All the buffers used for the purification were supplied with this kit. The 
manufacturers do not specify the concentrations of the compounds in the buffers 
and reagents solutions. The labelling IVT and purification steps were perfoimed 
for no-template negative controls in parallel with the samples.
4 j L i l  dsDNA fi'om the second round of amplification (50% of the total yield) 
was added to a mix composed of lOX IVT Labelling Buffer (2 jul), IVT Labelling 
NTP mix (6 pi), IVT Labelling Enzyme (2 pi), RNase-free water (6 pi). The 
reaction mix was incubated at 37°C for 16 hours in a thennocycler.
The labelled aRNA was purified according to the same procedure described 
for the purification of the first round IVT product (see above). The labelled aRNA 
was eluted in 30 pi RNase-fi'ee water. Aliquots of the eluate from the samples and 
the negative controls were used for the spectrophotometric quantification 
(NanoDrop, Wilmington, USA) and the quality assessment (Agilent 2100
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Bioanalyzer, using the RNA 6000 Pico LabChip kit; Agilent Technologies, Palo 
Alto, CA, USA).
2.2.8 Labelled aRNA fragmentation
The labelled aRNA must be fragmented prior to microarray hybridisation to 
obtain optimal assay sensitivity. The Fragmentation Buffer (Affymetrix, Santa 
Clara, USA) breaks down the full-length aRNA to 35 to 200 base fragments by 
metal-induced hydrolysis.
A volume of eluate from the previous step containing 15 pg aRNA was added 
to 6 pi Fragmentation Buffer. The fragmentation mix volume was adjusted to 30 
pi with RNase-free water. The mix was incubated at 94°C for 35 minutes, then 
immediately cooled on ice. Fragmented labelled aRNA was stored at -20°C until 
hybridisation.
2.2.9 Microarray Hybridisation
24 Rat Genome 230 2.0 GeneChip arrays (Affymetrix, Santa Clara, USA) 
were used for this study, each hybridising a sample derived from the four brain 
regions of six biological replicates. This array platfoim allows the analysis of
30,000 transcripts and variants from over 28,000 well-substantiated rat genes.
The hybridisation cocktail was prepared with the following components: 15 pg 
fragmented labelled aRNA (the entire product of the fragmentation reaction 
described above); 5 pi Control Oligonucleotide B2 (3nM, Affymetrix, Santa
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Clara, USA); 15 pl 20X Eukaryotic Hybridisation Controls bioB, bioC, bioD, cre 
(Affymetrix, Santa Clara, USA); 3 pl herring sperm DNA (10 mg/ml solution, 
Promega, Madison, USA); 3 pl bovine semm albumin (50 mg/ml solution, 
ïnvitrogen Life Teclmologies, Carlsbad, USA); 150 pl 2X hybridisation buffer; 30 
pl DMSO (Sigma-Aldrich); the volume was adjusted to 300 pl with RNase-free 
water. The 2X hybridisation buffer was prepared with the following components:
8.3 mL 12X MES Stock Buffer (1.22M MES, 0.89M [Na+]; MES hydrate and 
MES Sodium Salt were purchased from Sigma-Aldrich), 17.7 mL RNase-fi'ee 5M 
NaCl solution (Ambion, Austin, USA), 4.0 mL EDTA (0.5M EDTA Disodium 
Salt solution. Sigma-Aldrich), 0.1 mL 10% Tween-20 (Pierce, Rockford, USA),
19.9 mL DEPC-treated water. The hybridisation cocktail was heated at 99°C for 5 
minutes, and then cooled at 45°C for 5 minutes in a heat block.
Meanwhile, the arrays were equilibrated at room temperature and filled with 
IX hybridisation buffer, followed by incubation at 45°C for 10 minutes with 
rotation in the hybridisation oven (Affymetrix, Santa Clara, USA). This step was 
performed to ensure that the an'ays would be at the right temperature and 
hydration state for the hybridisation procedure. After incubation, the buffer was 
removed and discarded.
The hybridisation cocktail was centrifuged at 13,000 rpm for 5 minutes to 
remove all the insoluble material. 200 pl of the clarified hybridisation mixture 
was loaded onto the array, followed by incubation at 45°C for 16 hours with 
rotation at 60 rpm.
2.2.10 Microarray washing, staining and scanning
The washing and staining procedures were performed using the automated 
system “Fluidics Station 450/250” (Affymetrix, Santa Clara, USA). The Fluidics
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Station is operated using the GCOS/Microarray Suite software (Affymetrix, Santa 
Clara, USA), which instruct the machine to perfoiin standardised washing and 
staining steps according to the type of array used. Briefly, the fluidic station 
washes the hybridised aiTays using the washing solutions, stains the hybridised 
aRNA by filling the array with the staining solution, expels the staining solution 
and fills the arrays with washing solution for scanning.
The composition of the solutions used for the washing and staining is reported 
below. Non-stringent wash buffer, for 1,000 mL: 300 mL 20X SSPE (3M NaCl, 
0.2M NaHzP0 4 , 0.02M EDTA solution, BioWhittaker/Cambrex, Wokingham, 
UK); 1.0 mL 10% Tween-20 (Pierce, Rockford, USA); 699 mL of DEPC-treated 
water. The solution was filtered through a 0.2pm filter before use.
Stringent wash buffer, for 1,000 mL: 83.3 mL 12X MES stock buffer (see 
previous paragraph); 5.2 mL NaCl, 5M solution (Ambion, Austin, USA); 1.0 mL 
10% Tween-20 (Pierce, Rockford, USA); 910.5 mL DEPC-treated water. The 
solution was filtered tlirough a 0.2pm filter before use.
2X staining buffer, for 250 mL: 41.7 mL 12X MES stock buffer (see previous 
paragraph); 92.5 mL NaCl, 5M solution (Ambion, Austin, USA); 2.5 mL 10% 
Tween-20 (Pierce, Rockford, USA); 113.3 mL DEPC-treated water. The solution 
was filtered through a 0.2pm filter before use.
SAPE stain solution, for one an*ay: 600 pl 2X staining buffer (see above); 48.0 
pl BSA (50 mg/niL solution, Ïnvitrogen Life Technologies, Carlsbad, USA); 12.0 
pl Streptavidin Phycoerythrin (1 mg/mL SAPE solution. Molecular Probes, 
ïnvitrogen Life Teclmologies, Carlsbad, USA); 540.0 pl DEPC-treated water.
Antibody solution, for one airay: 300.0 pl 2X staining buffer (see above); 24.0 
p i BSA (50 mg/mL solution, ïnvitrogen Life Teclmologies, Carlsbad, USA); 6.0 
pl goat IgG (10 mg/mL goat IgG stock solution: 50 mg goat IgG (Sigma-Aldrich) 
resuspended in 5 mL 150 niM NaCl); 3.6 pl anti-streptavidin goat biotinylated 
antibody (0.5 mg/mL solution. Vector Laboratories, Peterborough, UK); 266.4 pl 
DEPC-treated water.
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After washing and staining, the an'ays were scanned using GeneChip Scanner 
3000 (Affymetrix, Santa Clara, USA). This machine is operated using the 
GCOS/Microarray Suite software (Affymetrix, Santa Clara, USA). The data are 
automatically acquired and stored for analysis.
2.2.11 Normalisation and analysis
After scanning, the image data were acquired and analysed using the 
GeneChip Operating Software (GCOS, Affymetrix). This software was also used 
to compute the signal intensities of each probe cell and the present calls.
The normalisation and statistical analysis of data were performed by Dr Pawel 
Herzyk at the Sir Henry Wellcome Functional Genomics Facility, University of 
Glasgow.
The intensity values were normalised according to the Robust Multichip 
Average (RMA) method (Irizarry al, 2003) implemented in module Affy in the 
Bioconductor microarray analysis software (http://www.bioconductor.orgI
The normalised data were analysed to individuate the statistically significant 
expression differences according to the Rank Product (RP) method (Breitling et 
a l, 2004). RP is a non-parametric, statistically rigorous method that is based on 
the calculation of rank products values, used to express the changed probe sets as 
a ranked list. This sophisticated methodology provides a straightforward way to 
select a reliable significance threshold on the basis of the False Discovery Rate 
(FDR), and therefore avoids the large numbers of false-positive results associated 
with traditional multiple t-tests. Additionally, it provides an estimate of the Fold 
Change (FC). The expression pattern of each region was compared to that of all 
the others.
The genes that showed localised expression were clustered in functional 
classes according to the “biological process” gene ontology. Annotations were
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obtained from Netaffx™ Analysis Center thttp : //www. affymetrix. com). Uni Gene 
thttp ://www.nebi.nlm.nih. gov/UniGenef and Gene Ontology
thttp ://www. geneontology.org/1 databases.
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2.3 Confirmation of regional expression by in situ hybridisation
2.3.1 Probe design
[^ S^] labelled oligonucleotide probes were used to validate the regional 
expression pattern of selected genes (table 4.1) predicted by the LMD/microarray 
study. Specific 45mer sequences were designed within the Affymetrix microairay 
target sequence corresponding to the gene of interest. This design strategy was 
chosen to ensure that the probes would detect the same mRNA as the micro array. 
The microarray target sequence was obtained from the NetAff database 
(www.affymetrix.com). The specificity of the 45mer probes was assessed using 
the Basic Local Alignment Search Tool (BLAST) software. The 45mers were 
compared by BLAST to the sequence databases available from the National 
Center for Biotechnology Information (www.ncbi.nlm.nih.gov) and the Ensembl 
project (www.ensembl.org). All the sequences showed specific alignment with the 
transcript of interest. Moreover, the secondary structure of the 45mer probes was 
predicted using the Oligo Calculator software (www.sigma-genosvs.eu.com). The 
sequences were accepted only when the predicted secondary structure was 
classified as “weak” or “moderate”. The HPLC-purified 45mers were purchased 
from Thermo-Electron Corporation, Ulm, Germany.
2.3.2 Oligonucleotide labelling
The 45mer probes were labelled using a modification of the method described by 
Wisden and Morris (1994). 2.0 pl oligonucleotide (5 ng/pl) was incubated with
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2pi terminal transferase reaction buffer (Roche Applied Science), 0.6pl cobalt 
chloride (25mM solution, Roche Applied Science)), 2.5 pl [a-^^S] dATP (specific 
activity 1250 Ci/mmol, NEN-PerkinElmer, UK), and 2.0 pl terminal transferase 
(TdT 25 units/pl, Roche Applied Science) at 37°C for 90 minutes. The reaction 
was stopped by addition of 60 pl DEPC-treated water. Labelled probes were 
purified using the QIAquick™ nucleotide removal kit (Qiagen). The activity of 
the probes was measured using a liquid scintillator counter (2200CA TriCarb, 
Packard). Probes with activity higher than 40,000 DPM/pl were hybridised on test 
sections (see below) to determine their specificity. Probes that produced a specific 
signal and low level of background were selected for hybridisation on 
experimental sections.
Probes were stored at -20°C after adding 4 pl of IM DTT as stabiliser.
2.3.3 Slide preparation and fixation
The brains for the in situ hybridisation (ISH) experiments were obtained from 
six male Hooded Long Evans rats (Harlan, Oxon, UK) according to the protocol 
described in section 2.2.1. The animals’ age and weight matched with that of the 
ones used for the LMD-microan'ay experiment.
10 pm coronal sections were cut in a cryostat (CM1850, Leica Microsystems, 
Wetzlar, Germany) at -20°C from the Bregma levels reported above and thaw- 
mounted on poly-L lysine coated glass slides (previously baked at 180°C and 
coated in a Q.01% poly-L-lysine solution made up in DEPC-treated water). The 
sections were air-dried at room temperature and fixed in a freshly prepared 
formaldehyde solution (4% w/v paraformaldehyde in phosphate buffered saline 
(PBS: 1.3M NaCl, 70mM Na2HP04 and 30mM NAH2PO4 in DEPC-treated 
water) for 5 minutes, followed by washing in PBS for 5 minutes and sequential
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dehydration in 70%, 95% and 100% ethanol (5 minutes each). The slides were 
then stored in absolute ethanol at 4°C until further processing.
2.3.4 Hybridisation and negative controls
Slides were removed from the absolute ethanol and air-dried at room 
temperature. The labelled probe was diluted in hybridisation buffer, and DTT was 
added as preseivative. The hybridisation mixture for each slide was composed of: 
4 pl probe, 16 pl DTT (IM solution in DEPC-treated water) and 200 pl of 
hybridisation buffer (50% deionised foimamide, 4X SSC (3M NaCl, 0.3M sodium 
citrate treated with DEPC), 10% dextran sulphate, 0.5M sodium phosphate, O.IM 
sodium pyrophosphate and 5 mg/ml polyadenylic acid; the final volume was 
adjusted with DEPC-treated water).
The negative control hybridisation mixture was prepared adding 16 pl cold 
probe (50 fold excess to the labelled probe).
The hybridisation mixture was applied to the slides and covered with 
Parafilm® to prevent dehydration. The slides were placed in a petri dish, with 
tissue soaked in 4X SSC to maintain humidity, and incubated at 42°C overnight.
Washing, development and image analysis
After overnight hybridisation, Parafilm® coverslips were removed in IX SSC 
at room temperature, followed by a high stringency wash in IX SSC at 60°C for 
30 minutes. Slides were then washed at room temperature in IX SSC, O.IX SSC, 
70% ethanol and 90% ethanol for 20 seconds each, followed by air-drying at 
room temperature. The slides were placed in X-ray cassettes and exposed to 
Biomax™MR films (Kodak) for 10-20 days.
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Biomax'^^MR films were developed using an automatic developer 
(HyperProcessor, Amersham, Piscataway, NJ, USA).
Quantitative optical density measurements were taken using computer based 
densitometry (MCID-5, InterFocus Imaging Ltd, Linton, UK). The optical density 
was quantified in the regions corresponding to the LMD samples. Non-specific 
signal was subtracted from this value to obtain specific quantitative 
measurements. Non-specific signal was measured in brain regions that did not 
show expression, usually in the white matter. The measurements were defined as 
relative optical density.
2.3.5 Statistical analysis
The optical density values measured in the PrL, VO, Ml and Rt of the 6 
biological replicates were compared using a within-subjects repeated measure 
ANOVA (repeated factor = brain region). In order to analyse the difference 
between regions, simple contrast was applied to the repeated measure ANOVA, 
setting one region as the control category. The control category region for each 
gene was the one identified as overexpressing the gene from the microarray (see 
section 3.3.5). This test allowed verification of whether the differences between 
the control category regions and all the others were statistically significant. The 
tests were performed using the SPSS statistics software package, version 11.0. 
Significance was accepted at P<0.05.
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2.4 Expression of localised genes in a chronic PCP model of 
schizophrenia
2.4.1 Chronic PCP administration (chronic-intermittent PCP model of 
schizophrenia) and tissue preparation
Male hooded Long Evans rats (Harlan, Oxon, UK) were housed under a 12h 
light/dark cycle and received food and water ad libitum. The animals, weighing 
180-220 g were treated with a daily i.p. injection of phencyclidine (PCP 
hydrochloride 2.58 mg/kg in 0.9 sterile saline n=6) or vehicle (0.9% sterile saline 
n=6) for 5 days. The rats were then injected with the same dose of PCP or saline 
on days 8, 10, 12, 15, 17, 19, 22, 24, 26.
72 hours after the last exposure to PÇP (day 29), the animals were killed by 
cervical dislocation and decapitated. The brains were quickly removed and frozen 
in isopentane at -42°C. The brains were stored at -80°C until further processing. 
Experimental procedures were carried out in accordance with the UK Animal 
(Scientific Procedures) Act, 1986 and associated guidelines.
2.4.2 In situ hybridisation
The sequences of the oligonucleotide probes used for this set of experiments 
(see chapters 5 and 6) are reported in tables 4.1 and 6.1. The probes specific for 
the genes described in chapter 5 were labelled according to the procedure 
described above. The same reaction was also used to label the probes specific for 
the genes described in chapter 6; however, these oligonucleotides were labelled
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with [a-^^P] dATP (specific activity 3000 Ci/mmol, NEN-PerkinElmer, UK), 
since in this case this reagent allowed higher yields of radiolabelled probes. The 
experimental procedures for slide preparation, fixation, in situ hybridisation and 
image analysis are outlined in sections 2.3.3 and 2.3.4.
2.4.3 Statistical analysis
The relative optical density values measured in the PrL, VO, Ml and Rt (if 
detectable) of the PGP-treated animals were compared to those measured in the 
coiTesponding brain region of the vehicle-treated animals using an independent 
sample t-test. The test was performed using the SPSS statistics software package. 
Significance was accepted at P<0.05.
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C h a p t e r  3. m R N A  Ex p r e s s io n  Pr o f il in g  in  
L a s e r -M ic r o d isse c t e d  B r a in  Re g io n s
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3.1 Introduction
3.1.1 Anatomical and functional heterogeneity of schizophrenia-related 
prefrontal cortical regions in the rat
The rat prefrontal cortex has generated wide interest in recent years, as the 
activation of this region is required for cognitive functions such as attentional 
processes, working memory and behavioural flexibility (Dailey et al, 2004). 
Despite the controversies about anatomical and functional homologies between 
brain structures of the prefrontal cortex in primates and rodents (Brown et al 
2002) (see also section 1.4.1.1), the use of rodent models has proved useful for the 
understanding of the pathophysiological processes that underlie psychiatric 
disorders such as schizoplmenia, attention deficit/hyperactivity disorder (ADHD) 
and drug addiction (van den Buuse et al, 2005; Sagvolden et a l, 2005) as well as 
the mechanisms of action of psychoactive drugs. Therefore basic research on the 
neurobiology of the rat prefrontal cortex has a multi-disciplinary value.
A number of recent studies focus on the functional heterogeneity of the 
prefrontal cortex, trying to associate specific aspects of cognitive and attentional 
processes to anatomical sub-regions (reviewed by Dailey et al 2004). The rat 
prefrontal cortex can be anatomically subdivided into a dorsal medial region; a 
ventral medial region, which includes the prelimbic cortex (PrL) and the 
infralimbic cortex; a ventral region, including the ventral orbital cortex (VO); and 
a lateral region.
This study focuses on the PrL and the VO, as they are particularly relevant to 
aspects of modelling schizoplirenia in rats. Recent findings suggest that the PrL is 
functionally analogous to the human dorsolateral prefrontal cortex (Floresco et al 
1997; Mizoguchi et al 2000; Brown et al, 2002), which is one of the brain 
regions where schizophrenia-related neurochemical and molecular alterations are
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more prominent (Harrison, 1999; Lewis et ah, 1999). Moreover, a metabolic 
hypo function has been reported in this area following chronic-intermittent 
phencyclidine (PCP) treatment in rats (Cochran et al,. 2003). This region-specific 
decreased neuronal activity reproduces the metabolic hypofunction observed in 
the human prefrontal cortex, known as hypoffontality, which is a landmark of 
schizophienia. Hypoffontality is considered to be associated with the presence and 
severity of negative symptoms and cognitive impaiiinents (Hazlett et al, 2000; 
Buchsbaiun et al, 1998; Cohen et al, 1997; Andreasen et al, 1992; Tamminga et 
al, 1992). The possibility to model this key neuropathological alteration in the rat 
PrL suggests that this region may be crucial for the cognitive abnormalities 
observed in the rat models of schizophrenia. Indeed, the chronic-inteimttent PCP 
treatment regime (Cochran et al, 2003) also produces cognitive deficits in rats 
(Egerton et al, 2006).
The VO could also be crucial to models of schizophrenia as it controls 
impulsive choice behaviour (Mobini et al, 2002) and response selection 
(Chudasama et al 2003 a; Chudasama et al 2003b). Furthermore it has been 
shown that the VO has a role in the neuropathology of schizophrenia (Crespo- 
Facorro et al, 2001; Glalin et al, 2005). Specifically, studies based on PET 
(Positron Emission Tomography) have consistently shown decreased activity in 
the ventral prefrontal regions in the schizoplirenic brain. The differences were 
observed both at rest and when perfonning cognitive tasks (Andreasen et al, 
1997; Crespo-Facorro et al, 1999). Moreover, a study based on MRI (Magnetic 
Resonance Imaging) showed that the cortical surface of the orbital-frontal cortex 
is significantly reduced in dmg-naiVe schizophrenia patients in the early stage of 
the illness (Crespo-Facorro et al, 2000). This structural abnormality is very 
striking, as it is not caused by drag treatments or hypothetical neurodegenerative 
processes; therefore the neuropathological alterations in the ventral region of the 
prefrontal cortex could also underlie aspect of the cognitive deficits observed in 
schizophrenia.
Interestingly, recent studies show that the PrL and the VO control different 
aspects of the attentional processes relevant to schizophrenia, suggesting a high
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degree of functional specialisation for these subregions of the prefrontal cortex. 
The PrL is crucial for the extradiinensional shift of the attentional set, which is the 
capability of shifting the attention from one perceptual dimension to another. In 
fact, lesions disrupting the PrL produce severe deficits in tasks testing the 
extradimentional set shifting. These deficits are not shown when the orbitofiontal 
cortex is disrupted (Dias et al, 1996; Dias et al, 1997). Conversely, lesions of the 
VO specifically impair reversal learning, which is the ability to re-learn the 
stimulus reward association under reversed reward values (Brown et al, 2002). 
These evidences are part of a growing body of information implying that the rat 
prefrontal cortex is a structure composed of interconnected functionally 
specialised subregions.
3.1.2 The thalamic reticular nucleus: modulation of the PFC-dependent 
cognitive processes
The reticular nucleus of the thalamus (Rt) is a thin sheet of neurons 
sun'ounding laterally the main body of the thalamus. The Rt is composed mainly 
of GABAergic intemeurons, exerting an inhibitory control over the thalamo­
cortical relay connections (Paxinos, 1995). The GABAergic intemeurons of the Rt 
receive collateral inputs from both the cortico-thalamic and the thalamo-cortical 
fibers, and respond to these stimuli with an inhibitory modulation of the latter 
pathway (Paxinos, 1995).
The specific role of the Rt as a gateway for the flow of information between 
the thalamus and the cortex suggests that this nucleus could be cmcial for those 
functions that require an accurate filtering of the stimuli, such as attentional 
processes. In fact, evidence fiom anatomical studies shows that the rostral part of 
the Rt directly controls the relay fibres connecting the medio dorsal thalamus and 
the prefrontal cortex (Cornwall et al, 1988). A more recent study shows that the
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Rt activity is required when cognitively demanding spatial memory tasks are 
performed (Vann et al, 2000). These evidences, supported by observations from 
lesion studies (reviewed by McAlonan et al, 2002), strongly suggest that 
cognition and attention are controlled by a complex circuitry, of which the 
prefrontal cortex specific subregions are the core structures, and the regulation of 
their activity exerted by the Rt is crucial.
The strong evidence in favour of the importance of the Rt for the functions 
mediated by the prefrontal cortex, points towards a possible role of this thalamic 
nucleus in the neuropathological alterations obseiwed when aspects of 
schizoplrrenia are modelled in rats. Strikingly, Cochran et al (2003) demonstrated 
that the metabolic hypofunction observed in the PrL of a rat model of 
schizophrenia, is also present in the Rt. The same study showed that the 
expression of parvalbumin, a calcium binding protein found in some specific 
subsets of GABAergic intemeurons, is decreased in the Rt of the rat model of 
schizophrenia (see chapter 4).
3.1.3 From functional specificity to molecular characterisation: the 
importance of gene expression profiling in brain
One of the main goals of neuroscience research is the understanding of the 
stmctural and functional diversity of the brain both at the macroscopic and 
microscopic level. As shown by the literature, a massive effort has been put into 
associating functional specificity to anatomically distinct stractures, employing a 
number of diverse approaches, such as lesion studies, functional neurochemistry, 
imaging techniques and behaviour studies.
The following step in the study of the modular organisation of the brain is 
identifying the association between functional specificity and molecular markers, 
such as gene expression profiles. Arguably, anatomical and functional diversity
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should correspond to specificity at the molecular level, and the specific 
transcriptome of a region could be of paramount importance in this context. The 
gene expression profile of a brain region is likely to underlie a number of 
characteristics, such as cytoarchitecture, neuronal composition and 
neurochemistry; therefore the mRNAs expressed in a specific brain region 
constitute an infonnative molecular fingerprint that could be essential for its 
specific neurobiological functions.
3.1.4 Laser-assisted microdisseetion, linear amplification and micro array 
analysis: innovative tools for high-throughput expression analysis
The identification of molecular markers in rat brain regions can be 
complicated by several factors. The dissection of the ftinctionally specialized 
cortical subregions for the downstream expression analysis requires a very high 
degree of anatomical precision. For this purpose conventional techniques, such as 
manual gross dissection, punch dissection and slices dissection, cannot guarantee 
that the specimens collected are free from unwanted material from neighbouring 
regions. Even a small amount of such contamination could introduce a significant 
bias that would affect the data interpretation altering their biological significance. 
The strict criteria for the dissection of cortical subregions and small thalamic 
nuclei can only be met by microscopy-based techniques that allow the exact 
identification of the structures of interest, coupled with a precise dissection 
system.
Laser-assisted microdissection (LMD) is a recently developed technique that 
can be used for the isolation of small structures, or even single cells, and can be 
successfully applied to neuroscience research (Bohm et al, 2005). Commercially 
available LMD instruments require a thin section of tissue (8-12 pm) mounted on 
a special slide and suitably stained for identification of the target structures; the
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laser technologies employed for the dissection step can be based either on an 
infrared or an UV beam.
The system manufactured by Arcturus Engineering employs a cap of 
thermoplastic film, which is placed onto the tissue mounted on a glass slide. A 
low-energy infrared laser beam is focused through the microscope objective onto 
the film. When the laser is pulsed on a selected area of the section, it melts the 
film onto it. The selected tissue is then collected by lifting the cap. The 
thermoplastic film carries over only the specific area of tissue where the laser was 
pulsed. This teclmique is often referred to as Laser Capture Microdissection 
(LCM).
An alternative to the LCM system is the cold LMD technology, where a 
pulsed UY-A laser is used to cut around the selected target area. Instruments 
manufactured by Leica Microsystems and PALM Microlaser are based on this 
technology. The first microscope, which is the one employed in the present study, 
requires the section to be mounted on a membrane slide made of polyethylene 
terephtalate (PET). When the laser is pulsed around the selected area, it cuts 
through the tissue and the membrane; then the microdissected sample is collected 
by gravity into a tube cap placed under the microscope stage. This collection 
strategy does not require any additional manipulation or force application after 
pulsing the laser.
The LMD systems allow collection of samples in nuclease-free conditions; 
therefore, provided that all the procedures performed prior to the microdissection 
do not affect the RNA integrity, microdissected samples are suitable foi- 
expression analysis. The key step for the RNA integrity preservation is the 
staining. Microdissection of specific structures or cells requires histological or 
immunohistochemical staining for the identification of the target area. Ordinary 
staining protocols often involve the use of cross-linking fixatives, such as 
paraformaldehyde (PEA), and prolonged incubation in aqueous environments. 
These conditions are unsuitable if high-quality RNA needs to be extracted from 
the stained sample. Due to the increasing popularity of the LMD technique, some 
studies were specifically aimed at developing fixation and staining protocols that
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would cause minimal damage to the RNA. Qin et al (2003) compared expression 
profiles horn PFA-fixed, paraffin embedded rat brain tissue, ethanol-fixed frozen 
rat brain tissue and non-fixed rat brain tissue. Van Deerlin et al (2002) perfonned 
a similar investigation using post mortem human brain tissue either flash-fi'ozen 
of paraffin embedded with prior fixation in formalin or ethanol. Both studies show 
that the RNA integrity is well preserved when precipitative fixatives are used in 
frozen samples, whereas cross-linking fixatives and paraffin embedding produce 
less reliable results. Detailed studies comparing different staining methods have 
also been published (Ginsberg et al, 2004; Burbach et al, 2004), showing that the 
key factor for reliable RNA integrity preservation is reducing the staining time, 
especially when the samples must be incubated in aqueous environments. Most 
immunohistochemistry protocols developed for LMD are shorter than 30 minutes; 
acceptable staining can be achieved in these conditions by increasing the primary 
antibody concentration.
The amount of total RNA varies according to the type of tissue and the size of 
the microdissected area. However, it is not usually sufficient to perform high- 
throughput expression analysis, especially using micro array methodologies. For 
this reason, a massive effort has been put in developing an amplification strategy 
that would allow gene expression profiling of small samples. The key features of 
such a methodology are reliability and preservation of the relative abundance of 
the mRNA transcripts. In fact, a standard exponential amplification would alter 
the composition of the mRNAs, nullifying the biological significance of the 
downstream expression analysis. Suitable strategies for linear RNA amplification 
were first developed by Van Gelder et a l (1990) and Eberwine et al (1992). 
Briefly, this approach is a linear, isothemial amplification based on in vitro 
transcription using T7 RNA polymerase where the mRNA is first reverse- 
transcribed into cDNA incorporating a functional T7-promoter, and then linearly 
amplified via in vitro transcription, obtaining amplified, antisense orientated RNA 
(aRNA). This procedure can be repeated to further increase the yield, and 
successfully maintain the original expression pattern (Poirier et al, 1997; Puskas 
et al, 2002). Many companies have developed commercially available kits for
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linear amplification of RNA based on this strategy. Although the original method 
remains valid and reliable, Baugh et al (2001) described a number of 
inconveniences than can occur especially when the amount of template is very 
low; such as the production of considerable amounts of non-template high 
molecular weight reaction artefacts and excessive shortening of the fragments. 
These problems can be circumvented with slight adaptations of the original 
method that have also been employed by the new generation commercial kits (see 
section 2.2.6 for details), making the procedure highly standardised and reliable.
The molecular characterisation of a specific tissue can be performed using a 
range of teclmiques to measure markers at the mRNA or protein level. 
Nevertheless, only the ability to obtain a simultaneous quantitative measurement 
of thousands of transcript can provide insightful information about the great 
complexity of specific brain regions. DNA microarray technology can be the 
answer to such teclmologically challenging investigation. DNA chips have been 
reliably used in recent studies for high-tlnoughput expression analysis in different 
research fields, and their popularity is constantly increasing in neuroscience (Cao 
et al, 2001; Gebicke-Haerter, 2005; Konradi,. 2005; Reimer et al, 2005). There 
are several different platforms that can be used for microarray-based expression 
analysis, ranging from self-spotted cDNA arrays to high-density oligonucleotide 
chips. Among them, the GeneChip technology developed by Affymetrix has been 
the platform of choice for many successful studies due to the vast amount of 
information produced and its reliability. The GeneChips consist of a solid support 
where DNA probes are chemically synthesized in situ. The highly standardised 
photolithographic process allows the synthesis of oligonucleotides (usually 
25mers) at very high density on small individual arrays, which can measure 
simultaneously tens of thousands different transcripts in a sample. This 
technology also confers good reliability due to the standardisation of the 
productive process, as opposed to other types of platfoim that can suffer from 
some degree of variability (reviewed by Reimer et al, 2005).
The complex objective of individuating gene expression profiles in specific 
brain regions can be achieved thanks to the technological advantages of laser-
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assisted microdissection, followed by linear amplification and microarray 
analysis. This powerful and imiovative combination of techniques will be 
employed in the present study for an extensive analysis of the transcriptome of the 
rat PrL, VO and Rt.
3.1.5 Gene expression profiling via LMD/microarray in neuroscience 
research
Although the LMD/microaiTay strategy has been developed only reeently, it 
soon captured the interest of neuroscientists due to its impressive potential. A 
number of studies have been published recently (reviewed by Bohm et ai, 2005), 
some of which focus on the optimisation and technical aspects of the process 
(Sanna et al, 2005). The attempts to identify gene expression profiles are in many 
cases focused on the study of the hippocampal region of both humans and rats 
(Bonaventure et al, 2002; Datson et al, 2004; Torres-Munoz et al, 2004). The 
hippocampus is particularly suited for this type of analysis as the subregions are 
easily identifiable after quick staining and are mainly composed of discrete and 
uniform layers of large pyramidal neurons; moreover, the functions of 
hippocampal subregions are well studied. Datson et a l (2004) demonstrated the 
feasibility of gene expression profiling in rat hippocampal subregions using the 
Leica AS LMD microdissection system and Affymetrix GeneChip arrays. This 
study focused on the expression comparison between the cornu ammonis 3 (CA3) 
and the dentate gyrus (DG) subregions, finding a substantial differential 
expression underlying morphological and functional differences. Specific 
expression pattern in closely related hippocampal subregions were also reported 
by Bonaventure et a l (2002) using the Arcturus LCM system. The amygdala is 
another region where molecular characterization has been performed using 
LMD/microaiTay approaches (Zirlinger et al, 2000; Zirlinger, 2003). This study
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also employs the Arcturus LCM system to dissect specific amygdaloid subnuclei, 
where differential gene expression was demonstrated.
Studies of the hippocampus and amygdala show the vast potential of the 
LMD/microarray approach for the construction of expression profile databases of 
specific brain regions. However, this novel technology can be implemented 
especially by the development of new, more comprehensive and robust 
microarray platforms. Further research is also needed to improve the 
reproducibility and robustness of the findings, as well as expanding the current 
knowledge to other interesting brain areas.
Although Sanna et al (2005) demonstrated the technical feasibility of 
expression profiling of rat thalamic nuclei, the literature is currently lacking 
detailed infoimation about genes specifically expressed or enriched in these 
regions. Also, the LMD/microaiTay approach has not been applied for the study of 
specific cortical subregions. The molecular characterization of the cortex is a 
challenging task, due to the cytoarchitectural and functional complexity of this 
area. In contrast to the hippocampus and other well-defined brain regions, cortical 
subregions are not characterized by the prevalence of one neuronal population, but 
consist of a complex structure composed of diverse neuronal subtypes. The global 
transcription profile of such structures represents the phenotype of their complex 
neurocircuitry and could underlie the neurobiology of higher cognitive functions.
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3.2 Aims
This study has multiple aims. Firstly, it will test the technical feasibility of 
molecular characterization of rat cortical subregions and thalamic nuclei using an 
approach based on laser-assisted microdissection, linear amplification and 
micro array analysis. The gene expression profiling will be performed on the 
Prelimbic cortex (PrL), Ventral Orbital cortex (VO) and Reticular Thalamic 
nucleus (Rt) for their relevance to cognitive processes and models of 
schizophrenia, and additionally on the Primary Motor cortex (Ml) as a control 
region.
Another aim is to test the hypothesis that the brain regions analysed show 
significant differential gene expression, reflecting structural and functional 
differences. The expression profiles of the four regions will be compared to assess 
both the variation between thalamus and cortex and the intra-cortical differential 
expression.
Finally, the genes that showed localised expression will be clustered into 
functional classes according to the “biological process” gene ontology. This 
analysis will be based on infonnation available fiom the literature and online 
databases, and will facilitate the identification of localised groups of functionally 
related genes. The expression profile of the Ml will be included in this analysis 
for comparative purpose. The Ml is a neocortical region not directly involved in 
attention, cognition and memory, therefore the comparison of the expression 
profile of this region to that of the PrL and the VO will help in the identification 
of gene clusters hypothetically involved in those functions.
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3.3 Results
3.3.1 Tissue staining and microdissection
The quick staining protocol optimised for the LMD allowed the unambiguous 
identification of the cortical subregions on the sections mounted on PET slides 
(figure 3.1). Even after dehydration, the toluidine-blue staining allowed the 
visualization of specific structures and landmarks of the neocortex, such as the 
white matter and the cortical layers. At higher magnification, single neurons were 
also easily recognisable.
The immunohistochemical staining of the anterior thalamus was very helpful 
for the identification of the Rt in the adjacent toluidine-blue stained sections. 
Although GAD65/67 immunoreactivity is present in other thalamic nuclei, the 
prevalence of GABAergic neurons in the Rt produced a remarkably stronger 
staining compared to the neighbouring regions (figure 3.2A). The structure 
showing strong GAD65/67 immunoreactivity could be clearly identified in the 
toluidine-blue stained section (figure 3.2B).
The LMD procedure was efficient and reliable for the microdissection of the 
required brain regions with a high degree of anatomical precision (figures 3.1 and 
3.2). All dissections were performed efficiently according to a conservative 
interpretation of the anatomical boundaries.
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PrL
Figure 3.1
Toluidine blue-stained rat brain section at the preffontai cortex level (Bregma 3.70 mm). 
The magnified photographs show part o f  the section after laser-assisted microdissection 
o f Ml (1), PrL (2) and VO (3). (AI: agranular insular cortex; Cgl: cingulate cortex area 
1; Cl: claustrum; LG: lateral orbital cortex; M l, primary motor cortex; M2, secondary 
motor cortex; MO: medial orbital cortex; OB: olfactory bulb; PrL: prelimbic cortex; VO: 
ventral orbital cortex; WM: white matter).
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Figure 3.2
A. GAD 65/67 immunoreactivity in the reticular thalamic nucleus (Rt) (Bregma -1,60 
mm). The GABAergic intemeurons of the Rt show stronger immunoreactivity than the 
neighbouring regions.
B. Toluidine blue-stained rat brain section, anterior thalamus level (Bregma -1.60 mm). 
Comparison with the adjacent immunostained section (A) facilitates the identification of 
the Rt.
C. Toluidine blue-stained rat brain section, anterior thalamus level, with the Rt 
highlighted (Bregma -1.60 mm). The magnified photograph shows part of the section 
after laser-assisted microdissection of the Rt. (Amy: amygdala; ant/vent thalamus: 
anterior/ventral thalamic nuclei; CA3, field CA3 of hippocampus; cc, corpus callosum; 
eg: cingulum; Cpu: caudate putamen; D3V: dorsal 3^^^ ventricle; ec: external capsule; fi: 
fimbria of hippocampus; HYP: hypothalamus; ic: internal capsule; LGP: lateral globus 
pallidus; sm: stria medullaris of thalamus).
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3.3.2 Total RNA quality control
The electropherograms showed that the degree of degradation of the total 
RNA extracted from the LMD samples was negligible (figure 3,3). In all samples 
the peaks corresponding to the 18S and 28S rRNA were clearly visible and had 
similar height. The intensity of the signal corresponding to fragmented RNA was 
very low. These results showed that the quality of the RNA obtained was very 
high; therefore all samples were suitable for the downstream processing and gene 
expression analysis.
The RNA 6000 Pico LabChip kit does not provide an accurate quantitative 
measure of the total RNA; however the estimated values suggested that each 
sample contained from 10 to 20 ng of total RNA.
3.3.3 Amplified aRNA quality control
The two-round linear amplification procedure yielded on average 45 pg of 
biotin-labelled aRNA. As expected, the electropherograms of all samples showed 
a fi'agment size range hom 200 to 3000 nucleotides (nt), with a maximum peak at 
800 nt (figure 3.4). The negative control amplification products showed very low 
concentration of small fragments, (fragments size <200 nt) (figure 3.4); probably 
reflecting the presence of carriers used during the purification steps. The amount 
of this material was below the sensitivity limit of the spectrophotometer. The 
absence of a significant amount of material in the negative controls and the 
uniformity of the samples suggested that the linear amplification procedure was 
specific and reproducible and that the labelled aRNA was free of reaction artefacts 
(Baugh et al. 2001).
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Figure 3.3
Representative electropherograms of total RNA extracted from LMD samples (brain 
regions are specified in the top right corner). The peaks corresponding to the 18S and 28S 
rRNA show that the quality of the RNA obtained was very high.
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Figure 3.4
Representative electropherogram of biotin-labelied aRNA (1:5 dilution) (brain regions 
are indicated in the top right corner), and electropherogram of no template negative 
control (neat). The qualitative and quantitative difference between the sample and the 
negative control shows that the labelled aRNA was free of reaction artefacts.
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3.3.4 M icroarray hybridisation
The average percentage of probes called present by the GCOS software was 
51.6% in the M l, 52.3% in the PrL, 49.0% in the VO and 43.5% in the Rt. The 
slightly higher percentage of transcript detected in the cortical areas could mirror 
the higher degree of complexity and cellular heterogeneity of the cortex in 
comparison to a relatively simple structure as the Rt.
To assess the reproducibility of the LMD-linear amplification-microarray 
analysis strategy, scatter plots of signal intensities were constructed and 
correlation coefficients were calculated between all samples. The Pearson 
correlation coefficients between biological replicates ranged from 0.972 to 0.995 
(figure 3.5). The correlation coefficients between samples from different cortical 
regions were also very high, ranging from 0.961 to 0.990. When the signal 
intensities obtained from cortical regions were correlated with those from the Rt, 
the coefficients ranged from 0.903 to 0.955 (figure 3.6).
The high percentage of transcripts detected in all the specific brain regions and 
the strong correlation between replicate samples supports the validity and the 
reliability of the LMD-linear amplification-microarray experimental strategy. 
Also, the Pearson correlation analyses show that the gene expression differences 
between the Rt and the cortical regions are greater than the intra-cortical 
variations.
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Figure 3.5
Scatterplots of normalised signal intensity (RMA method) of probe sets from 
representative biological replicates (regions are indicated by the axis legend). The 
Pearson coirelation coefficients between biological replicates ranged from 0.972 to 0.995.
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Figure 3.6
Scatterplots of normalised signal intensity (RMA method) of probe sets from 
representative samples (regions are indicated by the axis legend). The correlation 
coefficients between samples from different cortical regions ranged from 0.961 to 0.990, 
whereas those calculated comparing the Rt to cortical regions ranged from 0.903 to 0.955. 
The correlation analyses show that the gene expression differences between the Rt and 
the cortical regions are greater than the intra-cortical variations.
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3.3.5 Regional differential gene expression
The ranked lists of differentially expressed probes generated by the RP 
analysis were combined to identify the transcripts einiched in one region 
' compared to the others. This approach highlights the genes that are significantly 
overexpressed and, in some cases, specifically expressed in one region. Those 
genes could be relevant to the heurobiology of the region where they are enriched, 
as they may be essential for the specific functions of the region. This study 
focused on the specific gene expression pattern of the PrL, the VO and the Rt, 
since these regions show important changes in rat model of schizophi*enia 
(Cocliran et al. 2003) and play a key role in several aspects of cognition and 
attention that are relevant to modelling psychiatric disorders. Conversely, the Ml 
is not directly involved in attentional and cognitive processes and does not show 
prominent changes in the schizophrenic brain or in animal models; therefore its 
expression pattern was used for comparative analysis.
It was decided to consider all the probe sets that showed differential 
expression with a false discovery rate (FDR, see section 2.2.11) < 1%; therefore 
transcripts that were enriched in one region with an FDR below this threshold are 
defined as overexpressed. This threshold was conservative enough to keep to a 
minimum the number of false positives, while including a considerable number of 
probe sets to avoid the loss of important information.
When the Rt was compared to the PrL, VO and M l, 429 transcripts were 
overexpressed (table 3.1), whereas 881 were enriched in all three cortical areas. 
The gene expression difference is substantial, especially considering that 206 of 
the Rt-enriched genes (48%) showed a Fold Change greater than 3. These results 
suggest that the examined cortical areas express a wider range of genes than the 
Rt. This could reflect a higher diversity in terms of neuronal population and more 
complex functions for the cortical areas. On the other hand, the genes 
overexpressed in the Rt could be cmcial for the specific functions of this area, 
such as the inhibitory control over the thalamo-cortical relay projections.
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Intra-cortical expression differences were also substantial. 233 genes were 
enriched in the PrL compared to VO and Ml; whereas 83 genes were enriched in 
the VO compared to PrL and Ml (table 3.1). The intra-cortical differential 
expression is less prominent than that obseiwed when the Rt is compared to the 
cortical regions. This could be due to the fact that the cortical regions have a 
similar cytoarchitecture and neuronal composition. Interestingly, the PrL showed 
a more pronounced overexpression of genes than the VO. This finding could 
suggest that the PrL has higher functional complexity than the other cortical areas 
examined in this study.
Overexpressing Comparison regions 
region
m VO M1+V0
PrL 431 442 233
M1 PrL M1+PrL
VO 213 460 83
Rt
M1
730
PrL
637
VO
650
M1+PrL+V0
429
T a b le  3,1
Gene expression profile comparisons. Number of transcripts overexpressed (False Discovery Rate 
<1%) in the Prelimbic cortex (PrL, upper row), Vential Orbital cortex (VO, middle row) and 
Reticular Thalamic nucleus (Rt, bottom row) compared to the regions indicated in each column. 
(Ml= Primary Motor cortex).
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3.3.6 Biological function of localised genes
The region-enriched genes clustered into several functional classes. Different 
genes directly involved in synaptic transmission were selectively expressed in all 
the examined regions. Some GABAergic machinery-related genes, such as the 
two isofonns of glutamate decarboxylase (GAD65 and GAD67), were 
overexpressed in the Rt (see table 3.2, “Neurotransmission” functional class), in 
accordance with the prevalence of GABAergic intemeurons in this region. 
Another interesting finding was the different distribution of GABAa receptor 
subunits in the cortical regions. The a5 and the pi subunits were overexpressed in 
the PrL (see table 3.3, “Neurotransmission” functional class), whereas the ô 
subunit was predominant in the VO (see table 3.4, “Neurotransmission” 
functional class).
Genes controlling ion transport were also selectively expressed in all regions. 
Specifically, the Rt and the VO showed overexpression of a number of potassium 
channel subunits (tables 3.2 and 3.4); whereas the PrL overexpressed genes 
involved in the transport of calcium and sodium (table 3.3).
Differential expression of genes related to cell adhesion, metabolism, cell 
cycle, phosphorylation and transcription was also prominent, especially in the Rt 
(table 3.2). The calcium-binding proteins parvalbumin and calretinin, typically 
expressed in the GABAergic intemeurons, were also predominant in the Rt (see 
table 3.2, “Calcium binding proteins” frinctional class).
Another interesting finding was the overexpression of nine genes directly 
involved in neurogenesis and neurodevelopment in the PrL (see table 3.3, 
“Nem'ogenesis/neurodevelopment” functional class). This is a unique feature of 
this region, as neither the Rt nor the VO showed overexpression of genes involved 
in the regeneration or remodelling of the neural circuitry.
1 0 0
Functional class Probe set ID Gene Title Fold
Change
Cell adhesion 1374248_at
1370989_at
myosin binding protein 0, slow 
type
ret proto-oncogene
16.30
13.03
1370697_a_at nexllln 4.69
1369425__at cadherin 13 4.56
1368861_a_at myelln-assoclated glycoprotein 2.49
1371112_at ret proto-oncogene 3.69
1368135_at nlnjurin 2 2.62
Calcium binding 
proteins
1370214_at 
1370849_at 
1387133„at
parvalbumin
Hyaluronan and proteoglycan link 
protein 2
calbindin 2 (calretinin)
9.50
3.61
2.79
1368044_at secretogranin 2 3.16
Inositol phosphate 
mediated signalling
1369345_at 
1368119_at
Inositol polyphosphate-4- 
phosphatase, type II, 105kD
phosphatldylinosltol (4,5) 
bisphosphate 5-phosphatase, A
10.08
2.92
Neurotransmission 1369462_at
1368475_at
1387114_at
glutamate decarboxylase 2 
(GAD67)
collagen-like tall subunit (single 
strand of homotrimer) of 
asymmetric acetylcholinesterase
protein kinase 0, delta
6.63
6.17
3.07
1369926_at 
1369799_at 
1369384_at 
1368344_at
glutathione peroxidase 3
4-amlnobutyrate
aminotransferase
glutamate receptor, lonotropic, 4
(GluR4)
glutamate decarboxylase 1 
(GAD65)
7.83
2.43
3.10
2.50
Ion transport 1368524„at 
1367815_at
1369687_at
1367853_at
1368343_at
1370076_at
1380945 at
potassium voltage gated channel, 
Shaw-related subfamily, no. 1 
solute carrier family 5 {sodium- 
dependent vitamin transporter) n. 6 
potassium voltage gated channel, 
shaker related subfamily, beta n. 3
solute carrier family 12, n. 2
potassium voltage-gated channel, 
subfamily H (eag-related), n. 2 
potassium Inwardly-rectifying 
channel, subfamily J, n. 16
Transient receptor potential cation 
channel, subfamily C, n. 7
3.43 
2.48 
3.30 
1.92 
2.25
2.44
2.10
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Functional class Probe set ID Gene Title Fold
Change
Structural 
constituent of 
myelin sheath
1370500_a_at
1398257_at
myelin-associated 
oligodendrocytic basic protein 
myelin oligodendrocyte 
glycoprotein .
2.60
2.30
G protein 
mediated 
signalling
1387182_at
1368705_at
G protein-coupled receptor 37 
(endothelln receptor type B-like) 
endothelial differentiation, 
sphlngolipid G-protein-coupled 
receptor, 8
1.89
2.32
1367957_at regulator of G-proteIn signalling 3 3.15
1382967_at G protein-coupled receptor 64 1.97
Transcription/ 
RNA processing 1369681_at 
1370063_at 
1368933_at 
1370089_at 
1369590_a_at
ISLI transcription factor, 
LIM/homeodomaIn 1 
nuclear receptor subfamily 2, 
group F, member 2 
adenosine deaminase, RNA- 
speciflc, B1
peroxisome proliferative activated 
receptor, gamma, coactivator 1 
DNA-damage Inducible transcript 
3
5.01
4.55
3.30
2.33
2.34
1388133__at PIPPIn protein 4.11
1371899_at Similar to PKR-assoclatIng protein RAX 2.00
Metabolism 1368075_at lipase A, lysosomal acid 2.98
1370387_at cytochrome P450, family 3, subfamily a, polypeptide 13 1.95
1386954_at adenylate kinase 2 3.37
1367735_at acetyl-Coenzyme A dehydrogenase, long-chain 3.11
1388960_at Pyrophosphatase 2.69
1368092_at fumarylacetoacetate hydrolase 1.87
Phosphorylation 1367813_at protein phosphatase 1, regulatory (inhibitor) subunit 14A 3.19
1387114_at protein kinase C, delta 3.07
1388913_at 
1374310_at
phosphatidic acid phosphatase 
type 2c
protein phosphatase 2a, catalytic 
subunit, zeta isoform
2.54
2.57
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Functional class Probe set ID Gene Title
Cytoskeiefon 
organisation and 
biogenesis
1370933_at 
1370815_at 
1387157 at
myosin IE
neurofilament, heavy polypeptide
polyamine modulated factor 1 
binding protein 1___________
Fold
Change
5.12
1.87
2.27
Celi cycle/ 
a po ptosis 1371643_at 
1371112_at 
1367859_at 
1387957 a at
cyclin D1 3.99
ret proto-oncogene 3.69
transforming growth factor, beta 3 2.34
SH3-domain kinase binding
protein 1 1.95
Table 3.2
Genes clustered according to similar biological function that are enriched in the Reticular 
Thalamic nucleus (Rt). All the transcripts showed FDR< 1%. The Fold-change values 
refer to the mRNA level difference between the Rt and the M l.
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Functional class Probe set ID Gene Title Fold
change
Neurogenesis/
Neurodevelopment
1387141 _at 
1369999_a_at
Dihydropyrimidinase-like 5 
(DPYSL5)
Neuronatin
10.21
2.96
1367888_at MT-protocadherin 2.92
1388101 _at Dihydropyrimidinase-like 3 (DPYSL3) 2.81
1369358_a_at Huntlngtln-assoclated protein 1 2.53
1368677_at
1368358_a_at
Brain derived neurotrophic factor 
(BDNF)
Protein tyrosine phosphatase, 
receptor type, R
2.20
1.60
1379374_at Plasticity related gene 1 1.53
1374966_at Doublecortin 1.50
Ion transport 1370248_at FXYD domain-containing ion transport regulator 6 10.21
1368839_at Wolframln 3.79
1369691_at
1369160_a_at
1368398_at
Sodium channel, voltage-gated, 
type III, alpha polypeptide 
Solute carrier family 4, sodium 
bicarbonate cotransporter, no. 7 
Calcium channel, voltage- 
dependent, T type, alpha 1H sub
1.91
1.83
1.64
Neurotransmission 1368478_at Dopamine receptor 1A 2.82
1369019_at Cholinergic receptor, nicotinic, alpha polypeptide 5 2.54
1370431_at Synapsin 11 2.03
1387696_a_at Glycine receptor, alpha 2 subunit 1.99
1376345_at
1371057_at
1369904_at
Dopamine receptor D1 
interacting protein 
Gamma-aminobutyric acid A 
receptor, alpha 5 
Gamma-aminobutyric acid 
receptor, subunit beta 1
1.97
1.76
1.68
1367977_at Synuclein, alpha 1.63
Celi adhesion 1370312_at F-spondin 1.77
1370550_at Limbic system-associated membrane protein 1.67
1388936„at Cadherin 11 1.68
1384734 at Neural cell adhesion molecule 2 1.65
Table 3.3
Genes clustered according to similar biological function that are enriched in the Prelimbic 
cortex (PrL). All the transcripts showed FDR< 1%. The Fold-change values refer to the 
mRNA level difference between the PrL and the Ml.
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Functional class Probe set ID Gene Title Fold
change
Neurotransmission solute carrier family 17 (sodium- 1.881368564_at dependent inorganic phosphate 
cotransporter), member 6
1369048_at gamma-aminobutyric acid A receptor, delta 1.54
1368585_at cocaine and amphetamine regulated transcript 1.51
Transcription/ RNA 
processing 1388133_at PIPPin protein
1.90
1387260„at Kruppei-like factor 4 (gut) 1.81
1369007_at nuclear receptor subfamily 4, group A, member 2 1.54
Phosphorylation 1378209_a_at serine/threonine kinase 23 1.79
1370652„at neurotrophic tyrosine kinase, receptor, type 2 1.55
1370853_at CaM-kinase II inhibitor alpha 1.51
Table 3.4
Genes clustered according to similar biological function that enriched in the Ventral 
Orbital cortex (VO). All the transcripts showed FDR< 1%. The Fold-change values refer 
to the mRNA level difference between the VO and the Ml.
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3.4 Discussion
The combination of laser assisted microdissection, linear amplification and 
microarray has been shown to be a reliable method to identify gene expression 
differences in discrete regions of the rat brain, such as the hippocampus and the 
amygdala (Bonaventure et al. 2002; Datson et al 2004; S anna et al 2005). In this 
study the LMD-microarray approach was used for the first time to perform 
multiple comparison of the gene expression profiles from two subregions of the 
prefi'ontal cortex and one thalamic nucleus involved in the neurobiological 
changes observed in a rodent PCP model of schizophrenia (Cochran et al. 2003),
The high percentage of mRNAs detected by the microarray and the uniformity 
of the data confinn the consistency of the technique and shows that it can be 
reliably applied to analyse the gene expression in cortical subregions. The 
differential expression was substantial when the Rt was compared to the cortical 
regions, as expected from the very different cytoarchitecture and neuronal 
composition. The differential expression was also prominent and reliably detected 
when the cortical subregions were compared to each other. This finding showed 
that the gene expression profile of a brain region does not depend exclusively on 
the gi'oss cytoarchitecture and neuronal composition, which are relatively uniform 
in the cortical subregions studied. The mRNAs expressed in a specific cortical 
region constitute a molecular fingerprint that could reflect the presence of specific 
neuronal subtypes, the organisation of the synaptic connections, and could be 
essential for its specific neurobiological functions.
This study shows that the vast potential of the LMD-microarray approach can 
be applied to analyse expression differences between subregions of the neocortex 
that have similar cytoarchitecture and neuronal composition, but different 
functions. Understanding the role of the genes enriched in the PrL and the VO 
will clarify the neurobiological basis of functions such as attentional processes, 
executive function, working memory and behavioural flexibility, which are
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affected in psychiatric diseases such as schizoplirenia and drug addiction, and in 
animal models reproducing aspects of these conditions (Lee et ah, 2004; 
Chudasama and Robbins, 2004; Egerton et al., 2005; Morey et ah, 2005; Conklin 
et ah, 2005; Kalivas et ah, 2005). The genes enriched in the Rt are also crucial for 
the modulation of cortical activity, as they are likely to be the molecular basis of 
the inliibitory control over the thalamo-cortical relay pathways exerted by the Rt.
3.4.1 Functional classes of localised genes
The clustering of localised genes into functional classes highlighted that some 
specific biological pathways could be predominantly active in some regions.
The overexpression of genes with common function in a specific region can be 
due to the prevalence of a neuronal subpopulation or to the presence of anatomical 
structures such as white matter fibres. This interpretation is consistent with the 
biological characteristics of the Rt (see below).
When the neuronal composition and the anatomy of the regions are more 
uniform, like in the case of cortical subregions, these factors are likely to underlie 
the differential gene expression to a lesser extent. In this scenario, the differential 
expression of functional classes of genes could reflect how similar neuronal 
subtypes interact, forming complex networks in order to control specific 
functions. The organisation of the neurocircuitry and the inputs that neurons 
receive both from neighbouring cells and other brain stimctures are likely to have 
a relevant influence over the functional differences between specific brain 
regions, which can be mirrored at the molecular level by the differential gene 
expression observed in this study.
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3.4.2 Overexpression of neurodevelopment-related genes in the P rL
All interesting finding is the overexpression of nine genes directly involved in 
neurogenesis or neurodevelopment in the PrL (table 3.3).
Dihydropyrimidinase-like 3 (DPYSL3) and dihydropyrimidinase-like 5 
(DPYSL5), two genes belonging to the family of collapsin response mediator 
proteins, are enriched in this area; with DPYSL5 showing a FC of 10.21. Such a 
fold change value measured between cortical subregions with similar anatomy is a 
striking finding, as expression variations in the brain are usually small; therefore 
DPYSL5 could be considered a PrL-specific gene. The collapsin response 
mediator proteins have been implicated in developmental processes such as 
signalling of axonal guidance (Nacher et al. 2000; Hotta et al. 2005); DPYSL3 is 
expressed in the areas that show adult neurogenesis, such as the subventricular 
zone and the granular layer of the dentate gyrus (Nacher et al. 2000). 
Doublecortin, another gene directly involved in different aspects of 
neurodevelopment (Gupta et al. 2002; Friocourt et al. 2003) was also 
overexpressed in the PrL. The role of this gene in the development of mammalian 
cortex is well documented, as mutations are known to cause lissencephaly in 
humans, which is a type of cortical dysplasia (des Portes et al, 1998; Gleeson et 
al, 1998). The main function of doublecortin is to direct neuronal migration by 
interacting with the microtubules during the polymerisation process (Gleeson et 
al, 1999; Francis et al, 1999; Horesh et al, 1999). Althougli the overexpression 
of doublecortin in the PrL is less prominent than that of DPYSL5, (FC 1.50 as 
compared to 1 0 .2 1 ), the significant prevalence of a gene with such a specific role 
in neurodevelopment in the PrL is likely to be biologically relevant.
The prevalence of neurodevelopment-related genes in the PrL is supported by 
the overexpression of brain derived neurotrophic factor (BDNF) (table 3.3). The 
role of this neurotrophin in neurogenesis and development is well documented 
(reviewed by Thomas et al, 2005), as well as its involvement in a number of
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psychiatrie diseases, such as schizophrenia, depression and eating disorders 
(Durany et al, 2004; Newton et al, 2004; Hashimoto et al, 2005).
It is difficult to predict how these genes interact and their role in a region that 
does not show incontrovertible evidence of neuro genesis. It could be argued that 
the overexpression of development-related genes in the PrL is linked to the fact 
that this is the last neocortical area to complete development; in fact in humans 
the PFC does not become mature until adolescence. Nevertheless, this explanation 
is not very probable, as the animals used in this study were fully developed adult 
rats (see materials and methods, chapter 2). On the other hand, the overexpression 
of this class of genes in the PrL suggests that the neural network of this area is 
extremely dynamic and active. Interestingly, some of these genes are also 
expressed in the hippocampus, and could be crucial for the higher cognitive 
functions of these structures.
It has been proposed that neurotrophins play a key role in memory and 
learning, as these molecules are involved in synaptic plasticity (reviewed by Lu,
2003). hiterestingly, there is evidence of a reciprocal regulation between 
neurotrophin expression and synaptic activity (Thoenen, 1995; Beminger et al, 
1996; Lu et al, 1997). Many studies investigating the role of neurotrophins in 
cognition focus on BDNF, which is overexpressed in the PrL according to the 
present work. This molecule has an acute effect on neurotransmission in vitro; in 
particular, it enhances neurotransmitter release at neuromuscular synapses (Lohof 
et al, 1993). Other groups investigated the acute effect of BDNF on hippocampal 
synapses, and found that this neurotrophin facilitates the release of 
neurotransmitter via a presynaptic mechanism and regulates long-term 
potentiation (Figurov et al, 1996; Patterson et al, 1996). Interestingly, the acute 
modulation of presynaptic activity exerted by BDNF is due to its control over the 
phosphorylation state of proteins involved in the docking of synaptic vesicles, as 
demonstrated in isolated synaptosomes fiom rodent cortex (Jovanovic et al,
2000). This work showed that the BDNF dependent MAP kinase activation leads 
to the phosphorylation of synapsins, a group of presynaptic proteins that control 
the proportion of vesicles available for exocytosis in the presynaptic terminal (see
109
chapter 4). The activity of synapsins is finely modulated by their phosphorylation 
state; therefore BDNF acutely enhances the release of neurotransmitters by 
controlling the phosphorylation of synapsins (Jovanovic et ah, 2000). This finding 
is supported by the lack of BDNF dependent neurotransmission enhancement in 
mice lacking the synapsin I and/or synapsin II genes (Jovanovic et al, 2000). It is 
interesting that the LMD/microarray study also detected an overexpression of 
synapsin II in the PrL (see also chapter 4); therefore two genes that participate in 
the presynaptic control of long-tenn potentiation are specifically enriched in this 
cortical subregion, and are likely to be directly involved in the molecular 
mechanisms underlying PrL-dependent cognitive processes.
The neurotrophin-mediated control of synaptic transmission is not limited to 
an acute effect over the synaptic vesicles release; in fact BDNF has been shown to 
exert a complex long-term regulation over synapse development. This molecule 
has been implicated in processes such as dendritic and axonal growth in different 
brain areas, including new synapse formation in glutamatergic and GABAergic 
neurons of the hippocampus (Cohen-Cory et al, 1995; Rutherford et al, 1998; 
Vicario-Abejon e /u/., 1998; Sherwood e /u/., 1999).
More evidence for the involvement of neurotrophins in cognition derives from 
research investigating the activity-dependent synaptic expression of these 
molecules. Again, many studies focus on BDNF, finding that the expression of the 
mRNA encoding for this factor is increased in the hippocampus and preffontai 
cortex following exposure to enriched environment (Young et al, 1999; Ickes et 
al, 2000; Zhao et al., 2001), sensory stimulation (Rocamora et al, 1999; Nanda 
et al, 2000) and also physical activity and rumiing (Berchtold et al., 2001). 
Although the mechanism underlying the regulation of BDNF transcription under 
these conditions and their functional significance are not fully understood, these 
fascinating observations suggest there is a reciprocal control between the 
neurotrophins-mediated signalling and synaptic activity.
Most research in this expanding field is conducted on the hippocampus, due to 
the well-known involvement of this stmcture in long-term potentiation and 
memory. For the first time this thesis reports the overexpression of a cluster of
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genes involved in neurodevelopment in the PrL, another brain structure that is 
crucial for cognitive processes, attention and working memory. This finding is in 
accordance with the association between neurotrophic factors expression and 
cognition-relevant synaptic activity that is reported in the literature (Lu et al,
2003).
The complexity of the biological mechanisms that modulate higher cognitive 
functions is likely to require the involvement of multiple factors. In this scenario, 
micro array analysis could be exceptionally beneficial, as it allows the 
simultaneous investigation of many genes. In fact, this strategy led to the 
discovery that the PrL overexpress both BDNF and synapsin II, two genes that 
have a role in the same biological pathway modulating synaptic transmission and 
long-term potentiation (Jovanovic et al, 2000).
The role of other neurodevelopment-related genes overexpressed in the PrL 
(table 3.3) is less clear. The overexpression of genes such as DPYSL3, DPYSL5, 
doublecortin and also BDNF suggests that the PrL neurons may develop novel 
synaptic comiections more frequently than the VO and the M l, and that this 
highly dynamic organisation of the PrL neurocircuitry could underlie the specific 
functions of this subregion in cognitive and attentional processes. However, 
functional studies would be necessary to investigate this hypothesis.
The finding that the PrL overexpresses neurodevelopment-related genes also 
implies that this expression pattern could be considered as a molecular fingeiprint 
of areas involved in certain cognitive processes, especially memory. This is 
supported by the well-known expression of neurotrophins such as BDNF in the 
hippocampus, and their role in long-term potentiation and memory formation (Lu 
et al, 2003). The amygdala is another stmcture where neurotrophins are known to 
regulate the synaptic plasticity underlying fear conditioning and therefore 
amygdala-dependent learning and memory (Rattiner et al, 2005).
Although molecular characterisation of amygdaloid nuclei and hippocampal 
regions using microarrays has been perfomied (Zirlinger et al, 2000; Bonaventui'e 
et al, 2002; Zirlinger, 2003; Datson et al, 2004; Torres-Munoz et al, 2004), it is 
difficult to compare the expression profiles of neurodevelopment-related genes
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reported in these studies to the present work for multiple reasons. First, different 
research strategy, such as the choice of controls, can make direct comparison of 
expression profiles misleading. Second, comparison of microarray data obtained 
using different platforms can lead to unreliable conclusions due to the notorious 
lack of reproducibility across different arrays. However, results from the present 
study and evidence from the literature strongly suggest that the expression of 
neurodevelopment-related genes in specific brain regions is a landmark of a high 
degree of synaptic adaptability to external stimuli and potentially underlies 
cognitive and mnemonic processes.
The increased popularity of micro array analysis in neuroscience and recent 
technological advances have rapidly improved the reproducibility of results when 
the same platform is used. Therefore, the possibility of investigating the 
expression of this class of genes in other brain structures and cortical subregions 
can contribute to identifying the neurobiological basis of cognition.
3.4.3 Localised expression of genes involved in neurotransmission
The LMD/microan'ay analysis showed that each of the brain regions examined 
overexpresses a number of genes involved in neurotransmission. The genes that 
were classified as neurotransmission-related according to their gene ontology 
have a well-known function that is crucial to synaptic transmission; such mRNAs 
encoded for enzymes controlling the synthesis of neurotransmitters, membrane 
receptors and effectors.
Consistent with the prevalence of GABAergic inhibitory neurons in the Rt, 
this region overexpressed the two isoforms of glutamate decarboxylase GAD65 
and GAD67, which control the biosynthesis of G ABA (table 3,2, 
“Neurotransmission” functional class).
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The glutamate ionotropic AMP A receptor subunit GluR4 was also 
overexpressed in the Rt (table 3,2, “Neurotransmission” functional class); this 
finding was strongly significant as the False Discovery Rate was below 0.1% 
when the expression values recorded in the Rt were compared to the Frl, VO and 
Ml. Moreover, the Fold Change (FC) associated with the comparison between the 
Rt and the other regions ranged from 2.5 to 3.1; these values are remarkably high, 
as expression changes in the brain are usually very small.
These findings suggest that GluR4 may have a crucial role in the stimulation 
of the inhibitory intemeurons of the Rt. This brain region receives inputs from 
excitatory collateral fibres generating from the cortico-thalamic and thalamo­
cortical projections (Paxinos, 1995). It has been shown that in the rat the Rt also 
receives inputs from the brain stem and the basal forebrain, and that the majority 
of these fibres are cholinergic (Hallenger et al, 1987; Asanuma, 1989). The 
abundance of AMP A receptor GluR4 subunit in the Rt suggests that the 
stimulation exerted by the glutamatergic fibres originating from the cortico­
thalamic and thalamo-cortical projections could be predominant over the 
cholinergic inputs for the activation of this thalamic nucleus.
The Ô isoform of the protein kinase C (PKC6 ), a crucial enzyme for the 
transduction of signal mediated by protein Gq-coupled receptors (see chapter 4), 
was also overexpressed in the Rt. It is difficult to predict the functional 
implications of this finding, as PKCÔ activity can have multiple biological 
functions (see chapter 4); however, the observation that this gene is highly 
overexpressed in the Rt (Fold Change ranging from 3.1 to 4.7) suggest that PKCÔ 
may play a crucial role in the neurobiology of this brain region.
Another interesting finding is the localised overexpression of specific GABAa 
receptor subunits. The LMD/microarray study showed that the |31 and the a5 
subunits are overexpressed in the Prl, whereas the 5 subunit is overexpressed in 
the VO. Several studies analyse the regional distribution of GABAa receptor 
subunits in the rat brain both at the mRNA level and at the protein level, analysing 
the expression levels in major brain areas, such as neocortex, thalamic and 
hypothalamic nuclei, and cerebellum (Benke et al, 1991; Wisden et al, 1992;
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Fritschy et al, 1995; Pirker et al, 2000). The subunit composition of GABAa 
receptors within a specific brain region has a great biological importance, as it 
determines the physiological characteristics of the inhibitory synapses, as well as 
their pharmacological properties (Fritschy et al, 1995). Some publications 
highlight that the specificity of benzodiazepines for GABAa receptors depends on 
their subunit composition (Pirker et al, 2000). For the first time the present study 
clearly shows that not only the GABAa receptors subunits composition is specific 
to the brain areas, but also, at a higher level of anatomical specificity, subregions 
of the prefrontal cortex such as the PrL and the VO show overexpression of 
specific subunits. This finding highlights that the GABAa receptors subunits 
composition can be analysed with a greater degi'ee of anatomical specificity. It 
also suggests that the specific subunits overexpressed in the PrL and the VO may 
contribute to the electrophysiological and neurobiological characteristics that 
underlie the cognitive functions of these subregions.
3.4.4 Localised expression of genes involved in ion transport
Another interesting finding of the LMD/microarray study is the localised 
expression of genes involved in the control of ion transport. Four different 
potassium channels were overexpressed in the Rt. The potassium chamiels 
overexpressed in this area have different structure and biological properties.
One of the genes encoded for the Kv3.1 potassium chaimel, a member of the 
Kv3 subfamily. The Kv3 potassium channels allow the efficient re-polarization of 
the neuronal membrane after high-frequency repetitive firing (Rudy et al, 2001) 
and therefore are expressed in neuronal population that fire action potentials with 
high frequencies (Gan et al, 1998). Weiser et al (1995) reported that the Kv3 
potassium channels are expressed in the ventral thalamus, including the Rt; 
moreover this subunit is expressed in parvalbumin-containing intemeurons. The
114
LCM/microarray study showed that the Rt overexpresses both Kv3 potassium 
channels and parvalbumin, in accordance with the prevalence of GABAergic 
inhibitory neurons in this brain region. This finding suggests that Kv3 channels 
and parvalbumin (see chapter 4) could contribute to the specific neurobiological 
properties of the Rt inhibitory neurons.
K v ll.l is another potassium channel that was overexpressed in the Rt. This 
voltage-gated, six transmembrane domains chamiels belongs to the EAG-related 
subfamily, which was first described in Drosophila (reviewed by Bauer et al, 
2001). It is difficult to predict the biological function of K v ll.l in the Rt; 
however its overexpression in this area suggest that it may play a specific role in 
the ion trafficking in neurons of this area, contributing to the neurotransmission.
FXYD6  was the gene involved in ion transport that showed the most specific 
regional expression pattern. This gene, which is involved in the modulation of the 
Na-K-ATPase activity, was overexpressed in the PrL with a Fold Change ranging 
from 9.35 to 10.21; suggesting that ion trafficking is regulated in a region specific 
maimer (see chapter 4).
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C h a p t e r  4 . C o n f ir m a t io n  of  R e g io n a l  
E x p r e s s io n  Pr o fil e s  G e n e r a t e d  b y
LMD/MICROARRAY USING IN  SiTU
H y b r id is a t io n
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4.1 Introduction
4.1.1 Confirmation of microarray results
Standardised manufacturing processes and increased use in gene expression 
analysis have made micro array technology increasingly more reliable and robust. 
Moreover, the recent statistical packages for microarray data analysis allow a 
strict control over the false discovery rate (the FDR is a convenient method to 
express statistical significance of microaiTay data. The FDR value indicates the 
proportion of false positives in a certain set of tests declared positive by statistics; 
see chapter 3). However, a number of false positive results could still be detected, 
due to the amount of data generated by this type of experiment. In this scenario, 
confirmation of differentially expressed genes by alternative techniques is 
mandatory to validate the microarray results and to verify the reliability of crucial 
upstream manipulations, such as linear amplification.
In situ hybridisation (ISH) was selected as the technique of choice for the 
validation of the present microarray study. As the microarray experiment was 
designed to identify localised gene expression patterns, ISH was an obvious 
choice for the confirmation of this type of data. In fact, this technique has the 
advantage of visualizing the transcript in the anatomical structure where it was 
expressed; moreover, it is suitable for accurate quantification of the expression 
levels (Wisden and Morris, 2002). The ISH autoradiogi'ams also allow the 
analysis of the laminar expression in the cortical layers; this additional 
information is very useful to complement the data obtained with the 
LMD/microarray strategy. Another advantage of ISH is that this technique does 
not involve any amplification of the amount of mRNA originally expressed in the 
anatomical structure analysed; therefore it is helpful to verify the validity not only
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of the microarray hybridisation, scanning and analysis processes, but also the 
linearity of the amplification procedure.
Clearly, a comprehensive validation of the vast amount of data generated by a 
micro array study is not practically achievable; therefore, verification experiments 
can be perfonned only on a small number of selected genes. For the present study, 
13 genes were selected for validation using ISH (table 4.1). The selection criteria 
were based on the localised differential expression and the function of the genes. 
Firstly, genes enriched in all schizoplnenia related regions examined in the 
microarray study (PrL, VO and Rt) were selected for validation. Additionally, the 
validation experiments included genes that showed False Discovery Rate ranging 
from 0.00 to 0.93 and Fold Change ranging from 1.51 to 17.77 in order to verify 
both small and great expression differences. Lastly, the biological function of the 
genes was taken into account, giving priority to genes that could be involved in 
the neuropathology of schizophrenia and genes controlling crucial neurobiological 
mechanisms in the cortex and the Rt, such as neurotransmission and development.
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Regional
selectivity
Gene 45mer probe sequence
FXYD6 CTC AGA GGC AAG AAT TOC TGG GTG TTC TGT AAA GGG TGG GGC GGA
G A B A aP I AAG AAC ATT CGG GAC CAC TTG TCT ATG GAG TTC ACG TCA GTC AAG
PrL Synapsin II GCC CTC GTG TAT CTG AAG AGC TAA TCT GAA AAG AGG CTG GCA AAG
Wolframin CCT CAC AGC AAC ATG CAC CGA GGC GTC CTC CAG TGG CAG ACA CTC
Doublecortin TCT GGC CCA GAG GTT AAA AAT AGA TCT CCT ACC ACA ATT TCT ATC
CaMKlI Inhibitor a GCC GTC GCC GTA GGG GCT CAG CTT CTC GTC GCC GTA GGG CAG CAC
VO G A B A aô ATG GCG TTC CTC ACG TCC ATC TCT GCC CTT GGC TTC GTG ACC TTG
Stk23 ACC CAG CAG GTT GGG AGA ACA GCT CCC ACA GAG TGG AAG AAG TTG
RGS3 TTG TAA GTT AAG AAA ACT GAC AGG GTG AGG GCT CTC CTA TTA CCG
PLCp4 TGT GCC ATA CAT TGA CTT AAC CGG TAT TTA TTT GGT GTT AGG TTA
Rt PKCÔ TTC TTC ATG GGC AGT GCG GAT GCA AAC CAG GGC AGA TGG GCC TAC
Parvalbumin CCC CAG CTC ATC CTC CTC AAT GAA GCC ACT TTT GTC TTT GTC CAG
Calretlnin GAT ATT CAT CTC CTT CTT GTT CTT CTC ATA CAG ATC CTT CAG GAG
Table 4.1
Genes showing region-selective expression according to the LMD/microarray study that 
were selected for validation by in situ hybridisation. (Refer to chapter 2 for details on 
design o f  the specific 45mer oligonucleotide probes).
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4.1.2 Genes overexpressed in the P rL
4.1.2 JFXYD 6
The FXYD family is composed of small hydrophobic proteins with a single 
transmembrane domain (Cornelius et ah, 2003). This group of short proteins is 
named after their conserved four aminoacids motif, and are thought to regulate the 
activity of the Na-K-ATPase (Geering, 2006; Garty et al, 2005).
The Na-K-ATPase is a ubiquitous enzyme that is cmcial to actively maintain 
the physiological ionic concentration of the intracellular compartment. Some 
important biological roles of this transporter are the restoration of the resting 
membrane potential in excitable cells and providing energy for co- and counter- 
transport systems (Geering, 2005). Specific cells finely modulate the activity of 
Na-K-ATPase according to their biological characteristic using different 
mechanisms, such as phosphorylation, expression of specific isoforms of the 
enzyme and expression of specific modulator proteins (Geering, 2005).
The members of the FXYD family are thought to be tissue-specific regulators 
of the Na-K-ATPase and are preferentially expressed in electrically excitable 
cells, which require a complex and dynamic modulation of the enzyme (Crambert 
et al, 2002; Béguin et al, 2002; Geering et al, 2003). These proteins directly 
interact with the Na-K-ATPase via hydrophobic interactions and modify the 
enzyme kinetics (Cornelius et al, 2003).
FXYD6 , also known as phosphohippolin, has been recently characterised and 
cloned (Kadowaki et al, 2004). Protein expression studies in rat show that 
FXYD 6  is predominantly present in the brain, and in vitro evidence suggests that 
the protein is present in neuronal cells, but not in glial cells (Kadowaki et al,
2004). Interestingly, the expression level of FXYD6  in the forebrain, 
hippocampus, cerebellum and brain stem changes during postnatal development, 
decreasing after 3 weeks (Kadowaki et al, 2004).
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The role of FXYD6  suggests that this regulator protein could have a crucial 
role in the ion transport and neurotransmission in neurons of specific brain areas; 
moreover, the development related expression changes reported by Kadowaki et 
al, (2004) suggest that this protein may have a role in neurodevelopment.
4.1.2.2 Wolframin
The wolframin gene encodes an 890-aminoacid protein that does not show 
homology with any known sequence (hioue et al, 1998). Although the stmcture 
of this macromolecule is currently unknown, prediction suggests that it presents 
nine or ten transmembrane domains (Strom et al, 1998; Hofinann et al, 2003). 
Recent studies show that wolhamin is predominantly localised in the endoplasmic 
reticulum (Cryns et al, 2003; Osman et al, 2003), and that it is likely to be an 
integral endoglycosidase membrane glycoprotein (Takeda et al, 2001).
The exact biological function of wolframin is currently unclear; however, 
Osman et al (2003) showed that it is involved in calcium transport in the 
endoplasmic reticulum. In fact, overexpression of wolframin in oocytes resulted 
in increased intracellular calcium concentration, as a consequence of an increased 
release of this ion from the endoplasmic reticulum (Osman et al, 2003). 
Following these findings, it was suggested that wolfiramin might be a novel 
calcium chamiel located in the endoplasmic reticulum, or alternatively, a regulator 
of calcium chaimel activity in this sub cellular location. This function may be 
crucial for excitable cells, such as neurons, which require a rapid calcium transfer 
from the endoplasmic reticulum for ion homeostasis and regulation of secretion.
Most of the research on wolframin focuses on the role of this gene in Wolfram 
syndrome. This autosomal recessive neurological disease, also known as 
DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy and deafness) is 
caused by mutations on the wolframin gene, suggesting that loss of function of the 
wolframin protein leads to the neurop atholo gical changes underlying the complex 
sympomatology of Wolfram syndrome (Gerbitz et al, 1999). Patients suffer fr om
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non-inflammatory atrophic changes in pancreatic islets, optic nerve, chiasm, tracts 
and a number of brain structures such as lateral geniculate nuclei, basis pontis, 
hypothalamic paraventricular and supraoptic nuclei (Scolding et al, 1996; 
Shannon et al, 1999; Khanim et al, 2001). These widespread degenerative 
changes trigger the onset of diabetes, vision loss and serorineural deafiiess.
Interestingly, Wolfram syndrome patient show a high proportion of 
hospitalisation for psychiatric illness and self-reported mental illness (Swift et al,
2001). Although the role of wolframin in psychosis remains unclear, evidence 
show that mutations of this genes can be associated with at least some forms of 
psychiatric illness (see chapter 5).
4.1.2.3 Synapsin II
Synapsin II belongs to a family of proteins specifically expressed by neurons 
that are associated with the membrane of the synaptic vesicles (reviewed by 
Hilfiker et al, 1999; Ferreira et al, 2002). Synapsins, are encoded by three 
different genes, synapsin I, II and III; additionally, alternative splicing of the 
transcripts yields the isoforms la, Ib, Ila and Ilb (Kao et al, 1999).
The stmcture of synapsin isofonns includes variable domains, however some 
domains that are cmcial for their subcellular localisation and function are 
conserved in all isofonns (Sudhof et al, 1989). The domain A is present in all 
synapsins, and it forms the substrate for phosphorylation catalysed by both protein 
kinase A and Ca^Vcalmodulin dependent kinase I (CaMKI) (Hosaka et al, 1999). 
This site is crucial for the association of the protein with the membrane of the 
synaptic vesicle; . a molecular interaction that is finely regulated by 
phosphorylation (Hosaka et al, 1999). The domain C is also conserved; this 
stmcture is a binding site for ATP (Sudhof et al, 1989). Although synapsins do 
not show constituent ATPase activity, it has been suggested that synapsins may 
have an enzymatic role using the ATP hydrolysis to catalyse some unidentified
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reaction (Hilfiker et al, 1999). This hypothesis is supported by the structural 
similarity between the domain C and some bacterial ATP-dependent synthetases 
(Esser et al, 1998). Another important function of the domain C is the binding 
with other synapsins, which mediates the formation of homo- or heterodimers 
(Hosaka a/., 1999).
The role of synapsins is closely related to their subcellular localization. Their 
association with the synaptic vesicles suggests that these proteins regulate 
neurotransmitter release. In fact it has been demonstrated that synapsins regulate 
the availability of synaptic vesicles for exocytosis (Hilfiker et al, 1999). hi the 
presynaptic tenninals only a small number of vesicles, named the releasable pool, 
are located in the proximity of the plasma membrane and are available for 
immediate release. The reserve pool, which comprises the majority of vesicles 
available in the presynaptic terminal, is located away from the plasma membrane 
(Greengard et al, 1993). This organisation allows fine modulation of 
neurotransmission and important biological mechanisms such as synaptic 
plasticity. Synapsins play a central role in the organisation of presynaptic 
terminals, as they regulate the number of vesicles held in the reserve pool. The 
synapsin-held vesicles are required for neurotransmission during high levels of 
neuronal activity, such as upon high frequency stimulation that eUcits synaptic 
depression (Hilfiker et al, 1999).
Regulation of the proportion of vesicles held in the reserve pools is not the 
only mechanism by which synapsins modulate neurotransmission. Domain E, 
which is found in the la, Ila and III isoforms (Kao et al, 1998; Sudhof et al, 
1989), mediates control over neurotransmitter release kinetics. It has been 
suggested that domain E-containing synapsins directly slow the reaction of fusion 
between the vesicles and the plasma membrane, an event that is independent from 
the distribution of the vesicles in the releasable and reserve pools (Hilfiker et al,
1999).
Recent studies focus on additional functions of synapsins (reviewed by 
Ferreira et al, 2002). Along with the complex control over kinetics of 
neurotransmitter release, these proteins play a key role in synapse development
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and maintenance. Specifically, it has been found that suppression of synapsin II 
impairs synaptogenesis in developing hippocampal neurons and causes synaptic 
loss in neurons that had foiined their synapses (Ferreira et al, 1995). Moreover, 
synapsin Il-depleted hippocampal neurons show reduced and aberrant neurite 
elongation (Ferreira et al, 2002).
The multiple and complex roles of synapsin II in neurotransmission and 
development make the regional expression profile of this gene interesting and 
relevant to pathologies that may involve alteration of synaptic transmission. In 
fact, recent studies report the involvement of synapsin II in schizophrenia and in 
the neurochemical changes following antipsychotic administration (see chapter 5).
4J.2.4 GABAa/31
G ABA (y- anuninobutyrr ic acid) is the main inhibitory neurotransmitter in the 
mammalian brain. This molecule binds to three types of membrane receptors, 
classified as GABAa, GABAb and GAB Ac. The GABAa receptors are 
transmembrane ion channels with selective permeability to chloride ions that 
become activated when GABA binds to a specific domain on the extracellular 
side. These GABA-activated channels mediate fast inliibitory neurotransmission 
by allowing an influx of chloride ions in the postsynaptic neuron, and therefore 
hyperpolarizing the postsynaptic membrane.
GABAa receptors have a pentameric structure, which is assembled with 
subunits from at least 19 types classified according to their amino acid sequence 
homology in the following groups: a, p, y, 5, s, 7t, 0, and p (Rabow et al, 1995; 
Bonnert et al., 1999). Although all the subunit types could theoretically be 
assembled in thousand of different pentamers, the majority of the GABAa 
receptors present a fixed combination of two a, two p and one y subunits (Rabow 
e ta l, 1995).
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The exact subunit composition of the GABAa receptor determines its 
neurochemical and pharmacological properties (reviewed by Mehta et al, 1999). 
The affinity for the ligand and the pharmacological specificity for allosteric 
modulators such as benzodiapines are two key features that are strongly 
influenced by the presence of specific subunits (Bureau et al, 1990; Pritchett et 
al, 1990; Pritchett £z/., 1989).
The importance of the GABAa subunit composition is supported by their 
highly diversified expression across the brain (Laurie et al, 1992; Wisden et al, 
1992; Pirker et al, 2000), suggesting that differential expression of the genes 
encoding for these proteins is crucial to the neurochemistry of specific brain 
regions (Steiger et al, 2004). Moreover, GABAa subunit expression shows clear 
changes during post-natal development, probably reflecting changes in the 
neuronal composition and neurocircuitry (Laurie et al, 1992).
pi is one of the subunits that show very specific regional expression in the rat 
brain. Wisden et al (1992) reported that the mRNA encoding for the pi subunit is 
abundant in the hippocampus, with lower levels of expression in the amygdala, 
neocortex, basal nuclei and septum. The same study reported a higher expression 
in the deep layers of the neocortex compared to layers 1, 2 and 3. Interestingly, 
the expression pattern of the pi subunit is similar to that of the a5 subunit 
(Wisden et al, 1992), suggesting that the proteins may colocalise and that 
GABAa receptors containing them may have a role in the physiology and 
neurochemistry of areas such as the hippocampus and the neocortex.
Although the overall expression pattern of the GABAa receptor pi subunit has 
been reported both at the mRNA level and at the protein level (Pirker et al, 2000; 
Wisden et al, 1992), there is no quantitative study analysing the expression 
differences of this gene in specific cortical subregions.
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4.1.3 Genes overexpressed in the VO
4.1.3.1 GABAaS
Studies based on immunocytochemistry and in situ hybridisation show that the 
6  subunit of the GABAa receptor is expressed in the cerebellum, thalamus, 
hippocampus, neocortex and striatum (Pirker et al, 2000; Wisden et al, 1992).
Pirker et al (2000) also showed that the distributions of the y and the 5 
subunits are complementary, suggesting that these subunits do not co-localise, and 
that GABAaÔ could be incorporated in the pentameric complex instead of 
GABAAy with some specific a subunits. In fact GABAaÔ co-localise with the a4 
subunit in the thalamus and with the a6 subunit in the cerebellum (Pirker et al,
2000). Although it has been shown that a4 and a6 can form functional complexes 
with the y subunit as well, their specific co-localisation with the 5 subunit 
suggests that these receptors may have a specific function in the brain regions 
were they are expressed. A study analysing the subcellular distribution of 
GABAaÔ-uô complexes in the cerebellar granular cells showed that these 
receptors are exclusively localised in the extrasynaptic dendritic and somatic 
membranes, where they mediate tonic inhibition (Nusser et al, 1998).
The overall distribution of GABAaÔ in the brain cortex has been investigated 
both at the mRNA and at the protein level (Pirker et al, 2000; Wisden et al, 
1992); however there is no quantitative study analysing the expression differences 
of this gene in specific cortical subregions.
4.1.3.2 CaMKII inhibitor a
CaMKII (Calcium/calmodulin-dependent kinase) is a serine/threonin kinase 
activated by the Ca^Vcalmodulin complex (reviews by Hudmon et al, 2 0 0 2 ;
126
Yamauchi, 2005). This enzyme phosphorylates a broad range of substrates, 
including structural proteins, enzymes and important regulatory protein in the 
brain such as synapsins (Bemiett et al, 1983). Depending on the site of expression 
and the substrates, CaMKII modulates many biological pathways in response to 
increased intracellular calcium concentration. CaMKII catalysed phosphorylation 
is known to regulate cytoskeletal organisation, intracellular calcium homeostasis, 
carbohydrate metabolism and neurotransmission (Hudmon et al, 2002). Although 
CaMKII is ubiquitous, the expression in the brain is particularly prominent, 
suggesting that this enzyme is cmcial for the modulation of important neuronal 
functions and to coordinate the cellular response to Ca^ "^ , which is the most 
common second messenger.
One of the roles of CaMKII in the brain is the modulation of learning and 
memory. Strong evidence support the role of this enzyme in cognition; in fact its 
activity is necessary for long term potentiation, a form of synaptic plasticity that is 
cmcial for learning processes (Malinow et al, 1989; Fukunaga et al, 1993; 
Otmakhov et al, 1997; Guyang et al, 1997; Hinds et al, 1998).
Many features of CaMKII and its involvement in complex cortical functions 
depend on the regulation of the enzymatic activity, hi absence of stimulus, 
CaMKII is inliibited by an autoregulatory domain, which binds the catalytic 
domain preventing interaction with the substrate. Both catalytic and 
autoregulatory domains are located on the same polypeptide (Kemp et al, 1996). 
The bond with the Ca^^/calmodulin complex dismpts the interaction between the 
catalytic and the autoregulatory domain, exposing the site of interaction with the 
substrate and therefore activating the enzyme (Hook et al, 2001).
Along with the activation mechanism from basal state described above, the 
activity of CaMKII can be finely modulated by regulatory autophosphorylation, 
which disables the autoregulatory domain causing a Ca^Vcalmodulin independent 
activation (Hudmon et al, 2002). Moreover, CaMKII can be inhibited by the 
recently characterised specific inliibitor proteins (Chang et al, 1998; Chang et al, 
2001).
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Two isofonns of CaMKII inliibitor have been characterised and named CaM- 
KIINa and CaM-KIINp, as they co-localise with the a and P iso forms of the 
enzyme respectively. CaM-KIIN binds the catalytic domain of the enzyme 
causing a potent non-competitive inhibition. Although CaMKII is widely 
expressed in many types of cells, the expression of the inliibitor is much more 
restricted; interestingly, CaM-KIINa seems to be specific for the brain (Chang et 
al, 1998; Chang et al, 2001). These findings suggest that along with the 
Ca^^/calmodulin interaction and the autophosphorylation, CaMKII activity can be 
regulated at a further level in the brain. The tissue specific expression of CaM- 
KIIN may be crucial to the fine enzymatic modulation that underlies synaptic 
plasticity and therefore cognitive processes.
The regional distribution of CaM-KIINa mRNA in the rat brain has been 
described by Chang et al (2001). ISH analysis showed that the transcript is 
present predominantly in the forebrain and the hippocampus, with little or no 
signal in the midbrain and in the cerebellum. The same study reported expression 
also in the olfactory bulb and the caudate-putamen; moreover, the mRNA was 
more prominent in the layers II and III of the neocortex compared to the deep 
layers.
4.1.4 Genes overexpressed in the Rt
4.L4.1 RGS3
Guanine nucleotide-binding proteins (G protein) are ubiquitous effectors that 
are coupled to a vast number of membrane receptors. In the brain G proteins play 
a key role in the signal transduction of neurotransmitters binding specific 
receptors with seven transmembrane domains that are coupled with this 
mechanism (Manji, 1992).
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Wlien inactive, G proteins are a heterotrimeric complex constituted by the 
subunits a, p and y associated to the seven membrane-spanning segments 
receptor. The Ga subunit contains the binding site for the guanine nucleotide, and 
is associated to GDP in the inactive state. The GDP stabilises the interaction with 
the p and y subunits, maintaining the transduction system inactive when the 
receptor is not activated. Binding of the ligand on the specific site of G protein- 
coupled receptors elicits a conformational change that is transmitted to the 
intracellular side; consequently, the Ga subunit releases GDP and binds GTP. The 
guanine nucleotide switch is a key step in the activation/inactivation cycle of G 
protein mediated signal transduction, as the Ga subunit loses affinity for the Py 
complex., when it is bound to GTP. The dissociated Ga-GTP complex is the 
activated factor that interacts with specific effector enzymes stimulating their 
activity. Inactivation occurs when the GTP is hydrolysed to GDP, restoring the 
affinity of the Ga subunit for the py complex; the following re-fomiation of the 
heterotrimeric complex completes the cycle.
The Ga subunit has an intrinsic GTPase activity that is crucial for the 
termination of the signal. However, the rate of GTP hydrolysis in vitro does not 
correspond with the faster kinetics shown by the signal termination in vivo (Drats 
et al, 1987; Vuong et al, 1991), suggesting that other mechanisms contribute to 
the regulation of GTP hydrolysis in the G protein activation/inactivation cycle.
In fact, the GTPase activity of the Ga subunit is enlianced by a group of 
proteins known as regulators of G protein signalling (RGS). (reviewed by 
Dohlman et al, 1997; Ross et al, 2000) RGS interact directly with the Ga subunit 
and increase the rate at which the GTP is hydrolysed to GDP (Ross et al, 2000). 
Interestingly, RGS do not make direct contact with the GTP, and therefore are not 
likely to interact with the catalytic GTPase site. This suggests that RGS do not 
have a direct role in the Chemistry of GTP hydrolysis, but rather cause a 
conformational change in the Ga subunit structuie that increase the efficiency of 
the GTPase (Tesmer et al, 1997; Sprang, 1997).
The activity of RGS is crucial in the brain, as they determine the kinetics of 
tennination of the signalling initiated by a number of neurotransmitters.
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Currently, more than 2 0  different mammalian RGS proteins have been identified 
(Ross et al, 2000), and little is known about the exact physiological role of 
specific isoforms. Also, it seems unlikely that each RGS protein regulates one, or 
a small subset of Ga subunits (Dohlman et al, 1997; Bourne et al, 1991; Mittal et 
al, 1996); therefore it is difficult to understand the biological significance of the 
diversity of RGS proteins.
A degree of selectivity is given by the specific expression of RGS proteins. As 
expected, most of the RGS proteins are found in the brain, where fine regulation 
of signal transduction is paramount; however the expression of specific RGS is 
known to be restricted to anatomical structures (Gold et al, 1997). Gold and co­
workers showed that RGS3 is one of the isoforms with the most restricted 
expression pattern. No mRNA encoding for this protein was found in the cortex, 
except for very faint signal in the piriform cortex; expression was also low or 
absent in the brainstem and hypothalamus. The only site that showed prominent 
expression of RGS 3 according to Gold’s analysis was the thalamus.
4.L4.2PLCJ34
PLCps (phospholipase C p) are a crucial component of the Gq protein 
signalling pathway. The enzymes belonging to the PLC family degrade 
phosphatidylinositol-4,5 bisphosphate (PIP2) to produce diacylglycerole (DAG) 
and inositol-1,4,5 trisphosphate (IP3) (reviewed by Rhee, 2001). DAG and IP3 are 
second messengers with important functions, such as the activation of PKCs (see 
above) and the mobilization of Ca^  ^ions from the intracellular pool.
The enzymes belonging to the different PLC subclasses (p, y, Ô and e) do not 
have conserved sequences, except for the catalytic domains, known as the X and 
Y domains. The PH (pleckstrin homology) domain is present in the PLC p, y, and
5, although the aminoacidic sequence is partly specific; the differences in the PH 
domain contribute to the different mechanisms of activation of the isozymes 
(Litosch, 2002). The main structural difference between PLCps and the isozymes
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of the other subclasses is the presence of a long sequence of approximately 450 
aminoacids at the C terminal. This domain has several key functions, such as the 
subcellular localization of PLCPs to membranes or cell nucleus (Kim et al, 1996) 
and the specific activation of this subclass by G proteins (Wu et al, 1992).
The main mechanism of activation for PLCps is via the interaction with 
protein Gaq-GTP. The protein Gq is activated by the interaction of a seven 
transmembrane domains receptor with its specific ligand. This event is followed 
by the release of GDP from the Gaq subunit, which consequently binds GTP and 
dissociates from the Py subunit. The activated Gaq-GTP complex interacts with 
the C-terminal domain of PLCPs, causing the activation of the enzyme.
Although all the PLCPs are activated by Gaq, there are other mechanisms of 
activation that can be specific for some isofonns of the enzyme. Cunently, four 
isozymes are known, namely PLCpl, PLCp2, PLCpS and PLCp4 (Rhee, 2001). 
An alternative mechanism of activation is via the interaction with the Py subunit 
of G proteins after it is released from the a subunit (Smrcka et a l, 1993; Lee et al, 
1994). The py subunit is common to all the G proteins; therefore PLCPs can be 
activated not only by Gaq proteins, but also by the Py subunit released from the 
Gas and Gai proteins. PLCp4 is the only isozyme that is not activated by the Py 
subunit; hence it specifically requires Gaq interaction for its activity (Rhee, 2001).
The PLCp isozymes differ not only for the mechanism of activation, but also 
for their specific expression pattern. PLCp4 expression is restricted to the retina 
and some brain regions. Roustan et al (1995) reported that this isoform is 
abundant in the cerebellar Purkinje cells and is also present in the substantia nigra, 
the medial geniculate bodies and the thalamic nuclei.
4.L4.3PKCÔ
The PKCs (protein kinase C) are a group of serine/threonine kinases that are 
involved in a vast number of biological functions, including cell growth and
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apoptosis. The specific role of each isoform of the PKC family depends on the 
subcellular localization as well as on structural characteristics of the enzyme 
(reviewed by Steinberg, 2004).
The PKCs are single polypeptide chains, with a highly conserved C-terminal 
catalytic domain; this sequence contains the binding sites for the ATP and the 
substrate. The N-temiinal contains the autoregulatory pseudosubstrate domain and 
the membrane-targeting domains, named Cl and C2. The function of the Cl and 
C2 domains is to determine the subcellular localization of the enzyme, which is 
usually associated with the plasma membrane (Cho, 2001; Hurley et al, 2000). 
The N-terminal structure is not conserved, but varies in different isoforms and 
determines the mechanism of activation of the enzyme (Steinberg, 2004); in fact 
the PKCs are subdivided into thi*ee main families according to the structure of 
their regulatory domains.
The cPKCs (conventional PKCs) contain both Cl and C2 membrane targeting 
modules. The Cl domain is the binding site for DAG (diacylglycerol), which is 
crucial for the activation of the enzyme and for its translocation to the plasma 
membrane. The C2 domain binds anionic phospholipids on membranes in a 
calcium dependent manner, as this module contains multiple calcium binding 
residues. The cPKCs are therefore activated by DAG and Ca^ """, which are the 
second messengers released after activation of receptors coupled with protein Gq.
The nPKCs (novel PKCs), also have Cl and C2 domains; however, the C2 
module lacks the calcium binding motifs. Hence the nPKCs are activated mainly 
by DAG, and do not require increase of intracellular calcium concentration. PKCô 
belongs to this subclass; this isoform has a unique C2 domain containing a 
binding site for SFK (Src family kinase), therefore the phosphorylation of the C2 
domain is a specific regulatory mechanism for PKCô (Pappa et al, 1998)
Another class of PKCs is the atypical isofonns (aPKCs), which lack a C2 
domain and do not bind DAG, therefore the mechanism of activation of these 
enzyme is DAG/Ca^^ independent, and involves different phospholipid cofactors 
(Hirai et al, 2003; F ares e, 2002).
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The activation of PKCô is mainly dependent on the binding of DAG and the 
consequent translocation of the enzyme to the plasma membrane. The interaction 
between the DAG-Cl domain and the membrane cause a confonnational change 
that frees the catalytic domain from the autoregulatory pseudosubstrate domain, 
activating the enzyme (Steinberg, 2004), Phosphorylation of an activation loop is 
also an important mechanism of activation for PKCô, as suggested by recent 
studies (Hamaguchi et al, 2003; Rybin et al, 2003; Rybin et al, 2004).
The PKCs have multiple roles and participate in several complex biological 
pathways; their subcellular localisation seems crucial not only for the activation 
but also for the substrate specificity. It has been shown that PKCô is involved in 
the biological pathways controlling cell cycle and apoptosis (Steinberg, 2004). 
Unlike other isoforms, PKCô slows proliferation and promotes differentiation 
(Fukumoto et al, 1997; Ashton et al, 1999; Braun et al, 2003). PKCô also has a 
role in the modulation of inflannnatory processes, as it activates NFkB, which is a 
transcription factor controlling several biological processes including 
inflammation and immune response (Page et al, 2003). The exact biological 
function of PKCô in the brain and specifically in the Rt is unclear. However, the 
overexpression of the mRNA encoding for this enzyme in the Rt could have a 
relevant biological significance, as it is involved in the modulation of crucial 
biological pathways, such as the activation of the MAPK (mitogen-activated 
protein kinases) cascade and the response to neurotransmitters activating Gq 
proteins (Steinberg, 2004).
4.1.4.4 Parvalbumin
Paiwalbumin is a low molecular weight protein that binds Ca^ "^  ions with high 
affinity. The structure and the chemical properties of parvalbumin have been 
described by several authors (reviewed by Pauls et al, 1996). X-ray 
crystallography and NMR studies show that the parvalbumin polypeptide is
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folded into six helices, named A to F, that form three “EF hands” domains. These 
structures, composed by two helices spaced by a loop, are the binding sites for the 
Ca^  ^ ions (Pauls et al, 1996); in fact, the metal ions interact with seven residues 
situated in the Ca^  ^ binding loop (Strynadka et al, 1989). Only two of the 
parvalbumin EF hands are functional, hence this protein can bind two Ca^ "^  ions. 
In the third EF hand, the two helices are connected by a non-functional truncated 
loop, which is unable to interact with metal ions (Pauls et al, 1996).
Unlike many Ca^^-binding proteins that feature EF hands (see below), 
parvalbumin metal-binding sites are not specific to calcium. In fact, the 
paiwalbumiii EF hands are best described as Ca^^/Mg^  ^mixed metal-binding sites 
with high affinity for calcium and moderate affinity for magnesium, where the 
two metal ions compete for the same binding site (Haiech et al., 1979). The 
different affinity for calcium and magnesium is a key feature of parvalbumin and 
influence the buffering capacity of this protein, as the selectivity for the two metal 
ions depends on their relative concentration (Pauls et al, 1996).
Although the structure and the biophysical properties of paiwalbumin are very 
well known, its physiological role is still unclear, especially in non muscular cells. 
Parvalbumin is abundant in the sarcoplasm of muscle cells, where it may facilitate 
Ca^ "*" transport (Pauls et al, 1996).
It has been suggested that the buffering properties of parvalbumin and other 
calcium-hinding proteins can have a neuroprotective role in the central nervous 
system. Parvalbumin-dependent protection against the neurotoxicity caused by 
calcium overload has been shown in tissue from patients with motor neuron 
disease or temporal lobe epilepsy (Sloviter et al, 1989; Ince et al, 1993).
Interestingly, parvalbumin and other calcium-binding proteins are specifically 
expressed in certain subclasses of neurons; therefore this protein is commonly 
used as a marker to identify specific neuronal populations. In the cerebellum 
parvalbumin is abundant in the Purkinje cells, and is also expressed in two 
subclasses of intemeurons, the stellate and basket cells (Schwaller et al, 2002). 
The expression of parvalbumin has also been studied in the rat prefrontal cortex, 
where it is expressed in two subclasses of fast-spiking GABAergic intemeurons.
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the basket cells and the chandelier cells (Freund, 2003). Although the exact 
function of parvalbumin in these neurons is unclear, the Ca^  ^buffering properties 
could be important for the electrophysiological characteristics of chandelier and 
basket neurons, influencing their capacity to exert a synchronised inhibitory firing 
pattern (Freund, 2003).
Functional and expression studies on parvalbumin are mainly focused on the 
cerebellar physiology (reviewed by Schwaller et al, 2002) and the role of this 
protein in the neuropathological alteration observed in the schizophrenic 
prefrontal cortex (Lewis et al, 2005; Lewis et al, 2004; Eyles et al, 2002). In 
fact, it has been reported that the schizophrenic prefrontal cortex show specific 
alterations of the parvalbumin-containing chandelier intemeurons (Lewis et al,
2004). Parvalbumin is also likely to play a key role in the physiology of the 
reticular thalamus, where the mRNA encoding for this protein is very abundant, 
as shown by the LMD/microan'ay study. These interesting findings suggest that 
parvalbumin could be important for the neurophysiology of the GABAergic 
intemeurons of this brain region.
4.1.4.5 Calretinin
Calretinin is another calcium-binding protein that is overexpressed in the Rt 
according to the LMD/microarray study. Like parvalbumin, this protein is 
specifically expressed in some subclasses of inhibitory intemeurons; therefore the 
high abundance of mRNA detected in the Rt is consistent with the prevalence of 
GABAergic cells in this brain region.
The stmcture of calretinin includes six EF hands, of which five are functional 
and can bind Ca^ "^  ions (Schwaller et al, 1997). The polypeptide sequence 
fonning the EF hands is very consei-ved in different types of calcium-binding 
proteins, although small differences influence the cation specificity and kinetics 
(Schwaller et al, 2002). Interestingly, the sequences of the non-functional EF
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hands are also conserved in several calcium-binding proteins; these “degraded” 
structures may have an unknown functional importance.
Unlike parvalbumin, the Ca^  ^binding sites of calretinin are highly specific, so 
this protein does not bind other divalent cation such as Mg^ "^  (Haiech et al, 1979). 
The Ca^^-binding kinetic is another important biophysical property that is 
different in parvalbumin and calretinin; in fact the latter is considered a fast 
buffer, whereas the former is a slow-onset buffer (Lee et al, 2000; Schwaller et 
al, 2002). This property could be crucial for the specific physiological functions 
of the neurons where these proteins are expressed.
The exact functions of calretinin are still hypothetical, despite the abundance 
of data on the structure and biochemical properties of this protein. Like other 
calcium-binding proteins, the Ca^ "^  buffering capacity has been associated to a 
neuroprotective effect in neurons, hicreased resistance to induced excitotoxicity 
has been observed in vivo in neurons contained calretinin compared to neurons 
that do not express this protein (Mockel et al, 1994; Terro et al, 1998); the 
neuroprotective properties of calretinin have also been observed in cultured 
neurons (Lukas et al, 1994).
Along with the neuroprotective properties, it can be hypothesized that the Ca^  ^
buffering capacity of calretinin can be important for a number of biological 
processes, especially in excitable cells such as neurons, where the calcium 
homeostasis is crucial to their physiological functions. In fact calretinin can be 
part of a complex regulatory mechanism controlling the intracellular calcium 
concentration that also include membrane channels, intracellular compartments 
involved in calcium sequestration and release, and other calcium-binding proteins 
(Schwaller et al, 2002).
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4.2 Aims
The aim of this validation study is to confirm the regional expression profile 
of 13 genes using ISH. These genes were selected according to their localised 
expression shown by the LMD/microainay study and their function.
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4.3 Results
4.3.1 Genes overexpressed in the P rL
4.3.L1FXYD6
The autoradiograms (figure 4.1) showed that FXYD is strongly expressed in 
the medial prefrontal cortex, with the PrL showing a very strong signal (figure
4.1 A). A qualitative analysis suggested that in this region the expression varies 
with the cortical layers, as the signal was stronger in layer II and in the deep 
layers (figure 4. IE). The intensity of the signal was very low in the white matter, 
in the VO and in the motor cortex, whereas the transcript was present in the 
medial orbital and lateral orbital cortex. The expression levels were minimal in 
the thalamus and the hippocampus, but high in the hypothalamus (figure 4.IB).
Quantitative analysis and comparison of FXYD6 expression levels in the PrL, 
VO, Rt and Ml was concordant with the expression pattern shown by the 
LMD/microarray study (figure 4.1). The ANOVA revealed that the expression 
levels in the regions examined were significantly different for FXYD6 
(F(i,0 7 0 ,5 .3 4 8)= 2 1 2.3; p<0.001); the simple contrasts showed that the level of 
expression in the PrL was significantly higher than in the VO (F(i,s)= 190.7; 
p<0.001), the Ml (F(i,5)= 224.4; p<0.001) and the Rt (F(i,5)== 249.6; p<0.001).
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Figure 4.1
A. In situ hybridisation (ISH) autoradiogi'ara showing the expression of FXYD6  at the 
level of prefrontal cortex. The anatomical localisation of the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (Ml) is indicated by arrows. Note the 
differential expression of FXYD6  in the cortical layers of the medial prefrontal cortex 
(panel E). Scale bar: 5mm.
B. ISH autoradiogram showing the expression of FXYD6  at the level of anterior 
thalamus. The anatomical localisation of the reticular thalamic nucleus (Rt) is indicated 
by an arrow.
C. Quantification of FXYD6  expression in the PrL, VO, Ml and Rt by optical 
densitometry of ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(i.070,5.348)= 212.3; 
p<0.001); the simple contrasts showed that the level of expression in the PrL was 
significantly higher than in the VO (F(i,s)= 190.7; p<0.001), the Ml (F(i,s)= 224.4; 
p<0.001) and the Rt (F(i,s)= 249.6; p<0.001).
D. Average signal intensities of microarray hybridisation for the probe set specific to 
FXYD6  showing that this gene is overexpressed in the PrL compared to VO, Ml and Rt. 
Statistical significance is expressed by False Discovery Rate (FDR < 1%).
E. ISH autoradiogram showing the differential expression of FXYD 6  in the cortical 
layers of the medial prefrontal cortex.
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4.3.1.2 GABAaJSI
The quantitative analysis confirmed the overexpression of this gene in the PrL 
compared to the VO, Ml and Rt (figui'e 4.2). The ANOVA revealed that the 
regional differential expression measured was significant (F(3 ,i5)= 40.214; p< 
0.001); the simple contrast showed that the level of expression in the PrL was 
significantly higher that in the VO (P(i,5)= 333.661; p<0.001), the Ml (F(i,5)= 
66.546; p<0.001) and the Rt (F(î,5)= 51.248; p<0.001).
The ISH results fully correspond to the expression patterns shown by the 
LMD/microarray study, showing a slightly more pronounced overexpression of 
this gene in the PrL.
Concordant with the literature, the autoradiograms also showed that the 
expression of the GABAa receptor (31 subunit is prominent in the hippocampus 
and very low or absent in the thalamic area (figure 4.2B).
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A. In situ hybridisation (ISH) autoradiogram showing the expression o f GABAaPI at the 
level o f prefrontal cortex. The anatomical localisation o f the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (M l) is indicated by arrows. Scale bar; 
5 mm.
B. ISH autoradiogram showing the expression o f GABAaPI at the level o f anterior 
thalamus. The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated 
by an arrow.
C. Quantification o f GABAaPI expression in the PrL, VO, M l and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (P(3,i5)= 40.214; p< 
0.001); the simple contrast showed that the level o f  expression in the PrL was 
significantly higher that in the VO (F(i,s)= 333.661; p<0.001), the M l (F(i,5)= 66.546; 
p<0.001) and the Rt (F(i s)= 51.248; p<0.001).
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
GABAaPI showing that this gene is overexpressed in the PrL compared to VO, Ml and 
Rt. Statistical significance is expressed by False Discovery Rate (FDR < 1%).
142
4.3.L3 Wolframin
Wolfi'amin showed a very specific expression pattern. The autoradiograms 
(figure 4.3A) showed a strong signal in the medial prefrontal cortex, with very 
little or no expression in the white matter and other cortical areas. Hybridisation 
was very prominent in the superficial layers of the medial prefrontal cortex, with 
layer I showing the strongest signal (figure 4.3E). The signal intensity was 
decreased in layer II, and little or no expression was detected in layer III and the 
deep layers (figure 4.3E). The regional specificity was also evident at the level of 
the anterior thalamus; wolframin niRNA was abundant in the caudate-putamen, 
whereas it was absent in the thalamic nuclei; a very faint signal was detected in 
the hippocampal region (figure 4.3B).
The quantitative analysis fully reflected the expression pattern shown by the 
LMD/microarray study. Not only was the overexpression of this gene in the PrL 
confirmed, but also the small expression differences in the VO, Ml and Rt were 
consistently observed using both methodologies. Thus, there was a striking 
correspondence of the relative expression levels measured using the two 
independent techniques (figure 4.3C and 4.3D). The one way ANOVA showed 
that the regional expression was significant (F(3 ,i5)- 48.173; p<0.001); the simple 
contrast showed that the level of expression in the PrL was significantly higher 
that in the VO (F(i,5 )= 87.381; p<0.001), the Ml (F(i,s)= 52.215; p<0.001) and the 
Rt(F(i,5r  58.688; p<0.001).
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Figure 4.3
A. In situ hybridisation (ISH) autoradiogram showing the expression of wolframin at the 
level of prefrontal cortex. The anatomical localisation of the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primai-y motor cortex (Ml) is indicated by arrows. Note the 
differential expression in the cortical layers of the medial prefrontal cortex (panel E). 
Scale bar: 5 mm.
B. ISH autoradiogi'am showing the expression of wolframin at the level of anterior 
thalamus. The anatomical localisation of the reticular thalamic nucleus (Rt) is indicated 
by an aiTow.
C. Quantification of wolframin expression in the PrL, VO, Ml and Rt by optical 
densitometry of ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(3,i5)= 48.173; 
p<0.001); the simple contrast showed that the level of expression in the PrL was 
significantly higher that in the VO (F(i,5)= 87.381; p<0.001), the Ml (F(],5)= 52.215; 
p<0.001) and the Rt (F(i_5)= 58.688; p<0.001).
D. Average signal intensities of microarray hybridisation for the probe set specific to 
wolframin showing that this gene is overexpressed in the PrL compared to VO, Ml and 
Rt. Statistical significance is expressed by False Discovery Rate (FDR < 1%).
E. ISH autoradiogram showing the differential expression of FXYD6  in the cortical 
layers of the medial prefr ontal cortex.
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43.1.4 Synapsin lia
The LMD/microarray study showed that the isoform synapsin Ila is 
overexpressed in the PrL. Although the differential expression was highly 
significant, with a FDR lower than 1%, the regional differential expression was 
not as pronounced as for FXYD6 and wolframin (see figures 4.1 A, 4.3A and 
4.4A).
The autoradiograms showed that synapsin Ila is expressed tliroughout the 
cortical areas at the prefi'ontal cortex level, although the signal was remarkably 
stronger in the medial prefrontal cortex (figure 4.4A). The synapsin Ila mRNA 
was also clearly present in the Rt (figure 4.4B). In the structures visible at the 
anterior thalamus level, the signal was very prominent in the hippocampal 
fonnation, paraventricular thalamic nucleus and centrolateral/paracentral thalamic 
nuclei (figure 4.4B).
The quantitative analysis confirmed the expression profiles shown by the 
LMD/microarray study (figure 4.4). The ANOVA test revealed that Synapsin Ila 
regional differential expression was significant (F(3j5)=20.271; p<0.001); the 
simple contrast showed that the level of expression in the PrL was significantly 
higher than in the VO (F(i,5)= 61.912; p<0.001), the Ml (F(i,s)= 47.916; p<0.001) 
and the Rt (F(i^ 5)= 16.015; p<0.05).
146
B
PrL
M l
VO R t
0.09n
0.06
*** *** jfÿjm
P rL  V O  M1 R t
1250
1000-
D
g  750-
* ■  m
P rL  V O  M l R t
Figure 4.4
A. In situ hybridisation (ISH) autoradiogram showing the expression o f synapsin Ila at the 
level o f prefrontal cortex. The anatomical localisation o f the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (M l) is indicated by arrows. Scale bar; 
5 mm.
B. ISH autoradiogram showing the expression o f synapsin II at the level o f anterior 
thalamus. The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated 
by an arrow.
C. Quantification o f synapsin Ila expression in the PrL, VO, M l and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F (3 ,]S )= 20 .271;  
p < 0 .0 0 1 ) ;  the simple contrast showed that the level o f expression in the PrL was 
significantly higher than in the VO (F(i,s)= 6 1 .9 1 2 ;  p < 0 .0 0 1 ) ,  the M l (F (i,5)=  4 7 .9 1 6 ;  
p < 0 .0 0 1 )  and the Rt (F(i,s)= 1 6 .0 1 5 ;  p < 0 .0 5 ) .
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
synapsin II showing that this gene is overexpressed in the PrL compared to VO, M l and 
Rt. Statistical significance is expressed by False Discovery Rate (FDR < 1% ).
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4.3.2 Genes overexpressed in the VO
4.3.2J GABAaS
The autoradiograms showed that GABAaÔ is expressed in the prefrontal 
cortex, with a stronger signal in the superficial layers (figure 4.5A).
The quantitative analysis confirmed the expression profiles shown by the 
LMD/microan-ay study (figure 4.5C and 4.5D). The ANOVA test revealed that 
GABAa6 regional differential expression was significant (F(3 ,i2 )= 31.921; 
p<0.001); the simple contrast showed that the level of expression in the VO was 
significantly higher than in the PrL (F(i,4 )= 159.880; p<0.001), the Ml (F(i,4)= 
17.766; p<0.05) and the Rt (F(i,4 )= 23.980; p<0.05).
The autoradiograms also showed that this gene is expressed in the thalamus, in 
the striatum and in the dentate gyi'us of the hippocampus (figure 4.5B). These 
obseiwations are concordant with the distribution profiles reported in the literature 
(Pirker et al, 2000; Wisden et al, 1992).
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A. In situ hybridisation (ISH) autoradiogram showing the expression o f GABAaÔ at the 
level o f prefrontal cortex. The anatomical localisation o f the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (M l) is indicated by arrows. Scale bar: 
5 mm.
B. ISH autoradiogram showing the expression o f G A B A a Ô  at the level o f anterior 
thalamus. The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated 
by an arrow.
C. Quantification o f GABAaÔ expression in the PrL, VO, Ml and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(3.i2)= 31.921; 
p<0.001); the simple contrast showed that the level o f expression in the VO was 
significantly higher than in the PrL (F(i,4)= 159.880; p<0.001), the M l (F(i,4)= 17.766; 
p<0.05) and the Rt (F(,,4)= 23.980; p<0.05).
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
GABAaÔ showing that this gene is overexpressed in the VO compared to PrL, M 1 and 
Rt. Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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4.3.2.2 CaMKII inhibitor a
The LMD/microarray study predicted that CaM-KIINa is overexpressed in the 
VO; however the differential expression between this area and the Ml was 
significant hut very small (figure 4.6A and 4.6C). In fact, the VO overexpressed 
CaM-KIINa compared to the Ml with a statistical significance of 0.93% FDR, 
very close to the 1% threshold chosen for the LMD/microan'ay study and a Fold 
Change of 1.51 (see tahle 3.4, “Phosphorylation” functional class). The 
confirmation of this result using an independent alternative technique such as ISH 
was useful from this technical point of view.
The autoradiograms showed that CaM-KIINa is expressed in the cortical 
regions visible at the prefrontal cortex level (figure 4.6A). Concordant with 
published studies (Chang et al, 2001), the signal was more prominent in the layer 
II and III of the cortex compared to the deep layers.
The quantitative analysis confirmed the expression patterns shown hy the 
LMD/micro array study (figure 4.6c and 4.6D). The ANOVA revealed that the 
regional differential expression of CaM-KIINa was significant (F(3 ,is)= 113.6; 
p<0.001); the simple contrast showed that the level of expression in the VO was 
significantly higher than in the PrL (F(i,5)= 73.6; p<0.001), the M l (F(i,s)= 6.9; 
p<0.05) and the Rt (F(i,5)= 296.2; p<0.001). Interestingly, the ISH analysis 
confimied that the small overexpression of CaM-KIINa in the VO compared to 
the Ml was significant.
Additionally, the signal detected in the caudate-putamen was also concordant 
with the results reported by Chang et al (2001); however, this gioup reported a 
prominent expression of CaM-KIINa in the hippocampal formation that could not 
be observed in the present experiments.
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A. In situ hybridisation (ISH) autoradiogram showing the expression o f CaM-KIINa at 
the level o f  prefrontal cortex. The anatomical localisation o f the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (M l) is indicated by arrows. Scale bar; 
5mm.
B. ISH autoradiogram showing the expression o f CaM-KIINa at the level o f anterior 
thalamus. The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated 
by an arrow.
C. Quantification of CaM-KIINa expression in the PrL, VO, M l and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(3 ,is)= 113.6; 
p<0.001); the simple contrast showed that the level o f  expression in the VO was 
significantly higher than in the PrL (F(,,5)= 73.6; p<0.001), the M l (F(i,5)= 6.9; p<0.05) 
and the Rt (F(i,5)= 296.2; p<0.001)
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
CaM-KIINa showing that this gene is overexpressed in the VO compared to PrL, Ml and 
Rt. Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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4.3.3 Genes overexpressed in the Rt
4.3.3.1 RGS3
RGS3 was selected for validation because the overexpression the Rt detected 
by the microarray study has a gi*eat biological significance for neurotransmission 
and modulation of signal transduction. Additionally, the expression levels 
detected in the Rt by the LMD/microarray analysis showed an unusually high 
variability across the biological replicates (figure 4.7D). However, this variability 
did not affect the statistical significance of the overexpression, as the False 
Discovery Rate associated with this gene was < 1%).
The autoradiograms showed that RGS3 is not expressed in the prefrontal 
cortex (figure 4.7A). At the anterior thalamus level, the mRNA encoding for 
RGS3 was detected in the thalamus. Interestingly, the Rt showed expression only 
in the ventral part, whereas the dorsal Rt showed a very faint signal (figure 4.7B).
The quantitative analysis was performed measuring the expression levels in 
the dorsal and ventral Rt (figure 4.7C); The ANOVA test revealed that the 
differential regional expression was significant (F(i.g5 4 ,9 ,2 7 i)= 169.176; p<0.001). 
The simple contrast showed that the level of expression in the ventral Rt was 
significantly greater than in the dorsal Rt (F(f,5)= 134.678; p<0.001), the PrL 
(F(i,5)= 265.222; p<0.001), the VO (F(i,5)= 242.244; p<0.001); and the Ml (F(i,5)= 
308.699; p<0.001).
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Figure 4.7
A. In situ hybridisation (ISH) autoradiogram showing that RGS3 is not expressed at the 
level o f prefrontal cortex.
B. ISH autoradiogram showing the expression o f RGS3 at the level o f  anterior thalamus. 
The anatomical localisation o f the ventral and dorsal reticular thalamic nucleus (Rt) is 
indicated by arrows. Scale bar: 5 mm.
C. Quantification o f RGS3 expression in the PrL, VO, M l and Rt by optical densitometry 
o f ISH autoradiograms. Concordant with the microarray results (D), the expression levels 
in the regions examined were significantly different (F(i.854.9 .2 7 1)= 169.176; p<0.001). The 
simple contrast showed that the level o f expression in the ventral Rt was significantly 
greater than in the dorsal Rt (F(i.s)= 134.678; p<0.001), the PrL (F(,.5)= 265.222; 
p<0.001), the VO (F(i,5)= 242.244; p<0.001); and the M l (F(i,5)= 308.699; p<0.001).
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
RGS3 showing that this gene is overexpressed in the Rt compared to PrL,VO and M l. 
Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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4.3.3.2 PLC/14
The autoradiograms showed very low signal at the level of the prefrontal 
cortex, although some transcript was detected in the superficial layers of the 
motor cortex (figure 4.8A). At the anterior thalamus level, the expression of 
PLCp4 was prominent in the thalamic nuclei, including the Rt, whereas the signal 
was very low or absent in the other brain structures visible at this level (figure 
4.8B), Consistent with the expression pattern observed at the prefrontal cortex 
level, a low degree of expression was detectable in the superficial layers of the 
cortex.
The quantitative analysis of PLCp4 expression in the regions of interest 
confirmed the expression pattern shown by the LMD/microarray study (figure 
4.SC and 4.8D). The ANOVA test revealed that the differential regional 
expression was significant (F(3 ,i5)= 128.836; p<0.001); The simple contrast 
showed that the level of expression in the Rt was significantly higher than in the 
PrL (F(i,5)= 961.633; p<0.001), the VO (F(i,5)= 320.408; p<0.001) and the Ml 
(F(i,5)= 131.723; p<0.001).
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Figure 4.8
A. In situ hybridisation (ISH) autoradiogram showing the expression o f PLC(34 at the 
level o f prefrontal cortex.
B. ISH autoradiogram showing the expression o f PLCp4 at the level o f anterior thalamus. 
The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated by an 
arrow. Scale bar: 5 mm.
C. Quantification o f PLCp4 expression in the PrL, VO, M l and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(3,i5)= 128.836; 
p<0.001); The simple contrast showed that the level o f expression in the Rt was 
significantly higher than in the PrL (F(,.s)= 961.633; p<0.001), the VO (F(i,5)= 320.408; 
p<0.001) and the M l (F(,.s)= 131.723; p<0.001).
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
PLCp4 showing that this gene is overexpressed in the Rt compared to PrL,VO and M l. 
Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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4.3.3.3FKCÔ
Similar to RGS3 (see section 4.3.3.1), the LMD/microaiTay detected a highly 
significant overexpression of PKC6 (FDR < 1%) in the Rt compared to the 
cortical regions examined; however, the average level of expression of this gene 
in the Rt showed an unusually high standard error (figure 4.9D). For this reason 
and for its biological importance, PKCô was selected for validation by ISH.
The autoradiograms showed that PKCô is not expressed in any structure at the 
level of the prefrontal cortex (figure 4.9A). The mRNA was detected in the 
thalamus, while there was no signal in other structures such as the hypothalamus 
and the hippocampus.
Interestingly, the signal was only present in the ventral part of the Rt, whereas 
the dorsal Rt did not show expression of PKCô (figure 4.9B). This expression 
profile was very similar to that of RGS3 (see section 4.3.3.1).
The quantitative analysis was performed measuring the expression levels in 
the dorsal and ventral Rt (figure 4.9C); The ANOVA test revealed that the 
differential regional expression was significant (F(i.3 4 2 ,6 .7 0 9)= 173.710; p<0.001); 
The simple contrast showed that the level of expression in the ventral Rt was 
significantly different to the dorsal Rt (F(i,5)= 217.244; p<0.001), the PrL (F(i,5)= 
197.514; p<0.001), the VO (F(i,5)= 234.914; p<0.001); and the Ml (F(i,5)= 
169.019; p<0.001).
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A. In situ hybridisation (ISH) autoradiogram showing that PKC6 is not expressed at the 
level o f prefrontal cortex.
B. ISH autoradiogram showing the expression o f PKC6 at the level o f anterior thalamus. 
The anatomical localisation o f the ventral and dorsal reticular thalamic nucleus (Rt) is 
indicated by arrows. Scale bar: 5 mm.
C. Quantification o f PKCÔ expression in the PrL, VO, Ml and Rt by optical densitometry 
of ISH autoradiograms. Concordant with the microarray results (D), the expression levels 
in the regions examined were significantly different (F( 1.342,6.709)= 173.710; p<0.001); The 
simple contrast showed that the level o f expression in the ventral Rt was significantly 
different to the dorsal Rt (F(i,s)= 217.244; p<0.001), the PrL (F(i,5)= 197.514; p<0.001), 
the VO (F(i,5)= 234.914; p<0.001); and the M l (F(i,s)= 169.019; p<0.001).
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
PKCÔ showing that this gene is overexpressed in the Rt compared to PrL,VO and M l. 
Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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43.3.4 Parvalbumin
Concordant with the literature, the autoradiograms showed that parvalbumin is 
expressed in all cortical areas at the prefrontal cortex level (figure 4.10A). At the 
level of the anterior thalamus, the parvalbumin-specific radioactive probe 
produced a very intense signal corresponding to the Rt (figure 4.1 OB),
The quantitative analysis of parvalbumin expression in the regions of interest 
confirmed the expression pattern shown by the LMD/microarray study (figure 
4.IOC and 4.10D). The ANOVA revealed that the differential regional expression 
was significant (F(i.204,6.018)= 1480.958; p<0.001); the simple contrasts showed that 
the level of expression in the Rt was significantly higher than in the PrL (F(i,s)= 
2152.971; p<0.001), the VO (F(i,5)= 1239.496; p<0.001) and the Ml (Fp.sr 
1675.988; p<0.001).
Additionally, parvalbumin expression was also observed in the hippocampus 
and the lateral globus pallidus.
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Figure 4.10
A. In situ hybridisation (ISH) autoradiogram showing the expression o f parvalbumin at 
the level o f prefrontal cortex. The anatomical localisation o f the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (M l) is indicated by arrows.
B. ISH autoradiogram showing the expression o f parvalbumin at the level o f anterior 
thalamus. The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated 
by an arrow. Scale bar: 5 mm.
C. Quantification o f parvalbumin expression in the PrL, VO, M l and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(i.20 4.6 .0 18)= 
1480.958; p<0.001); the simple contrasts showed that the level o f  expression in the Rt 
was significantly higher than in the PrL (F(i,s)= 2152.971; p<0.001), the VO (F(i,5)= 
1239.496; p<0.001) and the M l (F(,,s)= 1675.988; p<0.001).
D. Average signal intensities o f microarray hybridisation for the probe set specific to 
parvalbumin showing that this gene is overexpressed in the Rt compared to PrL,VO and 
M l. Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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4.3.3.5 Calretinin
The autoradiograms showed that the expression levels of calretinin are very 
low at the level of the prefrontal cortex, whereas the signal was very prominent in 
the Rt (figure 4.11A and 4.1 IB).
The quantification of the relative optical density in the regions of interest 
confinned the expression profile shown by the LMD/micro aiTay study (figure 
4.11C and 4.1 ID). The ANOVA test showed that the regional differential 
expression of calretinin is significant (F(i.007,5.035)= 80.008; p< 0.001); the simple 
contrast showed that the level of expression in the Rt was significantly greater 
than in the PrL (F(i,5)= 80.082; p<0.001), the VO (F(i,5)= 80.900; p<0.001) and the 
Ml (F(i,5)= 79.674; p<0.001).
Additionally, the calretinin specific radioactive probe showed strong signal in 
other thalamic nuclei, such as the paraventricular nucleus, the ventromedial 
nucleus and the reuniensis and rhomboid nuclei. The hypothalamus also showed a 
uniform signal showing that calretinin is expressed in this area.
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Figure 4.11
A. In situ hybridisation (ISH) autoradiogram showing the expression o f cairetinin at the 
level o f prefrontal cortex. The anatomical localisation o f the prelimbic cortex (PrL), 
ventral orbital cortex (VO), primary motor cortex (Ml) is indicated by arrows.
B. ISH autoradiogram showing the expression o f cairetinin at the level o f anterior 
thalamus. The anatomical localisation o f the reticular thalamic nucleus (Rt) is indicated 
by an arrow. Scale bar; 5 mm.
C. Quantification o f cairetinin expression in the PrL, VO, M l and Rt by optical 
densitometry o f ISH autoradiograms. Concordant with the microarray results (D), the 
expression levels in the regions examined were significantly different (F(i.007.5.035)=  
80.008; p< 0.001); the simple contrast showed that the level o f expression in the Rt was 
significantly greater than in the PrL (F(i,5)= 80.082; p<0.001), the VO (F(i,5)= 80.900; 
p<0.001) and the M l (F(i,5)= 79.674; p<0.001).
£>. Average signal intensities o f microarray hybridisation for the probe set specific to 
cairetinin showing that this gene is overexpressed in the Rt compared to PrL,VO and M l. 
Statistical significance is expressed by False Discovery Rate (FDR < 1%).
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4.4 Discussion
4.4.1 Regional expression analysis by LMD-microarray and ISH: technical 
considerations
In this study in situ hybridisation was successfully employed for the validation 
of regional gene expression profiles detected using the LMD-microarray strategy. 
In fact, ISH allowed reproduction of the microarray results in a completely 
independent manner; moreover it produced additional information on the regional 
expression and clarified the laminar expression in the cortical areas of selected 
genes.
Comparison of the results obtained with the two teclmiques showed that the 
LMD/microarray approach is more sensitive than ISH in detecting low amounts of 
RNA in specific brain regions. The greater sensitivity is essential to detect 
differences of low abundance transcripts. The genes Doublecortin (Dcx) and 
Serine/threonine kinase 23 (Stk23) could not be detected by ISH, whereas the 
LMD-microarray showed regional overexpression in the PrL and in the VO 
respectively (see table 3.3, “Neurogenesis/neurodevelopment” functional class 
and table 3.4, “Phosphorylation” functional class). The linear amplification could 
contribute to the increased sensitivity of the LMD-microarray approach. 
Considering that the differential expression of the detectable genes measured by 
ISH always validated the LMD-microarray results, these findings suggest that the 
linear amplification not only preserves reliably the relative abundance of the 
niRNAs, but also increases the sensitivity allowing the detection of transcripts 
that would appear unexpressed according to a conventional technique such as 
ISH.
Although a full verification of the linearity of the amplification procedure was 
beyond the scope of this study, as the reliability of this teclmique has been
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previously tested (Scluieider et al, 2004; Patel et al, 2005), ISH results showed 
that the relative abundance of the inRNA of the genes investigated had not been 
altered in the amplification step for the genes selected for validation.
These findings confirm the vast potential of the LMD-microarray approach in 
neuroscience demonstrating that this technique is applicable to the study of 
differential gene expression in rat cortical subregions. Furthermore, the ISH 
results provided additional information about the intra-regional differential 
expression of PKC5 and RGS3 (see below); hence this technique not only was 
useful to confiim the validity of the LMD/microan'ay procedure, but also 
complemented the study with original observations.
4.4.2 Validation of genes overexpressed in the PrL
The ISH study confirmed the overxpression of four genes in the PrL detected 
using the LMD/microarray strategy. In all cases the expression profiles measured 
using the two techniques were remarkably similar both qualitatively and 
quantitatively.
FXYD6 showed the most specific expression pattern, as this transcript is 
found exclusively in the medial prefrontal cortex, and in particular in the PrL 
(figure 4.1). The biological significance of this interesting and original finding is 
likely to be relevant to the ion trafficking and neurotransmission in the PrL, as this 
gene has a crucial role in the modulation of the Na-K-ATPase (see section 
4.1.2.1). Although previous reports suggest that the members of FXYD family are 
tissue specific (see above), this is the first time that specific expression of FXYD6 
is demonstrated at the level of subcortical region using two independent 
techniques. This finding suggests that the activity of the Na-K-ATPase, which is 
crucial for the function of excitable cells, is differentially regulated at a very 
specific anatomical level in the rat brain.
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ISH results also provided interesting infonnation about the expression of 
Wolff amin in the PrL. The regional expression pattern of this gene was confirmed 
and the quantitative measurements using the two techniques were strikingly 
similar (figure 4.3). Moreover, the ISH autoradiograms highlighted that 
Wolframin is differentially expressed in the cortical layers (figure 4.3E). In fact, 
the autoradiogi’am showed a very strong signal in the superficial layers of the PrL. 
The intensity of the signal decreased gradually in the layer II; while the transcript 
appeared absent in the deep cortical layers. This expression pattern could not be 
detected by the LMD/microan*ay study, as the whole PrL was dissected. This 
finding shows that ISH not only is useful for the validation of LMD/microarray 
results, but also provides original information that may be very relevant for the 
neurobiology of the region examined.
The confirmation of the overexpression of GABAaPI and synapsin II in the 
PrL was important for the function of theses genes. GABAaPI was classified as a 
gene directly involved in neurotransmission after the Gene Ontology analysis of 
the LMD/microarray results. Synapsin II is also involved in the control of 
neurotransmission, as this protein controls synaptic function and modulates 
exocytosis of synaptic vesicles (see section 4.1.2.3). A number of genes belonging 
to this functional group showed regional overexpression according to the 
LMD/microarray study (see table 3.3). Although it would be unpractical to 
confiim the differential regional expression of all the neurotransmission-related 
genes, the validation of GABAApi and synapsin II strongly supports the finding 
that the genes belonging to this functional class have a specific pattern of 
expression in the regions examined.
The over expression of doublecortin (Dcx) in the PrL could not be confirmed 
by ISH, as the expression levels of this gene was below the sensitivity limit of this 
technique. This finding suggest that the amplification step included in the 
LMD/microarray strategy contributes to an improved sensitivity compared to 
techniques that detect the mRNA originally present in the sample, such as ISH. 
The increased sensitivity can be an important feature, as the differences observed 
using the LMD/microarray approach are likely to be biologically relevant. This
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finding also suggests that the validation of genes with low basal levels of 
expression might be better achieved using amplification-based techniques, such as 
real-time RT-qPCR.
4.4.3 Validation of genes overexpressed in the VO
The validation of the overexpression of CaM-KIINa in the VO demonstrated 
that the LMD/microarray strategy allows the detection of small expression 
differences with a high degree of reliability. In fact, the differential expression of 
this gene between the VO and Ml was associated with a False Discovery Rate of 
0.93%, which is very close to the 1% threshold chosen for this study. The 
quantitative difference was also marginal, with a Fold Change of 1.51.
The correspondence between the data obtained from the LMD/microarray 
study and the ISH validation experiment was remarkable both qualitatively and 
quantitatively (figure 4.6). In this case, the differential expression measured by 
ISH between the VO and the Ml was slightly smaller that that measured using the 
microaiTay strategy (figure 4.6). Similarly to the LMD/microarray, the difference 
measured by ISH was associated with a p value of 0.047, which is very close to 
the 0.05 tlireshold chosen for statistical significance. This finding suggests that the 
LMD/microarray approach can detect small expression differences as reliably as 
ISH, despite the complex manipulations of the RNA involved in this procedure, 
such as the linear amplification.
The validation of G A B A a5 was also remarkable, as this result confirm that the 
expression of G A B A a receptor subunits is highly localised in specific cortical 
subregions. Similar to CaM-KIINa, the differential expression of G A B A a§ 
between the VO and the Ml was associated with a relatively low Fold Change of 
1.54. Even in this case, the ISH could validate the small difference detected using
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the LMD/microarray strategy, confirming again the validity and the reliability of 
this approach.
Validation of the overexpression of the gene encoding for serine-threonine 
kinase 23 (Stk23) in the VO was also attempted. Similar to Dcx (see above), this 
transcript was below the limit of detection of ISH, confirming that the increased 
sensitivity of the LMD/microarray approach is advantageous to detect differences 
when the gene of interest has a low level of expression.
4.4.4 Validation of genes overexpressed in the Rt
The overexpression of five genes in the Rt was validated by ISH (figures 4.7 
to 4.11).
The LMD/microarray study showed a strong overexpression of the calcium 
binding proteins parvalbumin and cairetinin in the Rt. The ISH experiment 
validated this finding, confirming that high level of expression of these genes is a 
landmark of the Rt. Although both parvalbumin and cairetinin are expressed in the 
cortical regions examined (figures 4.10 and 4.11), their overexpression in the Rt is 
due to the neuronal composition of this nucleus, hi fact the Rt is mainly composed 
of GABAergic interneurons that are known to express calcium-binding proteins 
(Paxinos, 1995).
PLCp4 is another gene that was overexpressed in the Rt according to the 
LMD/microarray study and the ISH confirmation experiments. PLCp4 plays a 
crucial role in the transduction of the signal initiated by the activation of receptors 
coupled with Gq proteins (see above), and is likely to be relevant to the 
neurobiology of the Rt. Moreover, other genes involved in the same biological 
pathway such as RGS3 and PKCô were also overexpressed in the Rt (see above); 
therefore the validation of the expression pattern of PLC|34 predicted by the 
LMD/microaiTay study is useful to confirm these interesting results.
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The LMD/microarray study also predicted the overexpression of PKCô and 
RGS3 in the Rt. These genes are directly involved in the neurotransmission 
mediated by G-protein coupled receptors. The ISH confinuation of their regional 
expression pattern strongly supported the finding that a number of genes 
belonging to this functional group are overexpressed in the Rt. Interestingly, the 
data obtained from the ISH experiment not only confirmed the observations from 
the LMD/microarray study, but also provided original information about the sub­
regional expression pattern of PKCô and RGS3 within the Rt (figures 4.7 and 
4.9). The autoradiograms showed that these two genes are overexpressed in the 
ventral part of the Rt only, whereas the expression is marginal in the dorsal Rt. 
This finding confirms the biological importance of localised gene expression in 
brain regions and also suggests that the expression of some genes can be regulated 
at a sub-regional level in the Rt.
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5.1 Introduction
Phencyclidine (PCP) (figure 5.1) is a psychotomimetic compound that has 
been popular as an illicit recreational drug for its hallucinatory effects. Although it 
was first developed as a surgical anaesthetic, the therapeutic utility of PCP was 
severely limited by prominent side effects such as hallucinations, disordered 
speech, delirium, agitation and disoriented behaviour. Interestingly, these effects 
resemble very closely the symptoms experienced by patients suffering hom 
schizophrenia; therefore PCP has been extensively used in neuroscience research 
to model aspects of this disease (Morris et al, 2005).
Compounds with similar pharmacology, such as MK-801 and ketamine, are 
also usehil research tools for their psychotomimetic properties (figure 5.1) 
(Tamminga et al, 2003). Ketamine, which is similar to PCP both for the chemical 
structure and the pharmacology, has similar effects on the central nervous system. 
The psychotomimetic properties of this drug are less pronounced than PCP; 
therefore it is still used in veterinary and paediatric anaesthesia.
PCP
NHCH
Ketamine MK-801
Figure 5.1
Chemical sti'uctures o f  the N M D A  channel blockers PCP, Ketamine and M K-801.
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5.1.1 Pharmacology of PCP
PCP binds a number of different receptors in the central nervous system; 
hence the pharmacology of this drug is rather complex (Morris et al, 2005).
PCP is mainly a non-competitive antagonist of the N-methyl-D-aspartate 
(NMDA) glutamate receptor. This drug is classified as an open channel blocker, 
as its site of binding is within the chamiel pore and it is accessible to the 
compound only when the channel is open (Ferrer-Montiel et al, 1998). The 
NMDA receptors differ from the other types of ionotropic glutamate receptor for 
their specific permeability to Ca^ "^ , for the voltage dependent blockade exerted by 
Mg^ "^  and for the presence of the specific N/Q/R residue group within the channel 
that forms the binding site for the open channel blockers such as PCP (Mayer et 
al, 1994; Mayer et al, 1987; Zarei et al, 1994; Ferrer-Montiel et al, 1998). The 
NMDA receptors are heteroligomers composed of NRl subunits and one or more 
NR2 subunits (NR2A-D) that are probably arranged in a tetrameric structure 
(Hollmann et al, 1994; Ferrer-Montiel et al, 1996). The pore-lining structure is 
composed by the M2 transmembrane segment present in each subunit; this 
domain deteimines the ion specificity of the NMDA receptor and contains the 
residues forming the binding site for PCP (Sakinada et al, 1993; FeiTer-Montiel 
et al, 1995).
PCP also inhibits other ion channels, such as voltage-gated sodium and 
potassium chamiels, by binding to a specific site within the pore (Ffrench-Mullen 
et al, 1989). The nicotinic acetylcholine receptor is another ion chaimel inliibited 
by PCP in a non-competitive manner (Oswald et al, 1984). Moreover, it has been 
shown that this drug also interacts with sigma receptors and the dopamine and 
noradrenaline transporters (Garey et al, 1976; Contreras et al, 1988; Pubill et al, 
1998).
The interaction of PCP with the NMDA receptors is by far the most potent and 
it is likely to be the most biologically relevant mechanism of action of PCP- 
induced effects in the central nervous system at the doses commonly used.
170
However the interaction of this dmg with other ion channels and 
neurotransmitters receptors may contribute to its unique pharmacological profile 
and could play a role in the complex psychotomimetic properties of PCP (Morris 
et al, 2005).
5.1.2 Psychotomimetic effects of PCP in humans
The PCP-induced psychosis obseiwed after administration of this drug to 
normal humans was first reported by Luby et al {1959). This group also found that 
PCP exacerbates symptoms in schizoplirenic patients. Studies of the effects of 
PCP in humans were soon abandoned due to ethical reasons.
Similai', but less pronounced psychotomimetic effects were described for 
ketamine, a congener of PCP (Rainey et al, 1974). In fact, competitive NMDA 
antagonist also can reproduce some positive symptoms of schizophrenia in 
healthy subjects, suggesting that the interference with the glutamatergic 
transmission is a key feature of psychotomimetic dmgs (Tamminga et al, 1998). 
However, PCP is unique in reproducing not only the positive symptoms of 
schizoplrrenia, such as hallucinations, delusions and thought disorder, but also 
some of the negative symptoms such as social withdrawal. Moreover, there is 
evidence that the NMDA open channel blockers, especially PCP, can also cause 
some fonns of severe cognitive impairment. It has been reported that after 
administration of PCP, subjects showed deficits in memory, verbal fluency and 
impaired performance in the Wisconsin Card Sort Test. These findings show that 
PCP is able to reproduce not only the active psychotic symptoms of 
schizoplrrenia, but also the persistent cognitive dysfunctions that are considered a 
landmark of this disease (Krystal et al, 1994; Jentsch et al, 1999).
The popularity of PCP as an illicit recreational drug has allowed the 
collection of data on the long-term effects of this drug in humans (reviewed by
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Jentsch et al, 1999), Interestingly, the chronic administration of PCP not only 
prolongs the duration of some positive psychotomimetic effects, but also induces 
some qualitatively different alterations compared to the single-dose 
administration. For example, the PCP-induced hallucinations tend to be visual 
after a single administration of the drug; however, subjects report prolonged 
auditory and paranoid hallucinatory episodes after chi'onic exposure (Allen et al, 
1978; Kristal et al, 1994). These interesting findings suggest that the psychosis 
induced by prolonged exposure to PCP resembles the schizophrenia positive 
symptoms more closely than the acute effects of the drug (Jentsch et al, 1999). 
Another striking qualitative difference between the chronic and the acute effect of 
NMDA open channel blockers regards the frontal blood flow. This parameter is 
transiently increased after acute exposure to ketamine; however chronic 
administration of PCP causes a persistent decrease of the blood flow in the fr ontal 
lobe and reduced glucose utilisation (Breier et al, 1997; Hertzman et al, 1990). 
These long-term effects could be related to the specific cognitive impairments 
induced by clironic PCP and closely mirror hypofrontality, which is the reduced 
blood flow and metabolism in the frontal brain region observed in the 
schizophrenic brain.
In summary, the available data about the effects of PCP in humans suggest 
that the psychosis induced by this drug closely min’ors different aspects of the 
schizophrenia symptomatology, especially after prolonged exposure (Jentsch et 
al, 1999).
5.1.3 The utility of PCP in modeling aspects of schizophrenia in animals
Modeling aspects of schizophrenia in animals is very useful for neuroscience 
research. Therefore, many studies investigate the effects of PCP in non-primate 
mammals, in order to establish whether this drug could induce neurochemical and
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behavioural alterations that mirror some of the abnomialities observed in the 
human diseased brain.
The consequences of acute administration of PCP to rodents include an 
increased expression of immediate early genes in the prefrontal cortex, indicating 
and increased neuronal activity in this brain region (Gao et al, 1998). This initial 
stimulation is followed by a delayed decrease of the prefrontal cortical neuronal 
activity (Gao et al, 1993; Gao et al, 1998). Similar results were obtained using 
MK-801, another NMDA open channel blocker (Gao et al, 1998). These findings 
are in accordance with the increased frontal blood flow measured in humans after 
acute exposure to PCP, and the hypofi'ontality-like reduction of neuronal 
metabolic activity observed in the same brain region after prolonged exposure to 
the drug (see above). This scenario suggests that the delayed or chronic effects of 
PCP in rats are more likely to mirror the metabolic alterations of the 
schizopluenic brain.
Wlien evaluating the schizopln*enia-like alterations induced by PCP in 
animals, it is important to take into account the neurotoxicity of this drug. It has 
been demonstrated that a very high dose (50 mg/kg) of PCP can cause irreversible 
cell death in the rat brain (Olney et al, 1995; Corso et al, 1997); repeated 
administration of moderately high doses (15 mg/kg) also causes neuronal damage 
in the limbic brain regions (Olney et al, 1989; Corso et al, 1997). As there is no 
evidence of neurodegeneration in the schizophrenic brain, it can be argued that 
neurotoxic doses of PCP are of little use for modelling this disease.
hi fact, it has been demonstrated that very low doses of PCP (2.58 mg/kg) are 
sufficient to reproduce striking neurochemical and behavioural schizophreniform 
alterations in the rat (reviewed by Morris et al, 2005). After a single low dose of 
PCP, rats showed impaired performance in an attentional set-shifting task that 
correspond to the cognitive deficits assessed by the Wisconsin Card Sort Test in 
schizoplirenic patients (Egerton et al, 2005). Moreover, the same dose caused a 
decreased expression of parvalbumin in the rat prefr ontal cortex, suggesting that 
low doses of PCP can interfere with the GABAergic neurotransmission
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reproducing the abnomialities obseiwed in the intemeurons of the schizophrenic 
prefrontal cortex (Cochran et al, 2002; Lewis et al, 2004).
Interestingly, the decreased expression of parvalbumin in the prefrontal cortex, 
which is a strong evidence for specific dysfunction of the chandelier and basket 
subtypes of GABAergic intemeurons, was confiimed after chronic exposure to 
low doses of PCP (Cochran et al, 2003). Cochran et al (2003) also assessed the 
metabolic alterations induced by clironic low doses of PCP in multiple brain 
regions, showing that the glucose utilisation was decreased in the prefrontal 
cortex, in accordance with the hypofrontality observed in the schizophrenic brain. 
Metabolic alterations were also specifically observed in some auditory structures, 
in the hippocampus and in the reticular thalamic nucleus, whereas the majority of 
brain regions did not show significant changes.
The literature on PCP models of schizoplirenia shows that this dmg is a very 
useful tool to reproduce different characteristics of this psychiatric disease in 
rodents. The unique phaimacological profile of PCP allows modelling not only 
some cmcial cognitive and behavioural abnormalities (Egerton et al, 2005), but 
also a complex range of neurochemical and metabolic alterations that are 
landmarks of the human disease. In fact, the hypofrontality-like decrease of 
metabolic activity in the prefrontal cortex and the specific alterations of 
parvalbumin-containing GABAergic intemeurons after chronic administration of 
PCP (Cocluan et al, 2003) strongly support the utility of this model.
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5.2 Aims
In this section a well-established rat model of schizoplnenia based on clrronic- 
intermittent administration of PCP (Cocliran et al 2003) will be used to 
investigate possible expression changes of candidate genes that showed regional 
overexpression in the PrL, VO and Rt (see chapters 3 and 4). The candidate genes, 
selected on the basis of their regional expression patterns and their biological 
function, showed localised overexpression in one of the schizoplirenia-susceptible 
region both according to the LMD/microarray study and the ISH validation study 
(see chapters 3 and 4).
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5.3 Results
5.3.1 Genes overexpressed in the Rt
The expression of RGS3, PKCô and PLCp4 was analysed in the PCP model of 
schizoplirenia. These genes play a crucial role in the neurotransmission mediated 
by G protein-coupled receptor and showed a distinct overexpression in the Rt 
according to the LMD/microairay study and the ISH validation study (see 
chapters 3 and 4).
The quantitative analysis of the expression levels of RGS3, PKCô and PLCp4 
in the Rt of PCP-treated and control animals showed that there was no significant 
drug-induced expression change of these genes (figures 5.2, 5.3 and 5.4) (RGS3: 
t(10)= -0.557; p>0.05. PKCÔ: t(10)= 0.267; p>0.05. PLCp4: t(10)= 0.088; 
p>0.05).
The expression of parvalbumin and cairetinin in the PCP model of 
schizophi'enia was not investigated, as it has been described by Cochran et al 
(2003).
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Figure 5.2
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f RGS3 at 
the level o f anterior thalamus, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the reticular thalamic nucleus (Rt) is 
indicated by an arrow. Scale bar: 5 mm.
C. Quantification o f RGS3 expression in the ventral Rt following chronic PCP treatment 
by optical densitometry o f ISH autoradiograms. Expression levels were measured in the 
ventral Rt only, as RGS3 is specifically expressed in this part o f the Rt (see section 
4.3.3.1). No significant difference was measured between the PCP and vehicle treated 
animals (t(10)= -0.557; p>0.05).
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Figure 5.3
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f PLCp4 at 
the level o f  anterior thalamus, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the reticular thalamic nucleus (Rt) is 
indicated by an arrow. Scale bar: 5 mm.
C. Quantification o f PLCp4 expression in the Rt following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= 0.088; p>0.05).
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Figure 5.4
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f PKCÔ at 
the level o f  anterior thalamus, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the reticular thalamic nucleus (Rt) is 
indicated by an arrow. Scale bar: 5 mm.
C. Quantification o f PKCÔ expression in the ventral Rt following chronic PCP tretment 
by optical densitometry o f ISH autoradiograms. Expression levels were measured in the 
ventral Rt only, as PKCÔ is specifically expressed in this part o f the Rt (see section 
4.3.3.3). No significant difference was measured between the PCP and vehicle treated 
animals (t(10)= 0.267; p>0.05).
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5.3.2 Genes overexpressed in the VO
The quantitative analysis of the expression levels of CaMKII inhibitor a in the 
VO of PCP-treated and control animals showed that there was no significant 
expression change of this gene after chronic PCP treatment (figure 5.5) (t(9)= 
0.014; p>0.05). The expression of this gene after chronic PCP treatment was also 
analysed in the PrL, as the earlier autoradiograms showed that CaMKII inliibitor a 
is also expressed in this important area, although to a lesser degree than in the VO 
(figure 4.5). Similarly to the VO, the quantitative analysis did not show PCP- 
induced expression changes of CaMKII inhibitor a in the PrL (t(9)= 0.120; 
p>0.05).
The quantitative analysis showed that the expression of GABAaÔ have a 
tendency to decrease in the VO after clironic PCP treatment. However, the 
statistical analysis showed that the difference measured is not significant (figure 
5.6) (t(8)= 1.841; p>0.05).
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Figure 5.5
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f CaMKII 
inhibitor a at the level o f prefrontal cortex, after chronic treatment with vehicle (saline) 
(A) and PGP (2.58 mg/kg) (B). The anatomical localisation o f the ventral orbital cortex 
(VO) is indicated by an arrow. Scale bar; 5 mm.
C. Quantification o f CaMKII inhibitor a expression in the VO following chronic PCP 
treatment by optical densitometry o f ISH autoradiograms. No significant difference was 
measured between the PCP and vehicle treated animals (t(9)= 0.014; p>0.05).
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Figure 5.6
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f GABAaÔ 
at the level o f prefrontal cortex, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the ventral orbital cortex (VO) is 
indicated by an arrow. Scale bar: 5 mm.
C. Quantification o f GABAaS expression in the VO following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(8)= 1.841; p>0.05).
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5.3.3 Genes overexpressed in the PrL
The expression of the four genes that were overexpressed in the PrL according 
to the LMD/microaiTay study and the ISH validation study (see chapters 3 and 4) 
was analysed in the PCP model of schizoplirenia.
The quantitative analysis of the expression levels of FXYD6 in the PrL of 
PCP-treated and control animals showed that there is no significant expression 
change of this gene after chronic PCP treatment (figure 5.7) (t(10)= 0.317; 
p>0,05). As the autoradiograms showed that the expression of FXYD6 vary 
across the cortical layers of the PrL (see chapter 4) (figure 4.1), an alternative 
quantitative analysis was performed to investigate whether the PCP treatment 
caused a layer-specific expression change of this gene. This analysis did not show 
significant PCP-induced expression changes in layer II (t(10)= -0.42; p>0.05) or 
in the deep layers of the PrL (t(10)= 0.653; p>0.05).
Similarly, the expression of GABAaPI did not show significant PCP-induced 
changes in the PrL (t(10)= 0.086; p>0.05) (figure 5.8). Although this gene was 
clearly overexpressed in the PrL (see chapters 3 and 4), the autoradiograms 
showed that it is also expressed in the VO and in the hippocampus (figure 4.2); 
therefore the quantitative analysis was also performed in these regions, as they are 
relevant to crucial functions such as attention and memory. No significant 
expression changes were detected in the VO (t(10)= 0.516; p>0.05) or in the 
hippocampal regions CA3 (t(9)= -1.282; p>0.05) and dentate gyrus (DO) (t(9)= - 
1.541; p>0.05).
The quantitative analysis of the expression levels of synapsin II in the PrL of 
PCP-treated and control animals showed that there is no drug-induced expression 
change (t(10)= 0.148; p>0.05) (figure 5.9). The autoradiograms showed that this 
gene is also expressed in other regions of interest for cognition and schizophrenia, 
although to a lesser degree than in the PrL (refer to section 4.3.1.4). Hence, the 
quantitative analysis of synapsin II expression after chronic PCP treatment was 
also performed in the VO, in the Rt, and in the hippocampal regions CA3 and DO.
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No significant expression changes were observed in the above regions (VO: 
t(10)= -0.102; p>0.05. Rt: t(10)= -0.141; p>0.05. CA3: t(7)= 0.807; p>0.05. DO: 
t(7)= 1.747; p>0.05).
Finally, the expression of Wolframin was quantified and analysed in the PrL, 
where this gene is overexpressed according to the LMD/microarray study and the 
ISH validation study (see chapters 3 and 4). Interestingly, Wolfiramin mRNA 
expression showed a significant decrease of 19.8% after chronic PCP treatment 
(t(10)= 2.245; p< 0.05) (figure 5.10). Thus this is the only transcript of the 9 
studied to show PCP-induced expression changes.
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Figure 5.7
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f FXYD6 at 
the level o f prefrontal cortex, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the prelimbic cortex (PrL) is indicated 
by an arrow. Scale bar: 5 mm.
C. Quantification o f FXYD6 expression in the PrL following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= 0.317; p>0.05).
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Figure 5.8
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f GAB AaP 1 
at the level o f  preffontal cortex, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the prelimbic cortex (PrL) is indicated 
by an arrow. Scale bar: 5 mm.
C. Quantification o f GABA^pi expression in the PrL after chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= 0.086; p>0.05).
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Figure 5.9
A and B. In situ hybridisation (ISH) autoradiograms showing the expression o f synapsin 
II at the level o f prefrontal cortex, after chronic treatment with vehicle (saline) (A) and 
PCP (2.58 mg/kg) (B). The anatomical localisation o f the prelimbic cortex (PrL) is 
indicated by an arrow. Scale bar; 5 mm.
C. Quantification o f synapsin II expression in the PrL following chronic PCP treatment 
by optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= 0.148; p>0.05).
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Figure 5.10
A and B. In situ hybridisation (ISH) autoradiograms showing the expression of wolframin 
at the level of prefrontal cortex, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation of the prelimbic cortex (PrL) is indicated 
by an arrow. Scale bar: 5 mm.
C and D. Pseudocolour autoradiograms corresponding to A and B. Correspondence 
between colour and relative optical density (ROD) is shown on the left side of each 
autoradiogram. The anatomical localisation of the PrL is indicated by an arrow.
D. Quantification of wolframin expression in the PrL following chronic PCP treatment by 
optical densitometry of ISH autoradiograms. This gene was significantly downregulated 
in the PCP freated animals. (t(10)= 2.245; p< 0.05)
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5,4 Discussion
The expression analysis of nine genes overexpressed in schizophrenia related 
brain regions revealed that GABAaô has a tendency to be downregulated and 
wolframin is significantly underexpressed in the PCP model of schizophrenia 
(figures 5.6 and 5.10). Although the ISH study clearly showed that the expression 
of the majority of genes analysed is not modified by the PCP treatment, the 
interesting findings about GABAaÔ and wolframin are very encouraging, and 
support the validity of the strategy adopted in this project.
These results support the importance of the approach based on the anatomical 
specificity of the PCP-induced alterations, confirming that the extensive gene 
expression profiling obtained by LMD/microarray produced a database that can be 
a very useful source of information for research in schizophrenia and cognition.
5.4.1 GABAaô
Some alterations of the GABAergic system in the PCP model of schizophrenia 
were demonstrated by Cocliran et al (2003) and include reduced expression of the 
calcium-hinding protein parvalbumin in the prefrontal cortex and in the reticular 
thalamic nucleus (see section 1.3.4).
The present study suggests that the VO could also be specifically affected by 
the PCP-induced abnormalities of the GABAergic neurotransmission, as the 
G A B A aÔ receptor showed a trend to be downregulated in this cortical subregion.
Although the change did not reach statistical significance (figure 5.6), the 
importance of the GABAergic neurotransmission for the neuropathology of
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schizoplirenia (reviewed by Lewis, 2000) and the previous findings on the PCP 
model confer interest to this finding.
Fuilher investigations are needed to verify the validity of this result. 
Unfortunately the quantitative analysis of the ISH autoradiograms could not 
measure a statistically significant change, partly because the expression difference 
was very small, as commonly occurs in the brain. Nevertheless, this technique 
was very useful for investigating the expression of this gene in multiple specific 
brain regions; hence, increasing the number of biological replicates could be 
useful to increase the statistical power of the analysis without sacrificing the 
useful anatomical specificity of ISH.
5.4.2 Wolframin
Research on the wolframin gene in humans has been focused on the role of 
this gene in Wolfram syndrome, a complex neurological disease with symptoms 
including diabetes insipidus, diabetes mellitus, optic atrophy and deafness (see 
chapter 4).
Importantly, psychiatric illness is also a feature of Wolfram syndrome. Swift 
et al. (1990; 1991) emphasised this aspect of the disease reporting that a high 
proportion of Wolfram syndrome homozygotes had been hospitalised for mental 
illness, and committed or attempted suicide. Following these observations, it was 
hypothesized that the mutated wolframin could play a role in predisposing to 
psychiatric disease. In fact, it was reported that heterozygous carriers, who do not 
show the main Wolfram syndrome symptoms, are 26-fold more likely to suffer 
from psychiatric illness than non-carriers (Swift et al, 1998). The most consistent 
symptom self-reported by heterozygotes in this study was depression; suicide 
attempts, clironic anxiety, panic attacks and racing thoughts were also common.
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These findings strongly suggest that wolframin plays a role in the 
predisposition to some forms of psychiatric diseases, and paved the way to more 
investigations. Although some studies failed to confirm the association between 
wolframin mutations and psychiatric diseases (Martorell et al, 2003; Kato et al, 
2003); the increased tendency to suicide of the heterozygotes seems the most 
robust finding (Li et al, 2002; Sequeira et al, 2003).
For the first time, the present study showed that wolframin could be involved 
in the neuropathological alterations observed in a PCP model of schizophrenia. 
The ISH experiments measured a significant downregulation of wolframin in the 
PrL following the PCP chronic intennittent treatment. The consequences of this 
molecular abnormality are difficult to predict, partly due to the lack of knowledge 
on the biological functions of wolframin. Nevertheless, the reports that 
inactivating mutations of this gene predispose to some psychiatric symptoms in 
humans (Swift et al, 1991; Swift et al, 1998; Cryns et al, 2003) suggest that the 
underexpression of wolframin in the PCP model of schizoplirenia could be part of 
the complex neurobiological changes underlying the behavioural abnormalities of 
the model. It is also worth considering that this neuropathological change was 
specifically measured in the PrL, a cortical subregion that controls crucial 
functions such as working memory and cognitions and that shows schizophrenia- 
related metabolic and molecular alterations (see above; Cochran et al, 2003).
Although the exact function of wolframin is unclear, evidence suggest that this 
gene may be involved in the regulation of calcium homeostasis, and could 
mediate the transport of this ion from the endoplasmic reticulum to the cytoplasm 
(see chapter 4). Calcium transport is finely regulated in excitable cells such as 
neurons, as changes of the Ca^  ^ concentration in the cytoplasm modulate 
important neurobiological processes including exocytosis. The Ca^ "^  concentration 
in the cytoplasm of neurons is regulated by a complex network of membrane 
channels, buffering proteins and proteins associated with the intracellular 
reseiwoirs. The glutamate NMDA receptor is a membrane Ca^ *^  channel that is 
directly involved in the neuropathology of schizophrenia, and blockers of this 
chamiel such as PCP can cause schizophrenia-like effects in humans and animals
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(see chapters 1 and 5). Parvalhiimin, another protein that controls calcium 
homeostasis, is also involved in the neuropathology of schizophrenia and its 
expression is altered in the PrL of a PCP model (see above). Wolframin, that 
shows reduced expression in the PrL of the PCP model according to the present 
study, could be another gene involved in the complex mechanism that regulate 
calcium homeostasis in the preffontal cortex that has a role in the biological basis 
of some symptoms of schizophrenia. Functional studies would be needed to verify 
this fascinating hypothesis. Moreover, it would be interesting to investigate the 
cellular localisation of wolframin to understand whether a specific subset of 
neurons of the PrL is affected by the PCP-induced alteration.
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6.1 Introduction
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6.1.1 Chromosomal loci linked to schizophrenia
I
-i
It is now widely accepted that schizoplirenia is a disease with a major genetic 
component, mainly arisin from epidemiology evidence on families and twins (see 
section 1.5). In fact, it can be argued that schizophrenia has one of the highest 
heritabilities among the complex genetic disorders such as diabetes, cancer and 
coronary heart disease (Kirov et al, 2005).
This scenario has prompted a massive effort in trying to determine the specific 
genes that predispose a person to the disease. Such findings would be a 
tremendous step forward both for the understanding of the neuropathology of 
schizophrenia and for the development of novel treatments. However, this 
research has been as fascinating as daunting, because the complexity of the task 
has led in many cases to unclear or contradictory results (reviewed by Harrison et 
al, 2005; Kirov et al., 2005). It is clear that the heritability pattern of 
schizophrenia is very complex. There is no single gene or small cluster of genes 
that play a determinant role in the aetiology of the disease; in contrast, evidence 
suggest that multiple genes combined with epigenetic and environmental factors 
are likely to cause schizophrenia (see section 1.5).
Although some robust and convincing findings are reported in the literature 
(see below), there is still limited knowledge on how the schizophrenia- 
susceptibility genes interact with each other and with extra-genetic factors.
Moreover, schizoplirenia is not a homogeneous syndrome; in fact, patients 
diagnosed as schizophrenic can experience a different range of symptoms. This 
intrinsic variability makes the task of finding the “schizophrenia genes” even 
more difficult, as different molecular lesions could relate to different specific 
phenotypes. For these reasons the genome-wide linkage studies performed to date I
report interesting but sometimes uncertain and contradictory data (reviewed by 
Harrison et ai, 2005). However, two recent meta analyses have tried to clarify the 
useful infonnation reported in the single studies.
Combining the data from 18 independent studies, Badner et al (2002) 
concluded that thi*ee loci reached genome-wide significance: 8p, 13q and 22q. 
Lewis et a l (2003) used a different methodology to combine the data from 20 
independent genome-wide scans. Only one locus, 2p, was found significant when 
stringent statistical criteria were applied, whereas the loci 5q, 3p, 11 q, 2q, Iq, 22q, 
8p, 6p, 20p and 14q were significant under less strict conditions.
Despite the discrepancy between the two studies, it is noteworthy that two 
loci, 8p and 22q, were sigiificant in both. Arguably, the identification of 
schizoplirenia-susceptibility genes cannot be achieved by the linkage analyses 
alone for the above-mentioned difficulties, but the findings need to be supported 
by expression studies and other biological evidence (Harrison et al, 2005).
In this scenario, it is remarkable that the gene encoding for the catechol-0- 
methyl transferase (COMT), which has been associated with schizophrenia by 
several independent studies (Harrison et al, 2005), maps to the chromosomal 
locus 22q that is significant in both Badner’s and Lewis’ meta analyses. 
Paivalbumin, which consistently showed reduced expression in the prefrontal 
cortex of schizophrenic brain and a PCP model of the disease (see chapter 4) also 
maps to the locus 22q. These observations support the suggestions that this 
chromosomal region should be considered as a strong candidate for schizophrenia 
susceptibility.
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6.1.2 Localised expression of genes with chromosomal location linked to 
schizophrenia
As suggested by Hamson et al. (2005), the identification of schizophrenia 
susceptibility genes is not likely to come from linkage or association studies 
alone, but it requires additional biological evidence, hi this scenario, it is 
interesting to consider the regional expression of genes that have a chromosomal 
location linked to schizophrenia. If such genes show a localised expression in 
brain regions involved in the neuropathology of schizophrenia, they could be 
interesting candidates for expression analysis in the schizophrenic brain. The 
same concept can be applied to animal models: the selection of candidate genes 
for expression studies can be based on the localised regional expression of genes 
whose human orthologs have a chromosomal location linked to schizophrenia.
The LMD/microarray study identified 42 genes overexpressed in the brain 
region analysed (PrL, VO and Rt), whose human orthologs have a chromosomal 
location corresponding to the schizophrenia sites identified by the meta analyses 
of Badner et al. (2002) and Lewis et al. (2003). The majority of those genes (28) 
were overexpressed in the Rt, whereas 12 showed localised expression in the PrL 
and only 2 in the VO (figure 6.1). These genes can be considered as potential 
candidates for expression analysis in the PCP model of schizophrenia. For 
technical reasons and time constraint, four of these 42 genes were selected for 
expression analysis after chronic PCP treatment (table 6.1).
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Figure 6.1
Number of genes with schizophrenia-linked chromosomal location that show region- 
selective expression in the rat brain according to the LMD/microarray study.
Regionalselectivity Gene Chromosomallocation 45mer probe sequence
PrL
DPYSL3 5q TOG ATC OCT TCA AAG ATG TTG TAT TOC GOA ACC GAC TGG TGG TTC
DPYSL5 2p CAA AGC ACA GGG CCA TGT GTC GTC TCA GGA TTG ATA CAA CCT TAG
Rt GPX3
5q GGA GAA AGT GTG AAG GTG TTG TAG CAA ACC GTG AGC ACA GAT GGT
PIPPin 22q CTG TGC TCA CAT TTT ACT TCC AGA CTG GGT CTC ATA AAG GTC ATT
Table 6.1
Genes with region-selective expression and chromosomal location linked to 
schizophrenia in the human genome that were selected for expression analysis in the PCP 
model o f schizophrenia via in situ hybridisation. (Refer to chapter 2 for details on design 
on the specific 45mer oligonucleotide probes).
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6.1.3 Localised expression of genes w ith chromosomal location 5q
The locus 5q has been linked to schizophrenia by the meta analysis of Lewis et 
al (2003) (see above). Interestingly, the LMD/microarray study showed that 11 
genes that are overexpressed in brain regions relevant to schizophrenia are 
concentrated in this locus (figure 6.1).
Dihydropyrimidinase-like protein 3 (DPYSL3), also known as collapsin 
response-mediated protein-4, is one of the genes with location in 5q. The 
LMD/microarray study showed that the rat ortholog of tliis gene is overexpressed 
in the PrL. DPYSL3 is believed to play a role in neuronal differentiation, axonal 
outgrowth and possibly neuronal regeneration (Charrier et al, 2003). In fact, this 
gene belongs to the cluster of genes involved in neuiodevelopment that are 
overexpressed in the PrL (see section 3.4.1).
Glutathione peroxidase 3 (Gpx3) is another gene with location in 5q. The rat 
ortholog of Gpx3 was overexpressed in the Rt according to the LMD/microaiTay 
study. The enzyme encoded by this gene is involved in the glutathione 
metabolism, and therefore in the protection of cells from oxidative stress. It has 
been shown that fr'ee radicals generation and oxidative stress may have a role in 
neuropsychiatrie disorders (Ravikumar et al, 2000; Herken et al, 2001; 
Srivastava et al, 2001). Hence Gpx3 could be an interesting candidate for gene 
expression analysis in the PCP model of schizophrenia.
6.1.4 Localised expression of genes with chromosomal location 22q
The evidence that locus 22q is linked to schizoplirenia is supported by both 
Badner’s and Lewis’ meta analyses; moreover, this is the genomic location of 
genes that show expression changes in the schizophrenic brain, such as COMT
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and parvalbumin (see above). The rat orthologs of 6 genes with genomic location 
in 22q are overexpressed in brain regions relevant to schizophrenia according to 
the LMD/microarray study; respectively, 4 are preferentially expressed in the Rt 
and 2 in the PrL.
One of the Rt selective genes encodes for PIPPin, a brain-specific mRNA- 
binding protein (Castiglia et al, 1996; Nastasi et al, 1999; Raimondi et al, 
2003). This factor has recently attracted the attention of investigators for its role in 
the control of transcription. In fact, this protein specifically binds histone mRNAs, 
participating to the complex mechanisms regulating the transcriptional potential 
of the genome (Nastasi et al, 1999; Raimondi et al, 2003). The expression 
profile of PIPPin suggests that this gene could be important for the regulation of 
transcription in the Rt.
6.1.5 Localised expression of genes with chromosomal location 2p
2p is another interesting locus for schizoplirenia, as it is the only one that 
achieved significance according to the most recent meta analysis when stringent 
statistical criteria were applied (see above; Lewis et al, 2003). The rat orthologs 
of 3 genes with genomic location in 2p are overexpressed in brain regions relevant 
to schizophrenia according to the LMD/microarray study; 2 are preferentially 
expressed in the Rt and 1 in the PrL.
The PrL selective gene with genomic location in 2p is Dihydropyrimidinase- 
like protein 5 (DPYSL5). Similarly to DPYSL3 (see above), this PrL selective 
transcript belongs to the collapsin response mediator proteins (CRMPs) family. 
These proteins are directly involved in ap opto sis, proliferation, cell migration, and 
differentiation (see section 3.4.1; Charrier et al, 2003). Interestingly, two genes 
belonging to this family have a chromosomal location linked to schizophrenia and 
their rat orthologs are overexpressed in the PrL, a cortical subregion that is
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directly involved in the cognition and attentional processes (see chapter 3). These 
observations suggest that DPYSL5 could be an interesting candidate for gene 
expression analysis in a rat model of schizophrenia.
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6.2 Aims
The aim of this set of experiments was to analyse the gene expression of the 
rat orthologs of four genes with genomic location in schizophrenia-linked loci, 
after a chronic-PCP tretment regime that allows reproducing some aspects of 
schizophrenia in rats. The genes (DPYSL3, Gpx3, PIPPin and DPYSL5; see 
above) were selected on the basis of their expression profile in specific brain 
regions relevant to the neuropathological changes observed in the PCP model of 
schizoplirenia.
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6.3 Results ?
■1Genes overexpressed in the PrL
I
;DPYSL3 and DPYSL5 showed ovexpression in the PrL according to the
.LMD/microarray study (see table 3.3, “Neuro genesis/neurotransmission” 
functional class); therefore their expression level was analysed in this cortical 
subregion after chronic PCP treatment.
The quantitative analysis of the expression levels of DPYSL3 in the PrL of 
PCP-treated and control animals showed that there is no significant drug-induced 
expression change (t(10)= -0.937; p>0.05) (figure 6.2).
Similarly, DPYSL5 did not show significant expression change in the PrL of 
PCP-treated animals compared to vehicle treated controls (t(10)= 1.134; p>0.05)
(figure 6.3).
Genes overexpressed in the Rt
The quantitative expression analysis of Gpx3 and PIPPin was performed in the 
Rt after chronic PCP treatment, as these genes are enriched in this region 
according to the LMD/microarray study (see table 3.2, “Neurotransmission” and 
“Transmission/RNA processing” functional classes).
The quantitative analysis of the expression levels of Gpx3 in the Rt of PCP- 
treated and control animals showed that there is no significant drug-induced 
expression change (t(10)= 0.614; p>0.05) (figure 6.4),
Likewise, the quantitative analysis of the expression levels of PIPPin in the Rt 
after chronic PCP treatment did not show a significant expression change (t(10)= - 
0.183; p>0.05) (figure 6.5).
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Figure 6.2
A and B. In situ hybridisation (ISH) autoradiogram showing the expression o f DPYSL3 at 
the level o f preffontal cortex, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the prelimbic cortex (PrL) is indicated 
by an arrow. Scale bar: 5 mm.
C. Quantification o f DPYSL3 expression in the PrL following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= -0.937; p>0.05).
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Figure 6.3
A and B. In situ hybridisation (ISH) autoradiogram showing the expression o f DPYSL5 at 
the level o f preffontal cortex, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the prelimbic cortex (PrL) is indicated 
by an arrow. Scale bar: 5 mm.
C. Quantification o f DPYSL5 expression in the PrL following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= 1.134; p>0.05).
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Figure 6.4
A and B. In situ hybridisation (ISH) autoradiogram showing the expression o f GPX3 at 
the level o f anterior thalamus, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the reticular thalamic nucleus (Rt) is 
indicated by an arrow. Scale bar: 5 mm.
C. Quantification o f RGS3 expression in the Rt following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= 0.614; p>0.05).
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Figure 6.5
A and B. In situ hybridisation (ISH) autoradiogram showing the expression o f PIPPin at 
the level o f  anterior thalamus, after chronic treatment with vehicle (saline) (A) and PCP 
(2.58 mg/kg) (B). The anatomical localisation o f the reticular thalamic nucleus (Rt) is 
indicated by an arrow. Scale bar: 5 mm.
C. Quantification o f PIPPin expression in the Rt following chronic PCP treatment by 
optical densitometry o f ISH autoradiograms. No significant difference was measured 
between the PCP and vehicle treated animals (t(10)= -0.183; p>0.05).
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6.4 Discussion
The expression analysis of four genes with cliromosomal location linked to 
schizoplu'enia in the PrL and the Rt, following chronic PCP treatment, did not 
show drug-induced changes. The approach employed for this set of experiments 
was an attempt to combine the infonnation from the recent comprehensive linkage 
meta analyses (Badner et ai, 2002; Lewis et al, 2003) and the gene expression 
profiles obtained using the LMD/microarray strategy (see chapter 3) to choose 
candidate genes for expression analysis after a chronic PCP treatment regime that 
models some aspects of schizophrenia.
The negative results reported above illustrate the difficulty of individuating 
novel genes involved in the neuropathology of schizophrenia, especially when a 
small number of genes are investigated. However, the use of regional expression 
profiles for the choice of candidates has proved to be a valuable strategy (see 
chapter 5), therefore the combination of this infonnation with linkage data may 
still have a potential usefulness, if the analysis is extended to a greater number of 
candidates.
A comprehensive expression analysis of all 42 region-selective genes with 
chromosomal location linked to schizophrenia would provide useful data, 
especially if perfoimed using more than one teclmique, such as ISH and RT- 
qPCR. This type of study could be expanded to analyse these genes at the protein 
level. This approach is more likely to identify genes that show expression changes 
at the mRNA or protein level in the PCP model of schizoplirenia; however, such a 
comprehensive scan is beyond the scope of this thesis mainly due to time 
constraint.
Another approach that could be used to verify if these genes are changed in the 
PCP model of schizoplirenia is the combination of expression studies with 
behavioural tests. The expression levels of genes that are involved in cognitive 
and attentional processes in relevant brain regions such as the PrL and the VO
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could be influenced by enviromnental factors and adaptation changes may occur 
in specific conditions, such as when performing complex cognitive tasks. In fact, 
unpublished data from our laboratories suggest that the expression of some genes 
are changed in animals that had been perfonning cognitive tasks compared to 
control animals that had been treated in identical manner, but did not perform 
behavioural task, hi this scenario it is reasonable to hypothesise that some PCP- 
dependent expression changes may become apparent in some specific conditions 
only, such as during or soon after perfonning a cognitive task. Potential changes 
may only be revealed depending on the level of attentional load during cognitive 
testing in the model of scliizophienia. This hypothetical scenario could mirror 
some abnoimalities measured by fMRI in the human schizophrenic brain, which 
are mainly observed when the cognitive functions are challenged by specific tests. 
This interesting but complex experimental strategy is also beyond the scope of 
this thesis, but could be an efficient way to use the data from the LMD/microarray 
study (see chapter 3) to perfonn a characterisation of the PCP model of 
schizoplii'enia after relevant cognitive tasks.
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C h a p t e r ?. G e n e r a l  D is c u s s io n
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The overall aims of this PliD thesis were to identify genes enriched in three 
brain regions (PrL, VO and Rt) implicated in some aspects of cognition and in 
some schizophi'enia-like neiirobiological alteration observed after a specific 
clnonic PCP treatment regime in rats (Cochran et al. 2003). Additionally, the aims 
of this thesis included the expression analysis of selected enriched genes 
following chronic PCP treatment.
These objectives were fully met, as the transcriptome profiling strategy based 
on the combination of laser-assisted microdissection and micro array analysis 
produced a novel and useful characterisation of the gene expression in the regions 
of interest. These data were employed to select candidate genes for expression 
analysis following clrronic PCP treatment, allowing the detection of the 
downregulation of wolframin. This change may be a potentially important 
abnonnality in the PrL of the PCP-treated rats with relevance to the human 
disease.
7.1 Expression profiling in laser-microdissected brain regions
The LMD/microarray study is the most imiovative part of this thesis, and 
generated invaluable data that are the foundation of the research strategy 
employed to identify genes involved in the PCP-induced abnonnalities (see 
chapters 5 and 6).
This ambitious project allowed the transcriptome profiling of the rat PrL, VO 
and Rt. The relevance of these specific regions to schizoplirenia research is well 
documented, as they correspond to the structures affected by this psychiatric 
disease in the human brain (see chapter 3). Moreover they show crucial molecular 
and metabolic changes in a well-established model of schizophrenia that minor
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abnormalities observed in the schizophrenic brain (Cochran et al, 2003).
The combination of laser microdissection and microarray gene expression 
analysis is an innovative technique whose popularity is rapidly expanding in 
neuroscience research. This approach, which allows the identification of gene 
expression profiles in discrete structures of the brain, has recently been employed 
for the molecular characterisation of the hippocampus and the amygdala (Zirlinger 
et al, 2000; Bonaventure et al, 2002; Zirlinger, 2003; Datson et al, 2004; 
Ton-es-Munoz et al, 2004). In this study the LMD/microarray strategy was 
employed for the first time to investigate the gene expression profiles of 
subregions of the prefrontal cortex and one thalamic nucleus.
The results obtained are significant both from a technical and a biological 
perspective. In fact, in this study the LMD technique was optimised to identify 
and dissect specific cortical subregions with a high degree of reliability. The 
consistency of the technique was reflected by the uniformity of the data obtained 
fiom the biological replicates (see chapter 3).
The data obtained from the microarray analysis confirmed the hypothesis that 
the anatomical differences underlying the functional specificity of brain regions 
are associated with an unique gene expression profile. The differential gene 
expression between the Rt and the cortical regions examined was remarkable, and 
can be partly due to the gross anatomical differences and to the prevalence of 
GABAergic intemeurons in this thalamic nucleus. Interestingly, the intra-cortical 
gene expression differences were also very prominent, despite the neuronal 
composition of the subregions examined being relatively uniform. The specific 
expression profiles of the PrL and VO identified in this study can be interpreted as 
the molecular substrate underlying the complex cognitive and attentional 
processes that require the activation of these cortical subregions.
The bioinformatic analysis and the information available from online 
databases fhttp ://w w w. affvmetrix. com, http ://www.ncbi.nlm.nih. gov/UniGene. 
http ://www. geneontolo gv. ore/. http ://www. ensembl.orgf highlighted the 
functional significance of some clusters of genes that were overexpressed in the 
regions analysed (see chapter 3). Arguably, the most intriguing finding produced
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by this research is the overexpression of genes involved in neurodevelopment and 
neurogenesis in the PrL. The most plausible interpretation for the prevalence of 
such genes in the PrL (table 3.3) is their possible role in the mechanisms of 
plasticity that underlie cognitive and mnemonic processes. The involvement of 
neurodevelopment-related genes in cognition has been documented in the 
hippocampus, where neurotrophins such as BDNF, which is overexpressed in the 
PrL according to the present study, have an acute effect on synaptic transmission 
and regulate crucial processes such as long-term potentiation (Figurov et al, 
1996; Patterson et al, 1996 Jovanovic et al, 2000). The finding that this class of 
genes is overexpressed in the PrL, a cortical subregion that controls working 
memory and behavioural flexibility, suggests that this expression pattern could be 
considered as a molecular fingeiprint of areas involved in cognitive processes.
7.2 Confirmation of regional expression by in situ hybridisation
The results obtained from the validation study were cmcial to confirm and to 
complement the micro array analysis. Although the modem oligonucleotides 
aiTays are a very reliable tool for the exploration of gene expression, it is good 
practice to validate some of the data obtained with this teclinique using an 
alternative independent method such as ISH.
Remarkably, all transcripts that produced a detectable signal showed an 
expression profile corresponding to that predicted by the microarray analysis. The 
confirmation of the expression profiles of 11 genes supported the consistency not 
only of the microan'ay hybridisation and analysis, but also of upstream procedures 
such as the linear amplification. In fact, ISH allowed the quantification of the 
amount of transcript originally present in the brain regions of interest, as opposed
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to the LMD/microarray strategy, which involved two steps of linear amplification 
(see chapter 3). The correspondence of the results obtained using these two 
strategies demonstrated that the linear amplification step had not altered the 
relative abundance of the 11 transcripts analysed in the different brain regions and 
therefore strongly support the reliability of this procedure.
The validation results also suggested that the LMD/microarray technique is 
more sensitive than ISH, as two of the 13 transcripts selected for validation (Dcx 
and Stk23, see section 4.4.1) could not be detected using the latter methodology. 
The increased sensitivity is another advantage of the micro array approach that can 
be very usefril to investigate the expression of low-abundance genes.
Along with the invaluable confirmation data, the ISH experiments produced 
some useful information that complemented the expression profiles predicted by 
the LMD/microarray study for some of the 11 genes analysed. An example is the 
clarification of the laminar distribution of genes overexpressed in the PrL such as 
FXYD6 and Wolframin. The ISH also highlighted that RGS3 and PKC5, which 
were overexpressed in the Rt according to the LMD/microarray study, are 
expressed in the ventral part of this thalamic nucleus only. This expression pattern 
suggests that the ventral and the dorsal part of the Rt may have important 
frinctional differences in the rat brain.
7.3 Expression of validated localised genes in the chronic PCP 
model of schizophrenia
The research strategy of these experiments was based on the useful 
information obtained from the LMD/microarray and validation study. These data
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allowed the selection of 9 genes for expression analysis following a chronic PCP 
treatment regime that models some aspects of schizophrenia in rats (Cochran et 
al, 2003).
Although the majority of these genes did not show significant expression 
changes in the brain regions of interest after the PCP treatment, a significant drug- 
induced dowiu'egulation of the gene wolframin was measured in the PrL. This 
interesting result supports the validity of the strategy employed and suggests that 
the regional expression profiles of the PrL, VO and Rt obtained via 
LCM/microanay can be invaluable for gene expression research in relation to 
psychiatric disorders and cognition.
Wolframin is a protein localised in the endoplasmic reticulum with a role in 
calcium transport (Takeda et al, 2001; Cryns et al, 2003; Osman et al, 2003) 
that has been linked to some forms of psychosis (Swift et al, 1998; Li et al, 
2002; Sequeira et al, 2003). For the first time, the present study showed that this 
gene could be involved in the alterations observed in a PCP model of 
schizophrenia. The exact role of wolframin in these neuropathological processes 
is difficult to hypothesise due to the limited knowledge about its biological 
funtion. However, this gene, similar to NMDA receptors and parvalbumin, could 
be involved in the complex mechanisms that regulate calcium homeostasis in the 
PrL that have a role in the biological basis of some symptoms of schizoplurenia.
7.4 Expression of genes with chromosomal location linked to 
schizophrenia in the chronic PCP model
In this section the selection criteria for the transcripts to analyse in the PCP 
model were based on the regional expression (LMD/microaiTay study) and the
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genomic location of their human ortho log genes. This strategy combined the 
expression profiles in the PrL, VO and Rt obtained from the LMD/microarray 
study with the information from two recent meta analyses of schizophrenia 
linkage studies (Badner et al, 2002; Lewis et al, 2003) to designate four 
candidate genes. None of the candidates showed significant expression changes in 
the relevant brain regions in the PCP model of schizophrenia; however, the 
approach described above (see also chapter 6) could still be potentially useful if 
the analysis is extended to a greater number of candidates.
7.5 Further work
The interesting results reported in this thesis can inspire several fascinating 
questions. Above all, the gene expression profiles of the PrL, VO and Rt 
generated by the LMD/microarray study can be an invaluable source of 
information for gene expression research in the fields of molecular psychiatry and 
cognition.
These data could be integrated with protein expression studies. In fact, 
exploring the proteome of a specific brain region would add useful information 
and constitute a more complete “molecular fingerprint”. Currently, the 
development of protein microarrays cannot match that of oligonucleotides array 
for reliability and sensitivity; therefore a proteomic profiling of brain regions 
would be unpractical. However, an analysis limited to a restricted number of 
genes of interest, would still produce interesting data and allow clarification of 
how the regional overexpression of some genes is reflected at the protein level.
Elucidating the role of neurodevelopment related genes overexpessed in the 
PrL would also be a fascinating task. Knowing how these genes (table 3.3)
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participate to the neurophysiology of the PrL and how they interact with each 
other could be a major step forward in the understanding of the neurobio logical 
mechanisms underlying cognition. These questions could be partly answered by 
performing behavioural and cognitive tests on knock out or knock down animals 
for the genes of interest. Also, it would be interesting to investigate whether the 
expression of neurodevelopment related genes in the PrL is modulated when rats 
perform tasks designed to assess different aspect of the executive function. In fact, 
unpublished data from our laboratories suggest that gene expression may be 
changed in the PFC of animals that had been performing cognitive tasks 
compared to control animals that had been treated in identical manner but did not 
perform the behavioural task.
Reduced expression of wolframin in the PrL of the model of schizophrenia is 
one of the most interesting finding reported in this thesis. The confirmation of this 
dowm'egulation at the protein level would be a valuable goal to achieve, 
Wolframin specific antibodies have been successfully raised and employed in 
immunohistochemistry based experiments (Takeda et al, 2001; Ishihara et al, 
2004; Philbrook et al, 2005); in fact immunofiuorescence could be a suitable 
approach to investigate the expression of this protein in a specific brain structure 
such as the PrL. Moreover, co-localisation experiments could help clarifying 
whether wolframin is preferentially expressed in a specific subset on neurons of 
the PrL.
7.6 Conclusions
The present thesis reports a number of interesting findings relevant to 
cognition and modelling aspects of psychiatric disorders in rodents. The
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combination of laser microdissection and micro array technology, an innovative 
approach that is becoming more and more common in neuroscience research, has 
been employed here for the first time to analyse the gene expression profiles of 
the rat PrL, VO and Rt. The data obtained represent original and useful 
information about the molecular basis of the functional differences in the specific 
brain regions investigated (see chapter 3).
Importantly, these finding were validated using an independent teclinique. The 
results obtained from the ISH confirmation study strongly supported the 
consistency and the reliability of the strategy employed for the transcriptome 
profiling. The ISH experiments also produced some interesting information that 
complemented the expression profiles predicted by the LMD/microarray study for 
some of the 11 genes analysed (see chapter 4).
The strategy adopted to investigate PCP-induced gene expression 
abnormalities (chapters 5 and 6) was based on the information obtained firom the 
LMD/microaiTay study. This approach demonstrated that the chronic PCP 
treatment causes a downregulated of wolframin in the PrL of rats. This finding 
suggests that wolfiramin is directly involved in the neurobiological mechanisms 
that underlie the psychotomimetic effects of PCP, and could be potentially 
important in schizophrenia. This interesting original finding shows the potential 
utility of gene expression profiling of specific brain regions in neuroscience 
research. Further studies on the neurobiology of the proteins encoded by these 
genes may provide useful information for developing novel treatments for 
psychiatric disorders such as schizophrenia.
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